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1.1 Thesis Topic 
Human regulatory T cells (Treg) are a CD4+ T lymphocyte sub-population that regulates 
immune responses of conventional CD4+ T cells (Tconv) to maintain immunological 
homeostasis. They constitutively express FOXP3 and CD25 and characteristically show 
low expression of CD127 (Liu, et al., 2006). These markers are frequently used to 
distinguish them from other CD4+ Tconv populations. However, the expression of these 
markers on Tconv changes upon activation, and it can be difficult to separate Treg from 
activated Tconv cells. My thesis covers the heterogeneity of human CD4+CD25+ T cell 
populations. I investigated surface marker and RNA expression in natural and stimulated 
states, and compared CD4+ T cell population subsets between patients with the 
autoimmune disease type 1 diabetes and healthy controls. Finally, I examined the T cells 
generated by dendritic cell based tolerogenic priming of naïve T cells. These 
investigations are relevant to the development of biomarkers that can distinguish true 
Treg from CD4+ effector subsets in the development and application of therapies aiming 
at increasing or decreasing Treg numbers and function. 
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1.2 Immunity 
The human body is protected against a wide range of pathogens and their toxins by 
its immune system. Immunity includes a pattern recognition innate immune response, 
which is functional from birth on, and a specific receptor based adaptive immunity that 
develops during lifetime of an individual as it encounters a variety of pathogens.  
 
1.2.1 The adaptive immune system 
Major cellular components of the adaptive immune system are the T and B 
lymphocytes. They derive from a common lymphoid progenitor and differentiate in the 
bone marrow into B cells or in the thymus into T cells. Their broad antigen-specific 
response is made possible through highly variable antigen receptors on their surface, 
known as B cell receptor (BCR) on B cells and T cell receptor (TCR) on T cells. Before 
lymphocytes become activated by an antigen they are known as naïve lymphocytes. 
After pathogenic antigen encounter and activation they become effector lymphocytes 
and can differentiate into memory lymphocytes for long lasting immunity. 
The antigen-specific activation of T cells is driven by professional antigen presenting 
cells (APCs) such as dendritic cells (DCs), which take up antigens unspecifically, 
process and present the peptides on major histocompatibility complexes (MHCs). 
Therefore, dendritic cells bridge the gap between innate and adaptive immunity. The 
cellular response of helper T cells is mostly needed to activate the humoral response of 
B-cell antibody production through the secretion of pro-inflammatory cytokines. Cytotoxic 
T cells can directly kill pathogen infected cells by their lytic activities. The adaptive 
immunity also gives rise to a T cell type, called regulatory T cells (Treg) that is able to 
suppress other lymphocytes in order to avoid an overreaction of immune responses. 
 
1.2.2 Development of T cells 
T cells develop in the bone marrow from multipotent hematopoietic stem cells and 
mature into naïve T cells in the thymus, which are both primary lymphoid tissues. Mature 
naïve T cells are then released into the periphery i.e. blood stream and migrate to 
secondary lymphoid tissues such as lymph nodes and spleen. Their development in the 
thymus is comprised of different stages to generate a diverse repertoire of TCRs 
enabling an immune response against a wide range of pathogens. In brief, T cell 
progenitors, double negative (CD4-CD8-) thymocytes, undergo rearrangement of the α 
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and β- chains to form the TCRs and become CD4+CD8+ double positive cells that also 
express CD3 (Borowski, et al., 2002; Shortman and Wu, 1996). The fate of double 
positive thymocytes is driven by the recognition of self-peptide:self MHC molecules 
presented by thymic epithelial cells, a process which is called positive selection 
(Kisielow, et al., 1988; Marrack and Kappler, 1997). Those that recognize the self MHC 
complexes too strongly will undergo negative selection by the induction of apoptosis to 
eliminate self-reactive cells (Anderson, et al., 2002). T cells that recognize MHC class II 
molecules will become single CD4+ cytokine-secreting T helper cells and those 
recognizing MHC class I are programmed to become CD8+ cytotoxic T cells. In addition 
to the conventional CD4+ T cells a small functionally distinct CD4+ T cell subset called 
Treg also derives from the thymus (tTreg) and functions to maintain self-tolerance. They 
upregulate the transcription factor forkhead box protein 3 (FOXP3) during the maturation 
and require IL-2 receptor signaling by high expression of CD25 (IL-2α receptor). The 
Treg TCR repertoire is composed of high affinity self-peptide:self MHC complexes for 
agonist selection (Jordan, et al., 2001; Zheng and Rudensky, 2007). T cells that 
successfully passed the control mechanisms of the thymic central tolerance are released 
into the periphery as mature naïve T cells. Naïve T cells that recognize self-antigens in 
the periphery will be either eliminated or go into an anergic state (unresponsiveness) 
whereas the recognition of pathogen-derived antigens leads to the activation of T cells 
(Xing and Hogquist, 2012).  
 
1.2.3  Antigen specific activation of CD4+ T cells 
The antigen-specific activation of CD4+ T cells is MHC class II dependent, which is 
expressed on professional APCs such as DCs. They take up antigens, process them to 
generate peptide loaded MHC class II molecules and migrate to secondary lymphoid 
tissues for antigen presentation facilitating the recognition by the TCR and the activation 
of naïve T cells. 
 
Maturation of DCs and their antigen presentation  
DCs are a small and heterogeneous group of APCs in peripheral tissues. Their 
ability to efficiently activate T cells is also dependent on their maturation state. The 
process is triggered in vivo and in vitro through bacterial wall components (e.g. 
lipopolysaccharides (LPS)), viral products (e.g. dsRNA) or by pro-inflammatory cytokines 
such as IL-1, TNF-α. Complete maturation is achieved through helper T cell 
CD40/CD40L-dependent and independent mechanisms. Maturing DCs redistribute their 
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MHC molecules from the endocytic compartments to the cell surface; decrease their 
antigen uptake and upregulate co-stimulatory molecules for T cell activation. Further 
changes in morphology include the re-organization of the cytoskeleton to form dendrites 
and expression of chemokine receptors for the homing from peripheral tissues to the 
secondary lymph nodes (Banchereau and Steinman, 1998).  
DCs internalize extracellular antigens into endocytic vesicles or by phagocytosis. 
They are degraded by acid proteases into peptides, which associate with the MHC class 
II molecules to form MHC-peptide complexes. The transport of the complexes to the cell 
surface is upregulated upon induction of DC maturation of the DCs (Cella, et al., 1997). 
Another pathway of peptide presentation is the direct complex formation on the cell 
surface by empty MHC class II dimers that can be loaded with the peptide. This is also 
used as an in vitro approach for direct peptide presentation to bypass the endolysosomal 
pathway (Santambrogio, et al., 1999).  
 
T cell activation 
In general, the MHC class II bound peptides function as ligand for TCR recognition, 
which subsequently leads to the activation and differentiation of naïve CD4+ T cells into 
effector T cells (Figure 1.1) (Kapsenberg, 2003). This process of T cell activation 
requires a first signal provided by the interaction of a specific peptide bound to the MHC 
complex with the TCR. CD4 functions as a co-receptor, which is ligated to the MHC-TCR 
complex. The second signal, which promotes the survival and expansion of activated 
naïve T cells, is provided by co-stimulatory molecules. Here, the B7 molecules (CD80 
and CD86), a homodimeric immunoglobulin on the DC surface, bind to the receptor 
CD28 on naïve T cells to induce expression of IL-2 and the IL-2 receptor (Lenschow, et 
al., 1996). The IL-2 receptor is composed of three chains: α, β and γ. Prior to T cell 
activation, only the β and γ chains a present on the cell surface. Upon activation, the 
synthesis of IL-2 and the IL-2α chain (CD25) induced. The expression of CD25 forms the 
high affinity receptor that allows binding of IL-2 to trigger the signaling for activation and 
proliferation. The secretion of IL-2 and the induction of cell proliferation is conducted in 
an autocrine fashion (Gaffen, 2001). However, if a co-stimulatory signal is not provided, 
the cell will enter an anergic state or may undergo deletion (Gimmi, et al., 1993). 
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Figure 1.1 Priming and activation of naive T cells by antigen presenting cells requires three 
signals. Antigens are either internalized and processed by dendritic cells (DCs) or loaded directly onto the 
MHC class II molecules. Signal 1 is provided by the interaction of peptide loaded MHC class II present on 
DCs and the T cell receptor (TCR) expressed by T cells. The second signal is triggered by CD80/CD86 
expressed on DCs and CD28 as co-stimulatory signal or CTLA-4 acting as co-inhibitory signal. The third 
signal is provided by DC secreted cytokines required for the differentiation of naïve T cells into T helper cells. 
Figure was adapted from Kaspenberg, Nat. Rev. Immunol, 2003. 
 
In addition to the CD28 co-stimulatory signal there are other co-stimulatory 
molecules that sustain or modify the activation of T cells. One example is the inducible 
co-stimulator (ICOS), which is expressed on T cells upon activation. It binds to ICOS 
ligand (ICOSL) present on activated DCs, driving the expression of IL-4 and IFN-γ in T 
cell subsets. Another receptor for CD80/CD86 is the cytotoxic T lymphocyte antigen 4 
(CTLA-4), which competes for the B7 molecule interaction with CD28. It has an inhibitory 
effect on T cell activation by restricting IL-2 production and thereby limiting proliferative 
response of the T-cells (Hubo, et al., 2013). Other co-stimulatory signals belong to the 
tumor necrosis factor (TNF) - family. The CD40 receptor on DCs binds to the CD40 
ligand on activated T cells to induce activating signals to the T cells, but also to DCs for 
the upregulation of B7 molecules, thereby, enhancing T cell proliferation. Further, OX-40 
and OX-40L are expressed on activated T cells and DCs, respectively, to sustain T cell 
response CD40L stimulation and to promote survival as well as proliferation signals. A 
co-inhibitory signal is obtained by the programmed cell death-1 (PD-1) molecule and its 
interaction with the two DC ligands, PD-L1 and PD-L2. It suppresses cytokine 
production, impairs cell survival proteins and induces apoptosis (Watts, 2005). 
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The expression of co-stimulatory and co-inhibitory molecules on DCs and T cells 
essentially controls the priming of naïve T cells. The combination of several molecules 
defines the immune response as immunogenic or tolerogenic.  
A naïve T cell also requires a third signal for the differentiation into one of the 
different effector T cell subsets, which is provided by DC secreted cytokines and the 
overall inflammatory milieu (Curtsinger, et al., 1999). Effector T cell subsets will be 
discussed in more detail in the next chapter 1.2.4. 
 
1.2.4 Effector CD4+ T cells and their subsets 
Following activation, naïve T cells undergo rapid cell division and differentiation into 
effector T cells to synthesize molecules for their helper function. When an effector T cell 
encounters its specific antigen, no co-stimulatory molecules are necessary for T cell 
activation (Schweitzer and Sharpe, 1998). This enables the activation of B cells and 
macrophages, which have taken up the antigen, but do not express co-stimulatory 
molecules. 
 
From naïve to effector T cell: Changes in marker expression 
As discussed in chapter 1.2.3, naïve T cells upregulate the expression of co-
stimulatory and co-inhibitory molecules upon antigen specific activation. This change in 
marker expression ensures the sustainability of activation and supports T cell survival 
and proliferation. Differences in marker expression are also a useful tool to distinguish 
naïve T cells from effector and further central memory T cells for in vitro assays. 
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Figure 1.2 Phenotypic change of naive/ resting T cells after activation. The activation via the TCR-
MHC class II complex also involves the interaction of CD3 and CD4 which are constitutively expressed on 
CD4+ T cells. CD28 as a co-stimulatory signal is required for T cell activation and triggers the up-regulation 
of further co-stimulatory/ -inhibitory molecules such as ICOS and CTLA-4. CD127 (IL7Rα) is downregulated 
while CD25 (IL-2Rα) becomes upregulated after activation. A switch from naïve to memory T cells is 
characterized by the change from CD45RA to CD45RO expression and the downregulation of CCR7, while 
CD45 expression is maintained. The upregulation of nuclear FOXP3 expression can also be detected upon 
activation of T cells. 
 
In general, CD4+ T cells express CD3, CD4, CD45, CD28 and TCR on their surface. 
Naïve T cells express CD45RA, a glycosylation dependent isoform of CD45, on their 
surface. Upon antigen-specific activation the CD45 isoform changes to CD45RO within 
72 h (Johannisson and Festin, 1995). In addition, the homing receptor CCR7 is found on 
naïve T cells as well as on central memory (CM) T cells, but is downregulated on effector 
memory (EM) T cells (Sallusto, et al., 2000). This change in expression of CCR7 can be 
explained by the functional differences of T cell subsets. Naïve T cells need to home to 
secondary lymphoid organs to encounter their specific antigen by APCs and to become 
primed. They differentiate into effector memory T cells that need to be able to home to 
peripheral tissues, but not lymph nodes, which lead to the downregulation of CCR7. To 
maintain a rapid immune response upon secondary challenges, a small fraction of 
memory cells persist in the secondary lymph nodes. They become CD45RO+CCR7+ 
central memory T cells (Figure 1.2).  
Activated T cells furthermore upregulate CD25 (IL-2Rα), ICOS and CTLA-4 while 
downregulating CD127 (IL-7Rα), which has also been described for activated T cells. 
The cytokine IL-7 plays a pivotal role in the homeostasis of T cells, promoting survival of 
naive T cells and generation of memory cells (Berard and Tough, 2002; Fry and Mackall, 
2005). The IL-7R is internalized in the presence of IL-7 leading to a reduction of CD127. 
Also ex vivo memory CD4+ T cells were found to have CD127 downregulated (Zaunders, 
et al., 2014). The transcription factor FOXP3 is known as the key regulator of Treg 
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function, but was also identified in activated effector T cells. FOXP3+ activated CD4+ T 
cells were not superior in their suppressive function, which would have identified them as 
converted Treg with tolerogenic functions (Allan, et al., 2007; Mantel, et al., 2006).  
Early activation markers that have been used in functional in vitro assays for CD4+ T 
cells are the co-stimulatory molecules CD69 and CD154 (CD40L). They are upregulated 
within a few hours after the stimulation and reduced expression is already detected after 
24 hours Depending on the kind of stimulus, the time point of analysis and the cell type 
the above described and many more activation markers can be a tool for immune-
phenotyping. 
 
Effector CD4+ T cell subsets 
As briefly mentioned, activated T cells require a third signal that promotes 
differentiation into effector T cell subsets with different immunological functions. These 
subsets show a distinct profile of cytokines, transcription factors and also chemokine 
receptors, which are important for tissue specific homing. Three T helper (Th) subsets 
have been well known for years: Th1, Th2 and Th17. Recently, new subsets have been 
identified as Th9, Th22 and T follicular helper (Tfh) cells as shown in Figure 1.3 (Cosmi, 
et al., 2014; Wu, et al., 2014).  
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Figure 1.3 Differentiation of naive T cells into T helper cell subsets. Naïve T cells start to 
differentiate into different T helper cells (Th) after priming by antigen presenting cells. Depending on the 
cytokine milieu, naïve T cells can differentiate into Th1, Th2, Th17, Th9, Th22 or Tfh. Downstream signaling 
pathways are activated by the cytokines to promote the expression of master transcription factors such as 
the activation of T-bet by IL-12 and for Th1 differentiation. Th subset function is characterized by the 
secretion of the respective cytokines such as IFN-γ by Th1 and by expression of a distinct pattern of 
chemokine receptors on the cell surface (Th1- CXCR3+CCR5+). Figure adapted from Wu et al., Int J of Oral 
Sciences, 2014. 
 
Th1 cell differentiation is driven by IL-12 and IFN-γ that activate the transcription 
factors STAT-4 and STAT-1, respectively, to promote activation of the “master 
transcription factor regulator” T-bet. Th1 cells produce high amounts of IFN-γ for an 
immune response against intracellular pathogens. Th17 develop upon extracellular 
bacterial and fungal infections. The transcription factor RORγt is activated by IL-1β and 
IL-23 to induce differentiation into Th17, characterized by IL-17A and IL-17F secretion as 
immune response. Both, Th1 and Th17 play not only a role in foreign pathogen directed 
immune response, but are also known to play a role in organ-specific and systemic 
autoimmune disease pathogenesis. Same holds true for the Th2 subset; while it is 
crucial for protection against helminths, it can also promote inflammatory responses 
against allergens. This subset is induced by IL-2 and IL-4 for the activation of GATA-3, 
leading to the production of IL-4, IL-5 and IL-13. Similar to Th2, Th9 are involved in 
allergic reactions and moreover have been associated with autoimmune diseases 
(Chang, et al., 2010). Naïve T cells will differentiate into Th9 cells in the presence of 
TGF-β and IL-4 to express the transcription factor PU.1 and produce the pro-
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inflammatory cytokine IL-9. Th22 were named after their ability to produce IL-22 to 
maintain mucosal barrier function, but were also found to play a role in autoimmune 
diseases. The key Th22 transcription factor is AHR (Eyerich, et al., 2009). Last, Tfh were 
identified as key cell type for the formation of germinal centers in secondary lymph nodes 
to help B cells. IL-6 and autocrine IL-21 activate the transcription factor Bcl-6, driving the 
differentiation into Tfh (Ma, et al., 2012). 
All Th lineages can also be distinguished by their expression pattern of chemokine 
receptors that function as tissue homing receptors. While naïve T cells express high 
amounts of CCR7, this marker becomes downregulated upon T cell activation and 
differentiation. Therefore, all effector T cells are CD45RO+ CCR7-. Th1 are characterized 
by CXCR3 and CCR5 expression. Both Th2 and Th22, express CCR4, while Th2 can be 
further distinguished by CRTh2, CCR3 as well as CCR8. Th22 also expresses CCR10 
on the surface. Th17 can be identified by CCR6 expression and Tfh are CXCR5+. A 
distinct chemokine receptor profile for Th9 has not been conclusively reported until 
today. Some reports suggest that Th9 can be characterized as CCR3+CXCR3+CCR6+ 
(Bromley, et al., 2008).  
In addition to the different Th subsets, also “non-classical” subsets such as Th1/Th17 
or Th2/Th17 were shown to exist. They produce a mixture of the subset cytokines and 
express both subset specific chemokine receptors. Th subset plasticity is also increased 
by the differentiation from one lineage into the other upon change of the cytokine milieu 
(Annunziato, et al., 2008; Maggi, et al., 2012). The complexity of Th lineages and varying 
intermediate forms are yet not fully understood and new discoveries might lead to 
changes of the current lineage landscape. 
 
1.2.1 Regulatory T cells 
The thymus gives rise to functional naïve T cells and eliminates potential 
autoreactive T cells through central tolerance mechanisms of positive and negative 
selection. However, some autoreactive T cells escape the central tolerance, which 
requires further tolerance mechanisms in the periphery.  
Already in the 1970ies, researchers had described a functionally distinct lymphocyte 
subset, which was shown to be pivotal to immunological tolerance. Later it became clear 
that these cells were a subset of CD4+ T cells able to suppress T cell activation, 
proliferation and effector function and, therefore, are regulating peripheral immune 
responses (Gershon and Kondo, 1970; Sakaguchi, et al., 1995). These regulatory T cells 
(Treg) derive from the thymus by negative selection binding with medium to high affinity 
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with their TCR to self-peptide-MHC class II presented by thymic stromal cells. They may 
receive signals through the TCR to induce FOXP3 which promotes differentiation to Treg 
cells (Josefowicz and Rudensky, 2009). Both, IL-2 and IL-7 are required for Treg 
development in mice, which is thought to be similar in humans. (Sakaguchi, et al., 2008). 
In addition to tTreg (formerly called natural Treg, nTreg), it has been shown in murine 
studies that FOXP3- Tconv can differentiate into Treg in peripheral tissues, these are 
called pTreg (formerly induced Treg, iTreg) (Abbas, et al., 2013). However, the pTreg 
population in humans is controversial, since there has been no marker identified that can 
distinguish them from the tTreg pool. Differences observed between murine and human 
Treg prevents the ability to translate findings from one organism to the other (Yadav, et 
al., 2013). In recent years, the manipulation of Tconv to actively induce Treg in vitro for 
humans as well as in vivo in mice has widely expanded the characteristics of Treg. iTreg 
have become a potential approach for Treg specific therapies, which will be discussed in 
later sections (Shevach and Thornton, 2014).  
 
Phenotypic Characteristics 
Human tTreg cells were first characterized by the expression of CD4 and CD25 in 
2001 by several groups (Dieckmann, et al., 2001; Levings, et al., 2001; Ng, et al., 2001), 
based on the findings of mouse Treg by Sakaguchi et al. in 1995. Treg constitutively 
express CD25 and are dependent on the exogenous IL-2 for their survival and function 
(Baecher-Allan, et al., 2002; Taams, et al., 2002). The transcription factor forkhead box 
P3 (FOXP3) was identified as a human Treg key gene regulator in 2005 by Roncador 
and colleagues (Roncador, et al., 2005). That FOXP3 plays a role in the maintenance of 
self-tolerance was first shown in FOXP3 deficient scurfy mice and later on in patients 
with immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX). A 
mutation of FOXP3 results in severe autoimmunity and allergy resembling the phenotype 
of mouse experiments after the depletion of CD4+CD25+ Treg (Bennett, et al., 2001; 
Wildin, et al., 2001). However, it was shown that both, CD25 and FOXP3, can be 
upregulated upon activation of naïve T cells, without differentiation into Treg (Allan et al., 
2007; Gavin, et al., 2006). These FOXP3+ T cells can be discriminated from suppressive 
FOXP3+ Treg by the methylation status of the FOXP3 gene, which is only completely 
demethylated in Treg but not conventional T cells (Miyara, et al., 2009; Wieczorek, et al., 
2009). A stable and high FOXP3 expression of Treg is required for suppressive function, 
where long-term in vitro culturing can lead to a loss of FOXP3 and thus decreased 
suppressive capacity (Allan, et al., 2008; Hoffmann, et al., 2009). A disadvantage of the 
Treg associated marker FOXP3 is the intranuclear location, which requires fixation and 
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thus hinders its use to isolate living cells. In humans, CD25+ cells can make up to 30 % 
of peripheral blood CD4+ T cells, but only a small fraction of the highest CD25 expressing 
T cells show to be suppressive Treg (Baecher-Allan, et al., 2001). In mice on the other 
hand, CD25 and FOXP3 can be used to specifically identify Treg, as murine 
conventional CD4+ cells lack the transient upregulation of FOXP3 upon activation and 
only Treg express CD25 (Sakaguchi et al., 1995). In 2006, several groups identified that 
Treg populations that the expression of CD127 (IL-7Rα) inversely correlates with the 
expression of FOXP3 and suppressive function. In combination with high CD25 
expression, human Treg could be highly enriched for FOXP3+, as was shown in post-
sorts analyses (Liu et al., 2006; Seddiki, et al., 2006a). However, also this marker is not 
unique to Treg, as activated conventional T cells can also downregulate CD127.  
Many more markers have been proposed to discriminate human Treg from 
conventional T cells, but none of them have been shown to be exclusively present on 
Treg. CD62L (L-selectin) can be used to discriminate CD25+CD127lo Treg, which are 
CD62L+, from CD62lo recently activated conventional T cells (Battaglia, et al., 2003). 
CTLA4 and glucocorticoid-induced TNF-receptor-related protein (GITR) are associated 
with suppressive activity of Treg and have been used as Treg signature molecules 
(Walker, 2013; Wing, et al., 2008). ICOS, another T cell co-stimulatory molecule, is also 
associated with Treg stability, proliferative and suppressive ability, as was shown in 
murine models (Chen, et al., 2012). 
The heterogeneity of Treg is similar as to Tconv. They exert a CD45RA+ naïve and 
CD45RO+ memory phenotype, where naïve Treg are also FOXP3+ and show 
suppressive function. These naïve Treg are present in peripheral blood and highly 
enriched in cord blood (Seddiki, et al., 2006b; Valmori, et al., 2005). However, it was 
shown in mouse models that Treg need continuous stimulation of the TCR with their 
cognate self-antigen to be maintained in the periphery and may therefore not be truly 
naïve T cells (Fisson, et al., 2003). Most naïve Treg also express CD31 (PECAM1) 
which is a specific marker for recent thymic emigrants (RTEs), whereas CD45RO+ 
memory Treg do not. Delineation of naïve Treg can be based on the expression of the 
proliferation marker Ki-67: naïve Treg that are negative for Ki-67 can be considered as 
resting Treg (rTreg), whereas rTreg that are stimulated, upregulate FOXP3 expression 
and start proliferation, are called activated Treg (aTreg) (Miyara et al., 2009). Further 
discrimination of CD45RO+ Treg into central and effector memory Treg by the expression 
of CCR7 was shown by Tosello and colleagues in 2008. Similar to Tconv, CCR7+ CM-
like Treg are thought to control T cell homeostasis and the onset of immune responses in 
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secondary lymphoid organs and CCR7- EM-like Treg control the effector phase of 
immune responses in peripheral tissues (Tosello, et al., 2008).  
More recent work on potential Treg biomarker identified HELIOS, an Ikaros family 
transcription factor. The group of Evan Shevach showed in 2010 that the majority (>70%) 
of thymus derived Treg expressed HELIOS, whereas induction of Treg in the periphery 
did not upregulated the marker. Therefore the group claimed that the use of HELIOS can 
distinguish between tTreg and pTreg. However, Himmel et al. showed in 2013 that naive 
tTreg also contain a HELIOS negative population with similar suppressive capacity as 
HELIOS positive Treg (Himmel, et al., 2013). Although the marker does not appear to be 
suitable for distinguishing tTreg and pTreg, both groups showed that even upon 
stimulation of Tconv they did not upregulate HELIOS. Therefore, HELIOS can be used 
as a Treg specific marker.  
Also the inverse correlation of markers on Treg has been proposed for the 
characterization of this population. Salgado et al. published in 2012 that CD26 is not 
expressed on CD4+CD25+FOXP3+ Treg in contrast to effector T cells (CD4+CD25-). This 
marker, known as an indicator for immune activation and effector function in T cells, is 
also not upregulated upon stimulation of Treg (Salgado, et al., 2012). Two years later, 
Garcia Santana and colleagues showed that the negative or low expression of CD6 is 
specific for tTreg, which they defined as CD4+CD25+FOXP3+ (Garcia Santana, et al., 
2014). Both markers have not been used frequently for the characterization of Treg, 
unlike FOXP3 or CD127, as there have been only few publications including CD26 or 
CD6 as Treg specific markers. 
As noted before, none of the proposed markers for Treg identification is exclusively 
found on Treg, most can also identify Tconv in general, recently activated or effector 
Tconv. Therefore only the combination of multiple markers can delineate Treg from 
Tconv. The most commonly signature for Treg is CD4+CD25+CD127loFOXP3+, where the 
FOXP3 marker cannot be included for live Treg isolation. 
 
Suppressive function 
In vivo and in vitro mouse studies have shown that Treg cells exert their regulatory 
function through several mechanisms: modulation of the cytokine environment, metabolic 
disruption of the target cell, alteration of DC activating capacity and through cytolysis 
(Sakaguchi et al., 2008; Shevach, 2009; Vignali, et al., 2008). Suppressive mechanisms 
in humans remain to be determined since Treg functional studies have been limited to in 
vitro assays. The mechanism of suppression is thought to be by Treg cell/T effector 
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direct contact and/or release of cytokines. The cells need to be in close proximity for 
Treg to suppress responder cells, as it was shown that Treg failed to suppress Tconv 
when separated through a trans-well system (Takahashi, et al., 1998; Thornton and 
Shevach, 1998). 
The primary mechanism of Treg appears to be the direct suppression of Tconv 
through various ways. The compensation of exogenous IL-2 from activated Tconv has 
been widely accepted as a major pathway of Treg suppression. Treg are thought to be 
dependent on IL-2 for cell survival as they do not produce it on their own, but keep the 
low affinity receptor CD25 constantly upregulated (Pandiyan, et al., 2007). They thus 
compete with activated Tconv for IL-2, which leads to suppression of T cell proliferation 
and eventually to cell death due to cytokine deprivation (Thornton and Shevach, 1998). 
This mechanism of Treg, however, has been under dispute, since many Treg in vitro 
assays function with magnetic bead isolated CD4+CD25+ T cell populations, which can 
contaminate the Treg population with activated T effector cells. The Tconv cells may play 
a role in the uptake of IL-2 for continuous proliferation and therefore inhibiting 
proliferation of responder cells. Tran and colleagues were able to show that even by 
specifically blocking CD25 on Treg they were still able to exert there suppressive 
function (Tran, et al., 2009a). IL-2 deprivation alone, is not required by which Treg can 
suppress Tconv activation and therefore, suppressive capacity may as well be IL-2 
independent (Oberle, et al., 2007).  
Several inhibitory cytokines have been identified as soluble factors for Treg 
suppressive mechanisms: IL-10, IL-35 and TGF-β. In vivo studies in mice showed that 
both, IL10 and IL-35 are efficient cytokines to exhibit a short distance suppressive effect 
(Collison, et al., 2007). Although, IL-35 producing Treg in humans are still under debate 
as it was shown that they do not constitutively express IL-35 and have only been 
identified as Th35 (or iTr35) cells upon in vitro induction from naïve T cells (Bardel, et al., 
2008; Collison, et al., 2010). Similar observations have been made for the suppressive 
mechanism by IL-10; IL-10 producing T cells were described as in vivo or vitro induced 
Tr1 that can be generated by tolerogenic IL-10 producing DCs. They have been 
described as Treg population that does not constitutively express FOXP3+ unlike the 
tTreg population (Asseman, et al., 1999; Groux, et al., 1997; Roncarolo, et al., 2006). 
The immunoregulatory character of IL-10 has been described mainly in chronic 
infections; it can inhibit Th1 and Th2 immune responses in diseases like tuberculosis, 
malaria or hepatitis C (Boussiotis, et al., 2000; MacDonald, et al., 2002; Plebanski, et al., 
1999). 
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The inhibitory cytokine TGF-β is not only known as suppressor molecule, but has 
similarly been shown to play a critical role in the induction of FOXP3+ Treg (Chen, et al., 
2008; Liu, et al., 2008). The suppressive mechanism of TGF-β has been first described 
by Nakamura and colleagues, where TGF-β is bound to the cell surface by a receptor 
mediating suppression in a cell contact-dependent fashion. They proposed that activated 
Treg bind the latent TGF-β on their surface and deliver it directly to Tconv where it is 
locally converted into its active form (Nakamura, et al., 2001). TGF-β is bound to the 
latency associated peptide (LAP) forming the latent TGF-β LAP and is not detected on 
resting Treg. Upon activation via the TCR a high percentage of Treg, both human and 
murine, had LAP upregulated on their surface and suppressive activity could be blocked 
by anti-TGF-β (Andersson, et al., 2008; Tran et al., 2009a). In 2009, several groups 
identified GARP as the Treg surface receptor where LAP binds to. It was shown that 
platelets and activated Treg contain both GARP and latent TGF-β and that GARP 
appears to be critical for the surface expression of latent TGF-β by binding to the 
complex and functioning as its cell surface receptor (Tran, et al., 2009b; Wang, et al., 
2008).  
Other reported mechanisms of direct Tconv suppression are the cytolysis of Tconv 
by granzyme A or B and the secretion of galectin 1 for Tconv cell cycle arrest. In brief, 
granzymes are serine proteases that enter target cells through perforin pores to induce 
apoptosis by the activation of caspases. They have long been only associated with 
natural killer cells and CD8+ cytotoxic T cells, although CD4+ T cells also exhibit cytotoxic 
activity (Lieberman, 2003). Human Treg cells have been shown to secrete granzyme A 
to kill Tconv in a perforin-dependent manner (Grossman, et al., 2004). Further, galectin-1 
secreting Treg can induce apoptosis of Tconv by cell-cycle arrest and it has been shown 
in vitro that galectin-1-deficient Treg have a reduced regulatory activity (Garin, et al., 
2007). The β- galactoside binding proteins binds to glycoproteins on Tconv surface such 
as CD45 and CD7, consequently leading to T cell apoptosis.  
To inhibit the priming and differentiation of Tconv, Treg can directly target the 
activating functions of APCs. Thus, in the presence of APCs, CTLA4 expressing Treg 
can directly downregulate the co-stimulatory function of APCs by binding to CD80/CD86 
(Misra, et al., 2004; Wing et al., 2008). This process is called infectious tolerance, which 
allows the expansion of a regulatory environment in a bystander fashion. 
Another Treg surface molecule is the lymphocyte activation gene 3 (LAG-3), which is 
a CD4 homolog and can directly bind MHC class II molecules on APCs. The interaction 
induces an inhibitory signaling suppressing the maturation and immune-stimulatory 
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capacity of immature DCs. Activated Tconv can also express MHC class II, which might 
also result in a Treg mediated ligation via Lag-3 (Liang, et al., 2008). 
The metabolic disruption of APCs as well as Tconv is mediated by the anti-
inflammatory mechanism of CD39- and/or CD73, also expressed on Treg. CD39 is an 
ectoenzyme that hydrolyzes ATP or ADP to AMP. Extracellular ATP functions as an 
indicator of tissue destruction and can upregulate CD86 expression on DCs. The 
hydrolysis of ATP by CD39 may allow the Treg cells to enter inflamed regions and to 
quench ATP-driven pro-inflammatory processes on DCs. The immunomodulatory effects 
of removal of ATP by CD39 can be amplified by the generation of adenosine. Adenosine 
can be generated by CD39 can generate Adenosine together with the 5′-ecto-nucleoside 
CD73, which dephosphorylates AMP. Adenosine signals via the A2A adenosine receptor 
and thus inhibits the functions of DCs as well as T cells (Deaglio, et al., 2007). 
Neuropilin-1 (Nrp-1) is receptor for class III semaphorins and a co-receptor for 
vascular endothelial growth factor and has been proposed to directly interact with 
immature DCs, therefore, blocking the antigen presentation. However, Nrp-1 has only 
been identified as a specific marker of murine Treg whereas human Treg appear not to 
express this marker. It was reported that upon in vitro- activation human Tconv induce 
expression of Nrp-1 and that the marker should rather be used as activation marker in 
humans (Milpied, et al., 2009).  
 
Treg based therapeutic approaches 
The tolerogenic functions of Treg are pivotal to maintain immune homeostasis. They 
are essential in the avoidance of immune overreaction such as graft versus host disease 
(GvHD) after transplantation, and their important role in the control of autoimmune 
diseases such as rheumatoid arthritis (RA), multiple sclerosis (MS) and type 1 diabetes 
(T1D). Therefore, the focus on therapeutic use of Treg has become of increased 
importance over the last years. However, several aspects had to be considered:  
In vivo derived Treg can be generated in the thymus as well as in the periphery, 
where they derive from Tconv. In general, isolation of FOXP3+ Treg does not distinguish 
between tTreg or pTreg, as there is a lack of markers that can separate the two 
populations. The average population size of Treg ranges between 1-2.5 % of peripheral 
blood mononuclear cells (PBMC) of healthy adults, which results in a very low cell 
number that is insufficient for therapeutic approaches. 
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A successful method to polyclonally expand Treg was developed by Jeffrey 
Bluestone and other groups. They have shown that CD4+CD25+ magnetic bead isolated 
Treg can be expanded 1500 fold on average within 14 days by artificial TCR stimulation 
using αCD3αCD28 microbeads and IL-2 (Earle, et al., 2005; Godfrey, et al., 2004; 
Hoffmann, et al., 2004; Putnam, et al., 2009). The addition of the mTOR inhibitor 
rapamycin selectively inhibits cell cycle progression of Tconv and is therefore increasing 
the Treg purity (Battaglia, et al., 2006; Battaglia, et al., 2005). The polyclonal expansion 
appears to be even more efficient when cord blood is the cell source, with higher 
expansion rates, purer Treg populations and increased suppressive capacity (Theil, et 
al., 2015b). Since consumables for Treg expansion became also available in good 
manufacturing practice (GMP) grade, several clinical studies were initiated to test safety, 
efficacy and feasibility of the adoptive Treg transfer (Brunstein, et al., 2011; Marek-
Trzonkowska, et al., 2012; Trzonkowski, et al., 2009). Despite its great potential for 
clinical applications there are some drawbacks (Tang and Bluestone, 2013). It was found 
that Treg lose their FOXP3 expression upon repeated stimulation even in the presence 
of rapamycin, which is likely due to the destabilization of FOXP3 expression in Treg 
rather than the outgrowth of a few contaminating Tconv (Hippen, et al., 2011b; Hoffmann 
et al., 2009). Their polyclonal character and thus systemic suppressive effect might also 
not be specific enough to be used as safe Treg therapy in autoimmune diseases. 
Other than polyclonal Treg, the application of antigen-specific Treg is thought to be 
more effective in terms of specifically targeting auto-reactive T cells in autoimmune 
diseases. However, the isolation of antigen-specific tTreg/ pTreg is nearly impossible. 
Inducing Treg from naïve Tconv can circumvent this problem. iTreg were shown to be 
generated polyclonally by a combination of cytokines and compounds, allo-specifically by 
the use of tolerogenic B-cells or DCs and antigen-specifically by antigen-loaded 
tolerogenic DCs. The relatively large pool of naïve T cells will result in a sufficient 
number of induced Treg for therapeutic use. 
Many studies with mouse models have first shown that naïve T cells can be 
manipulated in such a way that they exhibit Treg characteristics. TGF-β has been 
identified as an inducer of Foxp3 expression in T cells, where IL-2 is required in the 
development of iTreg (Chen, et al., 2003; Davidson, et al., 2007). In vitro, the iTreg were 
able to suppress the proliferation of naïve Tconv stimulated with anti-CD3, whereas they 
have been suggested to lose Foxp3 expression when transferred in vivo (Selvaraj and 
Geiger, 2008). In humans, however, the presence of TGF-β and IL-2 induced high 
FOXP3 expression, but unlike mouse iTreg the human iTreg proliferated and failed to 
suppress Tconv when being stimulated via TCR. In addition, the FOXP3+ T cells 
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produced IL-2 and IFN-γ (Tran, et al., 2007). Other studies have suggested that the 
addition of retinoic acid or rapamycin resulted in anergic and suppressive iTreg that 
stably expressed FOXP3 (Hippen, et al., 2011a; Lu, et al., 2010).  
Also TCR stimulation strength appears to affect the generation of iTreg; a low 
occupancy of the TCR by a high affinity peptide favors iTreg production over a low 
affinity peptide (Gottschalk, et al., 2010; Yuan and Malek, 2012). The in vivo 
administration of sub-immunogenic doses of antigen in murine models has proven that 
naïve T cells converted into Foxp3 expressing Treg with suppressive activity 
(Kretschmer, et al., 2005). The stability of Treg has been linked with the demethylation of 
the FOXP3 CpG islands to maintain an active chromatin state (Floess, et al., 2007; 
Polansky, et al., 2008). However, iTreg and also Treg redifferentiated into Tconv, which 
seem to be unstable, showed increased CpG methylation consistent with FOXP3 
transcriptional inactivity (Zhou, et al., 2009). 
The selection of Treg by antigen-based TCR stimulation via APCs has been thought 
to be more favorable than the antibody-bead stimulated expansion of Treg. In 
transplantation, the identification of alloantigen-reactive Treg by donor-derived APCs or 
autologous APCs pulsed with donor peptides appeared to decrease the risk of systemic 
immunosuppression in the recipient (Golshayan, et al., 2007; Landwehr-Kenzel, et al., 
2014). 
In general, mature DCs prime Tconv and initiate immune responses, whereas 
immature DCs exhibit a tolerogenic phenotype with higher levels of co-inhibitory 
molecules and anti-inflammatory cytokines (Lutz and Schuler, 2002). Treg can maintain 
the DCs in an immature state by downregulating the co-stimulatory molecules CD80 and 
CD86 on the DCs surface. The modulation of DCs via an anti-inflammatory milieu, using 
TGF-β and IL-10, can also promote the expansion of antigen-specific Treg and induce 
the generation of Treg in the periphery (Chen et al., 2003; Jonuleit, et al., 2002; 
Yamazaki, et al., 2006). Besides using cytokines to obtain tolerogenic DCs, various 
chemical compounds have proven that they also drive DCs into an immature state with 
an anti-inflammatory profile. Several research groups have shown that tolerogenic DCs 
can be differentiated from monocytes in tolerogenic microenvironments, e.g. in the 
presence of active 1α,25-OH(2)Vitamin D3 (VD3). The inactive form of VD3 is generated 
in the skin in response to sunlight and is converted into the active form by an enzymatic 
cascade. It has been shown that VD3 inhibits the differentiation and maturation of DCs, 
which leads to a decrease of pro-inflammatory IL-12 and increased anti-inflammatory IL-
10 production (Griffin, et al., 2000; Piemonti, et al., 2000). VD3 in combination with the 
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corticosteroid dexamethasone can induce cells with strong regulatory properties 
(O'Garra, et al., 2008).  
Tolerogenic DCs have become of interest for clinical studies, because they have the 
potential to induce iTreg in vivo as therapeutic vaccines. The strategy appears to be 
suited to re-establish tolerance in autoimmune diseases, as they are in general 
characterized by a Tconv/Treg imbalance (Gross and Wiendl, 2013). In 2010, Torres-
Aguilar et al. showed that monocyte derived DCs treated with IL-10 and TGF-β that were 
loaded with insulin, were able to reduce the response of CD4+ effector T cells to insulin 
from T1D patients (Torres-Aguilar, et al., 2010). Similar effects were observed with VD3 
treated tolerogenic DCs that were able to induce hypo-responsiveness in antigen-
specific T cells from MS patients (Raiotach-Regue, et al., 2012).  
The importance of Treg and therapeutic application of iTreg in the autoimmune 
disease Type 1 diabetes will be discussed within the next chapters. 
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1.3 Type 1 Diabetes 
1.3.1  T1D is an autoimmune disease 
Type 1 diabetes is a chronic autoimmune disease, which is caused by T-cell 
mediated functional loss of insulin-producing beta-cells in the islets of Langerhans of the 
pancreas. The first clinical signs for patients with diabetes are excessive thirst, hunger 
and urination, which are caused by hyperglycemia. Persistent hyperglycemia can cause 
severe complications including kidney failure, ketoacidosis, heart disease and blindness. 
Unlike Type 2 Diabetes, T1D patients have little or no detectable insulin and are 
therefore life-long dependent on exogenous insulin replacement. T1D has also been 
known under the term juvenile-onset diabetes, since it usually occurs in people younger 
than 30, although it can occur at any age (van Belle, et al., 2011).  
Over the past 60 years, incidence rates of T1D have constantly risen in developed 
countries and are predicted to double in children under the age of five by 2020 
(Patterson, et al., 2009). T1D is most common in Finland with more than 60 cases per 
100,000 people/ year, whereas China and India have reported only 0.1 cases per 
100,000 people/ year (Maahs, et al., 2010). Current incident rates for Germany with 22.9 
cases per 100,000 people/ year with an annual increase in incidence of 2.6 % shows that 
the country belongs to the higher risk countries for childhood T1D. European wide data 
collection on incidence rates has drawn a picture of a north-south gradient as well as 
west-east gradient, with lower incidences in Southern and Eastern Europe (Bendas, et 
al., 2015). Mechanistic causes of the differences in geographical incidences and the 
increasing incidence rates for T1D are not fully understood, but have been associated 
with environmental factors, changes in life style over the past decades and also seasonal 
changes of viral disease incidences (Atkinson, et al., 2014). The increasing incidence 
rates in developed countries raise the importance to completely understand the 
autoimmune disease T1D and to develop preventive strategies as well as therapeutic 
approaches. 
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Natural history of Type 1 diabetes  
Although T1D onset can occur at any age, autoimmunity starts early in life. Based on 
the model of George Eisenbarth, the natural history of T1D can be divided into 3 main 
stages (Figure 1.4):  
Pre-stage: Genetic susceptibility and environmental risk factors 
1. Appearance of autoantibodies  
2. Dysglycemia and onset of diabetes with pre-clinical symptoms 
3. Symptomatic type 1 diabetes 
 
 
Figure 1.4 staging and pathogenesis of type 1 diabetes. Type 1 diabetes (T1D) is characterized by 
the functional beta cell loss over a time period of months or years. The proposed model is a “relapsing-
remitting” decline of functional beta cell mass. The progression towards disease onset can be divided into 
three stages: stage 1 is characterized by the of beta cell autoimmunity and the appearance of 
autoantibodies, while patients maintain normoglycemic; in stage 2 beta cell function continues to decline 
leading to dysglycemia without clinical symptoms; stage 3 marks the onset of T1D with symptomatic 
dysglycemia due to a near complete loss of insulin secretion. The stages are preceded by a general genetic 
and environmental risk for T1D. The pathogenesis of functional beta cell loss is immune mediated and 
involves the interaction of CD4+ and CD8+ T cells with dendritic cells (DCs) as well as B cells. The exposure 
of B cells to beta cell autoantigens leads to the production of islet-autoantibodies, which serve as biomarkers 
of presymptomatic T1D. TCR-T cell receptor; BCR-B cell receptor. Figure adapted from Katsarou et al. 2017, 
Nat Rev Dis Primers. 
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Type 1 diabetes is a polygenic disorder with more than 40 gene loci identified up to 
date that affect the disease susceptibility. A strong risk association was identified with 
specific human leukocyte antigen (HLA) class II alleles, located on chromosome 6, 
where heterozygous haplotypes DR3/4-DQ8 (DRB1*0401-DQB1*0302 and DRB1*0301-
DQB1*0201) showed greatest susceptibility while DRB1*1501 and DQA*0102-
DQB1*0602 were protective (Erlich, et al., 2008). These MHC class II alleles are critical 
in shaping the T cell repertoire during thymic selection emphasizing the importance of T 
cells in the disease pathogenesis. However, only 30-50 % of T1D patients have the 
DR3/4-DQ8 genotype, which implies for more factors that can trigger the disease. HLA 
class I genes were also associated with T1D, but to a much lesser extent than HLA class 
II. Many more loci have been identified to increase the risk of T1D, but only few non-HLA 
gene polymorphisms are associated with odd ratios greater than 1.1: the insulin variable 
number of tandem repeats (VNTR) region, PTPN22, CTLA4 and IL2RA (Atkinson et al., 
2014). Insulin polymorphisms have the strongest association with T1D among the non-
HLA genes (Pociot, et al., 2010; Torn, et al., 2015). 
Besides the genetic risk factors, environmental influences are constantly under 
discussion as potential triggers of T1D. Nutrition of infants and children, vitamin D levels 
and viral infections have been in the focus of research. As ofr viral infections, 
enteroviruses and rubella viruses are commonly in the focus of studies and their 
proposed mechanistic associations include the T cell cross-reactivity between virus and 
islet autoantigens or the exposure of autoantigens to virus-related inflammation (Boettler 
and von Herrath, 2011).  
The first sign of beta-cell autoimmunity is the appearance of autoantibodies, which 
can be detected years before diagnosis. Four types of islet-autoantibodies are commonly 
measured: autoantibodies against insulin antigen (IA), glutamic acid decarboxylase 65 
(GAD65), insulinoma-antigen 2 (IA-2) and zinc transporter 8 (ZnT8) (Wenzlau, et al., 
2007). The appearance of autoantibodies often occurs sequentially, where genetically at-
risk children have rarely been detected autoantibody positive before 6 months of age 
(Ziegler, et al., 1999). The appearance of IAA usually peaks first at the age of 9-24 
moths, followed by GADA at 36 months, whereas IA-2A and ZnT8A tend to occur later 
(Krischer, et al., 2015; Regnell and Lernmark, 2017). The detection of multiple 
autoantibodies greatly increases the risk to progress to overt diabetes; around 70 % of 
diabetic children have three or four autoantibodies, while only 10 % have a single 
autoantibody (Andersson, et al., 2014). 
I used proinsulin and GAD65 as autoantigens for in vitro studies of autoreactive T 
cells. In general, the insulin protein is a dimer consisting of an A- and a B-chain, which 
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are linked by two disulfide bonds. It is generated from the single chain polypeptide 
preproinsulin (PPI) that goes through several posttranslational modifications until the 
final form, mature insulin, is stored in vesicles awaiting secretion. In brief, after protein 
folding of PPI, the signal peptide, essential for translocation into the lumen of the 
endoplasmic reticulum, is cleaved, forming proinsulin (PI). Subsequently, the C-peptide 
is cleaved by endopeptidases from the middle of the molecule, and the C-terminal amino 
acids of the B chain are further cleaved by carboxypeptidase E, producing the mature 
and active form of insulin. PPI, PI and insulin have all been reported to be antigens 
targeted by autoreactive T cells (Di Lorenzo, et al., 2007). GAD65 is the 65 kDa isoform 
of glutamic acid decarboxylase that catalyzes the decarboxylation of glutamate to 
gamma-aminobutyric acid (GABA). In humans, GAD65 is specifically expressed in 
GABA-secreting neurons and in beta-cells, inside which GAD65 is anchored in the 
membrane of microvesicles (Christgau, et al., 1991; Kaufman, et al., 1992). 
Once beta-cell autoimmunity is initiated, the functional beta cell mass declines what 
was hypothesized to be in a linear fashion (Eisenbarth, 1986). However, the model has 
been changed to a “relapsing-remitting” decline of beta cell function, since this process 
proceeds in a variable pace in individual patients (Bonifacio, et al., 1999). Stage 1 marks 
the appearance of autoimmunity, while the individuals are still asymptomatic for 
diabetes. The duration of this stage can vary from a few months to decades. When a 
critical functional mass of beta-cells has been lost, patients will develop impaired glucose 
tolerance, but will still remain asymptomatic. The progression to stage 3 is marked by a 
symptomatic onset of diabetes, where the remaining functional beta-cells produce 
insufficient amounts of insulin and patients suffer from typical clinical symptoms such as 
polyuria, polydipsia and polyphagia.  
 
1.3.2  Immune relevance 
The loss of beta cell function and the destruction of beta cells begins after the onset 
of autoimmunity and is believed to be mostly initiated by activated autoreactive 
lymphocytes. Early appearance of autoantibodies implicates a contributing role of 
antibody-producing B cells. They appear to infiltrate the pancreas during the early stages 
of insulitis as was shown in non-obese diabetic (NOD) mouse models as well as human 
patient biopsies (Pescovitz, et al., 2009; Willcox, et al., 2009). They can also function as 
APCs by presenting islet autoantigens to autoreactive CD4+ helper T cells and CD8+ 
cytotoxic T cells. Beta-cell destruction is most likely mediated by CD8+ T cells, as they 
are the most abundant immune cell population in insulitis lesions. They can get activated 
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directly by MHC class I expressed on beta-cells, upon upregulation of IFN-α (Foulis, et 
al., 1987). The destruction leads to a release of beta-cell antigens that can be taken up 
by neighboring APCs which migrate to the secondary lymph nodes to activate CD4+ T 
cells. The role of CD4+ T cells is understood as to providing help to B cells and CD8+ T 
cells by cytokine secretion and a positive feedback loop via CD40L-CD40 interaction with 
DCs (see Figure 1.4). Both, CD4+ and CD8+ T cells, produce cytokines such as IFN-γ 
that induce IL-1β and TNFα production through activation of macrophages. IFN-γ also 
induces expression of the FAS death receptor and chemokine production by β-cells 
enhancing inflammation and together with IL-1β and TNFα leads to induction of reactive 
oxygen species (ROS) which act as mediators of apoptosis (Lehuen, et al., 2010). The 
autoimmune inflammation in the pancreas may lead to a stimulation of beta-cell 
proliferation, which can temporarily resurrect beta-cell mass and result in the relapsing-
remitting phase of beta cell destruction (van Belle et al., 2011) 
In the proinflammatory environment of pancreatic tissue the effector T cell response 
is favored over Treg tolerance, indicating a dysfunction of the immune regulation in the 
periphery. Initially, the importance of functional Treg cells and the link to autoimmunity 
became clear with the understanding of immunodysregulation polyendocrinopathy 
enteropathy X-linked syndrome (IPEX) (Wildin et al., 2001). In this disease, a functional 
mutation in the FOXP3 gene leads to systemic inflammation and strong autoimmunity, 
including T1D. It was further shown that autoreactive T cells are not only present in T1D 
patients, but also in healthy individuals, suggesting that the negative selection of 
autoreactive T cells in the thymus is not impaired (Monti, et al., 2007). The role of Treg in 
the prevention of autoimmunity was demonstrated in animal studies by the absence or 
depletion of Treg leading to the development of autoimmune gastritis, thyroiditis, 
inflammatory bowel disease and diabetes (Brunkow, et al., 2001; Ochs, et al., 2007; 
Sakaguchi et al., 1995). Most importantly, adoptive transfer of Treg was shown to 
reverse autoimmune disease (Sakaguchi et al., 1995). A myriad of studies have tried to 
identify changes in Treg populations in T1D patients, but are mostly not conclusive. 
Differences in the nomenclature of Treg and the associated markers as well as the 
various disease stages of the study samples make it difficult to compare the results. 
Early studies were limited by limited low number of available markers to identify Treg and 
therefore used CD4+CD25+ signature for discrimination (Kukreja, et al., 2002; Putnam, et 
al., 2005). Later, investigators included FOXP3 and CD127, but failed to identify changes 
in Treg frequency (Brusko, et al., 2007; Long, et al., 2010). Study cohorts either 
consisted of T1D recent onset, T1D established or autoantibody positive patients and 
healthy controls (Qiao, et al., 2017; Zhang, et al., 2012). Rather than an alteration in 
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frequency, there is the possibility that a shift in Treg subtype distribution may be present 
in T1D. In this line, Okubo et al. detected a reduced frequency of activated Treg in T1D 
(Okubo, et al., 2016). Defective IL-2 receptor signaling was suggested by others, based 
in the observation that CD4+CD25+ T cells from T1D patients had decreased FOXP3 
expression when cultured with IL-2 (Long et al., 2010). Another study found that patients 
had similar Treg frequencies, but an increase in IFN-γ expressing Treg that are 
presumably peripherally derived and might control Th1 inflammatory responses 
(McClymont, et al., 2011). 
Beside the possibility of an altered Treg frequency in T1D, the possible loss of 
tolerogenic functions has also been in the focus of research. Lindley at al reported in 
2005 an impaired Treg function analyzing the capability of the Treg to suppress 
autologous T effector cells from T1D patients as compared to age and HLA-matched 
healthy controls (Lindley, et al., 2005). These findings have since been confirmed by 
other researchers (Brusko, et al., 2005; Glisic-Milosavljevic, et al., 2007). In these early 
studies Treg were isolated using suboptimal markers available at the time which could 
have resulted in T effector contamination of the Treg population. In addition, it could not 
be ruled out that the observed effect was due to an impaired responsiveness of the 
autologous effector T cells. More recent studies could demonstrate Treg intrinsic inability 
to suppress T effector cells in only some patients and ascribed the major cause of 
impaired suppressive mechanisms in T1D to a resistance in suppression of the effector 
cells (Lawson, et al., 2008; Schneider, et al., 2008). Both investigators studied patients 
with established T1D, raising the issue of whether the resistance to suppression is a 
cause or an effect of T1D (Buckner, 2010).  
In conclusion, whereas overall differences in the frequency of Treg in T1D patients is 
unlikely, it is yet unclear whether there is a local pancreatic decrease or difference in 
global or islet antigen-specific Treg in T1D patients compared to healthy subjects. T1D 
effector T cells seem to be partially resistant to suppression and a partial functional 
defect of Treg cannot be ruled out. It remains to be elucidated to what extend the 
inflammatory cytokine milieu affects suppressor function and whether this can lead to 
local abrogation of suppression. 
 
1.3.3  Immune monitoring, prevention and modulation  
Once patients reach stage 3 of T1D with symptomatic diabetes they will be 
dependent on a lifelong exogenous insulin administration. Although the treatment is 
highly successful, if tightly controlled, it cannot always provide the metabolic regulation 
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necessary to avoid short term e.g. hypoglycemic episodes due to the tight glycemic 
control as well as long-term complications such as nephropathy, retinopathy or vascular 
disease (Atkinson et al., 2014; Melendez-Ramirez, et al., 2010). Modern insulin 
treatment can compensate the loss of pancreatic beta cells rather well, but it can neither 
halt beta cell loss nor restore beta-cell function. The profound costs for a lifelong insulin 
treatment, impaired quality of life and possible complications associated with the disease 
led to extensive investigations in preventive strategies for different stages of the disease. 
The identification of T1D risk factors and the appearance and detection of 
autoantibodies made the disease predictable to some extent. Preventing the disease at 
an early stage before the appearance of autoantibodies is the focus of primary 
prevention studies: dietary modifications such as infant formula composition or vitamin D 
administration (Knip, et al., 2014) or antigen-specific immunization to obtain immune 
tolerance. After the development of autoantibodies, secondary prevention trials attempt 
to target immune tolerance to halt beta cell destruction. A major problem of prevention 
trials is the time it takes to draw conclusions on stopping or delaying T1D onset. 
Challenges of these studies are the good prediction of at-risk individuals and the safe 
intervention that causes no harm in individuals who would have never developed T1D. 
Therefore, intervention (tertiary prevention) studies are more affordable and T1D patients 
can be easily identified. Intervention treatments are performed to target functional beta-
cell preservation, regeneration as well as transplantation (van Belle et al., 2011). 
 
Immune monitoring in prevention trials 
Genetic susceptibility is an important factor in the study setup of prevention trials. 
The combination of HLA and non-HLA risk genes determines the risk of an individual to 
develop T1D. In addition family history of T1D increases the risk by 10-15 times. About 3 
– 7 % of risk-gene carriers will develop T1D (Achenbach, et al., 2005). The focus of 
recruiting individuals for prevention studies lies therefore on relatives of T1D patients. A 
new approach is the screening of whole populations for risk-carriers. Two studies in 
Germany aim to identify at-risk children during routine pediatric visits, Fr1da in Bavaria 
and Fr1dolin in Lower Saxony (Beushausen, 2017; Raab, et al., 2016). In addition, the 
Freder1k study in Saxony, as part of the global platform for prevention of autoimmune 
diseases (GPPAD), initiated a newborn screening in hospitals to address genetic risk 
factors directly after birth (Ziegler, et al., 2016).  
Early identification of children with high genetic-risk factors for the development of 
T1D can then be included in the routine screening for islet autoantibody appearance. 
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The association of the development of multiple autoantibodies and progression to 
diabetes has been shown in several studies (Achenbach et al., 2005; Bingley, et al., 
2006). However, antibody titer and possible antibody fluctuations do not appear to 
correlate with T1D onset. The DAISY study showed that 95 % of prediabetic children 
were IAA positive, but only 50 % continued to express insulin autoantibody at diabetes 
onset (Barker, et al., 2004) 
The important contribution of autoreactive T cells to disease pathogenesis is not 
routinely assessed, majorly due to the lack of robust assays to detect the low affinity 
and/or low frequency T cells. Especially CD4+ T cell responses show a limited 
reproducibility (Herold, et al., 2009). The detection of autoantigen-specific T cells can be 
realized by MHC class I mimicking tetramers or dextramers loaded with a peptide for 
CD8+ T cells and for MHC class II presentation for CD4+ T cells (Buckner, et al., 2002; 
Coppieters, et al., 2012). However, the restriction to HLA specific donors for tetramer 
analyses is a limiting factor for prevention studies. The application of functional T cell 
assays, however, holds clear advantages. The enzyme-linked immunospot (ELISPOT) 
determines the qualitative and quantitative antigen-specific immune response on a 
single-cell level with regard to cytokine secretion (Meierhoff, et al., 2002). Antigen-
specific T cell proliferation assays are used to measure rare T cell response to a specific 
auto-antigen. In combination with a fluorescent proliferation dye, responding T cells can 
be easily detected and also sorted for further characterization e.g. single cell gene 
expression or RNAseq (Eugster, et al., 2015; Mannering, et al., 2003). The identification 
and characterization of autoreactive T cells has already been used in several prevention 
trials such as the BABYDIET study (Heninger, et al., 2017) and Pre-POINT study 
(Bonifacio, et al., 2015) to measure trial outcome. 
 
Immune modulation 
Immune suppressive or immune modulating agents are used in primary and 
secondary prevention trials aiming for the inference in immunological mechanisms in 
T1D to prevent seroconversion and/or improve beta-cell survival. While non-specific 
immune suppression broadly inhibited the immune system, it failed to specifically target 
autoimmunity. The first clinical trial with an immunosuppressive agent was cyclosporine 
A, a calcineurin inhibitor. The treatment led to a lack of IL-2 and other cytokines, which 
reduced the function of effector T cells, but also of Treg. It induced the remission of T1D, 
but the side-effects were unacceptable for the risk-benefit ratio (Assan, et al., 1985; 
Parving, et al., 1999). 
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Targeted immunomodulators instead of systemic suppression appeared to be more 
specific and could theoretically curb autoimmunity while avoiding side effects. Immuno-
modulatory trials with biologicals involved CTLA-4Ig (abatacept) for the blockage of co-
stimulation (Orban, et al., 2011); anti-CD20 (rituximab) for B-cell depletion (Pescovitz et 
al., 2009); and anti-CD3 (teplizumab) for the modulation of T cell response and 
generation of Treg (Herold, et al., 2002). Especially the anti-CD3 treatment showed 
promising initial results with preservation of C-peptide levels and decreased insulin 
requirements. However, patients never reached normo-glycemia and also the formation 
of anti-idiotypic antibodies was detected (Keymeulen, et al., 2005).  
The concept of antigen-specific immune modulation relies on the induction of 
tolerance when an antigen is presented to the immune system. The immunizations with 
the immune response-triggering agents have already proven to be highly efficient in 
allergy. Desensitization of children with egg-white or peanut allergy by feeding a daily 
dose of the allergen was extremely successful (Du Toit, et al., 2015; Jones, et al., 2016). 
The hypothesized generation and expansion of antigen-specific Treg is critical to achieve 
immunological tolerance and the induction via the mucosal immune system appeared to 
be efficient, without the side effects of immune suppression. Oral or intranasal 
administration of antigens is commonly used in clinical trials. Antigen-specific Treg are 
believed to primarily regulate APCs loaded with antigen they recognize. However, a 
process called linked suppression was discovered in the field of transplantation that is 
thought to enable these Treg to control responses against antigens that are presented 
on the same APC. Furthermore, once specifically activated, Treg will likely suppress in a 
local bystander fashion rather than exerting specific suppression. In T1D immunization 
studies linked suppression would regulate immune responses against several 
autoantigens when the therapy is based on a single islet antigen (Davies, et al., 1996). 
Most antigen-specific prevention studies are based on the oral or intranasal 
administration of (prepro-) insulin or GAD65. Insulin is the only autoantigen exclusively 
produced by beta-cells and is considered as the main contributor to autoimmunity. 
Studies in animal models resulted in disease prevention and showed that the dose-
efficacy needs to be tightly regulated. In addition, the type of insulin appeared to be 
important, as different optimal doses were found for porcine and human insulin, although 
they differ only little in sequences. Translating this into human trials, the Pre-POINT 
study aimed to identify optimal timing, dose and route of administration with oral insulin 
in genetically at-risk children (Achenbach, et al., 2008). The dose escalation trial 
identified a dose of 67.5 mg as optimal for the induction of insulin-responding Treg, 
whereas 7.5 mg, which was used in other previous studies (Diabetes prevention trial) 
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(Skyler, et al., 2005) showed no effect (Bonifacio et al., 2015). An alternative route of 
administration is the nasal insulin inhalation, arguing that the antigenic structure is 
preserved until in contact with the mucosal immune system, unlike the breakdown in the 
gut. The intranasal insulin trial (INIT I) included autoantibody positive children to show 
safety and biomarker effects (Harrison, et al., 2004). A second larger trial with intranasal 
insulin, however, found no delay on progression to T1D onset (Nanto-Salonen, et al., 
2008). Several phase 2 trials using subcutaneous administration of GAD65 in aluminum 
hydroxide (alum) for safety, dose-escalation and efficacy studies in recent onset patients 
showed beneficial effects towards C-peptide preservation and long term tolerizing effects 
(Agardh, et al., 2009; Ludvigsson, et al., 2011). However, further phase 2 and 3 trials 
could not verify the beneficial effects of GAD-alum (Ludvigsson, et al., 2012; Wherrett, et 
al., 2011). Therefore, it remains to be determined whether ongoing antigen-specific 
clinical trials can identify factors that can prevent seroconversion of at-risk individuals 
and/or halt disease progression.  
 
Cell-based tolerogenic therapy 
The important regulatory functions of Treg in disease settings have already been 
discussed in the previous sections. To achieve tolerance in T1D at-risk children by 
strengthening existing and generating de novo antigen-specific Treg is a main goal of 
T1D therapeutic strategies. The most direct way to obtain antigen-specific Treg is the in 
vitro induction of Treg for Treg cell transfer. Unlike polyclonally expanded Treg, iTreg are 
generated from naïve T cells in an antigen specific manner.  
The first human study in T1D with Treg cell therapy was the intravenous infusion of  
ex vivo expanded autologous polyclonal Treg  in patients with recent T1D onset 
(Bluestone, et al., 2015). The open label, dose escalating phase 1 trial led by Jeffrey 
Bluestone focused on safety and included the assessment of beta cell function as well as 
markers of diabetes immune responses. First results suggested that a single infusion of 
autologous polyclonal Treg is safe and well tolerated, whereas the efficacy remains to be 
determined (Gitelman and Bluestone, 2016). Contemporaneous, a similar study was 
conducted by Marek-Trzonkowska and colleagues with expanded autologous polyclonal 
Treg in children with onset T1D. According to the authors, patients after one year of 
treatment showed a more robust beta cell function, which was assessed by C-peptide 
levels (Marek-Trzonkowska, et al., 2014). However, a 2 year follow-up showed that all 
patients had reduced C-peptide levels and were insulin dependent. Treg analysis 
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showed a shift towards a central memory phenotype and increasing proinflammatory 
immune responses (Marek-Trzonkowska, et al., 2016). 
Antigen-specific Treg are thought to be more potent than polyclonally expanded Treg 
in preventing organ specific-autoimmune diseases such as T1D (Sagoo, et al., 2011). 
The difficulty to identify autoantigen-specific Treg led to the concept of inducing antigen-
specific Treg by presenting the antigen of interest to naïve T cells via tolerogenic DCs 
(tDCs). Due to the combination of linked suppression and infectious tolerance of the DCs 
the T cells would be directed to differentiate into Treg (Sagoo et al., 2011). First results 
with immunomodulatory compounds VD3 and/or Dex have shown to generate 
tolerogenic DCs from monocytes in vitro that were also capable to induce Treg in a 
allogeneic fashion (Kleijwegt, et al., 2010; Unger, et al., 2009). Further studies of tDCs 
generated from T1D patient monocytes and loaded with GAD65 were able to induce 
Treg with suppressive capacity. TDCs were then adoptively transferred into NOD-SCID 
mice where they delayed T1D onset (Danova, et al., 2017). Other researchers showed 
similar results using tDCs generated by the addition of IL-10 and TGF-β from T1D 
patients. The tDCs were loaded with either GAD65 or insulin and found to induce 
antigen-specific T-cell hyporesponsiveness, while unrelated antigen response remained 
unaffected (Segovia-Gamboa, et al., 2014). The ultimate goal of this cell therapy is that 
the infectious tolerance of antigen-specific iTreg could shape the immunoregulatory 
responses by re-educating mature DCs in the microenvironment to be direct inducers of 
Treg themselves (Kleijwegt and Roep, 2013). Until today, no application of tDCs for cell 
therapy in T1D has been translated into clinical phase 1 trials. 
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Regulatory T cells play an important role in the peripheral tolerance mechanisms of 
the immune system. Their suppressive function on autoreactive T cells can prevent 
autoimmunity. In type 1 diabetes, Treg have been inconsistently reported to be impaired 
in their capability to suppress autoreactive T cells though they are present in similar 
frequencies as in healthy controls (Tan, et al., 2014; Zhang et al., 2012). 
While exogenous insulin replacement in T1D is a necessary therapeutic approach, 
immune-based interventions are highly desirable because of their potential to restore the 
tolerance and thus prevent and halt further beta cell destruction. Treg display such 
therapeutic potential. In general, several Treg subpopulations have been described, but 
the characteristic thymus-derived Treg (tTreg) express the major markers CD4, CD25 
and the FOXP3. Treg can also be generated from naïve CD4+ CD25- T cells in the 
periphery and are termed peripherally-derived Treg (pTreg) (Abbas et al., 2013). An 
additional aspect is the expression of Treg-associated markers on activated conventional 
T cells (Miyara et al., 2009). In terms of antigen-specific activation we need to ensure 
that in vitro results mirror the actual in vivo status by using reliable analysis tools. 
Further, state of the art tools such as RNAseq enable a more precise search for the 
incapability of Treg to restore tolerance in T1D. A deeper understanding of Treg in health 
and disease is essential for successful use of immune-based therapies. 
The objective of my project is a better and more defined understanding of human 
Treg in the context of type 1 diabetes and immunotherapy in type 1 diabetes. 
Specifically, I will address:  
1. phenotypic heterogeneity of Treg and conventional T cells in healthy controls and T1D 
patients;  
2. gene expression profiles of Treg in patients with type 1 diabetes at onset by 
performing RNAseq; 
3. the identification of Treg and conventional T cell specific gene expression pattern of 
antigen-responsive cells;  
4. conversion of naïve T cells into induced Treg using tolerogenic DCs and characterize 
these iTreg by phenotyping and functional assays 
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3.1 Materials 
3.1.1 Chemicals and reagents 
Chemicals and reagents listed in table 3.1 were used for assays, buffer preparations 
and technical equipment: 
 
Table 3.1 Chemicals and reagents 
3 Materials and methods  
Chemical name Supplier 
1x PBS In house prepared by media kitchen, CRTD 
BD FACS™ Clean Solution BD Biosciences; San Jose, CA, USA 
BD FACS™ Rinse Solution BD Biosciences; San Jose, CA, USA 
Bovine serum albumin (BSA) Sigma-Aldrich, Inc., St. Louis, MO, USA 
ddH2O In house prepared by media kitchen, CRTD 
Diethylpyrocarbonate (DEPC) In house prepared by media kitchen, CRTD 
DMSO Sigma-Aldrich, Inc., St. Louis, MO, USA 
DNAZap™ Solutions Life Technologies, Carlsbad, CA, USA 
EDTA Sigma-Aldrich, Inc., St. Louis, MO, USA 
Ethanol Carl Roth GmbH + Co.KG, Karlsruhe, Germany 
Ethanol absolute Carl Roth GmbH + Co.KG, Karlsruhe, Germany 
Formalin (37%, acid free) Merck; Darmstadt, Germany 
Histopaque-1077 Hybri-Max Sigma-Aldrich, Inc., St. Louis, MO, USA 
Luminex® xMAP® sheath fluid Luminex Corp.; Austin, TX, USA 
Lymphocyte Separation Medium Lonza, Wakersville, MD, USA 
Nuclease-free water Qiagen; Hilden, Germany 
Phosphoric acid solution H3PO4, 85% Carl Roth GmbH + Co.KG, Karlsruhe, Germany 
Rapamycin Axxora Dtl., Lörrach, Germany 
RNaseZap® spray Ambion Inc.; Austin, TX, USA 
Sodium azide Sigma-Aldrich, Inc., St. Louis, MO, USA 
Sulforic acid, 2N H2SO4 Carl Roth GmbH + Co.KG, Karlsruhe, Germany 
Trichlormethan/Chloroform, >99%, p.a. Carl Roth GmbH + Co.KG, Karlsruhe, Germany 
Tris base Carl Roth GmbH + Co.KG, Karlsruhe, Germany 
Trypan blue stain GIBCO®, Invitrogen Ltd., Paisley, UK 
Tween 20 Sigma-Aldrich, Inc., St. Louis, MO, USA 
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3.1.2 Buffers 
Buffers were prepared for cell culture, flow cytometric use and ELISA procedures 
and were not part of commercial kits. All recipes are listed in table 3.2. 
 
Table 3.2 Buffers and their compositions 
Buffer name Composition 
FACS buffer 0.1% BSA; 0.01% sodium azide in 1x PBS 
MACS buffer 0.5% BSA ; 2 mM EDTA in 1x PBS 
PBST wash buffer 0.05% Tween 20 in 1x PBS 
FACS sort buffer 1% human serum in 1x PBS 
Coating buffer 4% BSA in 1x PBS 
 
3.1.3 Media and supplements 
Table 3.3 lists cell culture media and bovine and human sera used in this study. Sera 
stocks were heat inactivated in a water bath at 56°C for 30 min. Heat inactivated human 
serum was subsequently filtered through a 0.45 µm steriflip filter (Millipore) to remove 
protein aggregates. Aliquots were stored at -20°C. When thawed, they were kept at 4°C 
and used for up to 4 weeks. Freshly prepared culture media were filtered through a 0.22 
µm steritop filter (Millipore). Media were kept in the fridge and used within one month of 
preparation. 
 
Table 3.3 Media and supplements 
Name  Manufacturer 
DMEM 4,5g/l glucose w/o L-Glutamine Lonza; Verviers, Belgium 
X-VIVO 15 Lonza; Verviers, Belgium 
RPMI 1640 medium, no glutamine Life Technologies, Carlsbad, CA, USA 
CellGro DC Dendritic Cell Medium CellGenix GmbH, Freiburg, Germany 
Fetal bovine serum (FBS) Invitrogen Ltd., Paisley, UK 
Human AB serum (HS) PAA Laboratories GmbH; Pasching, 
Austria 
L-Glutamine 200 mM (L-Glu) Lonza; Verviers, Belgium 
Penicillin - Streptomycin (P/S) Lonza; Verviers, Belgium 
 
When using RPMI for cell culture assays, the medium was supplemented with 5% HS, 
1% L-Glu and 1% P/S. X-VIVO was used for Treg assays with an addition of 10% HS. 
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3.1.4 Human samples 
Buffy coat preparations from adult peripheral blood were obtained from the Deutsche 
Rote Kreuz (DRK; Blutspendedienst Ost GmbH Dresden, Germany) as a side product of 
a 400 – 500 ml blood donation for clinical erythrocyte isolation. Use of the buffy coat was 
approved by ethic committee and informed consent of the donors (EK240062016). 
Blood samples from the T1D patients and healthy controls were obtained as Li-Heparin 
or CPT venipuncture samples through collaboration with the central laboratory of the 
Institute of Diabetes Research, Helmholtz Center, Munich, Germany. PBMC were 
isolated by ficoll based density gradient centrifugation, frozen in FBS with 10 % DMSO 
and stored in liquid nitrogen. Samples from patients with recent onset T1D, who are 
registered within 6 months of diagnosis, were obtained from the DiMelli study (Thumer, 
et al., 2010; Warncke, et al., 2013). Patients were aged 7.9 to 10.3 years. Age-matched 
samples of islet autoantibody positive (aAb+) children and healthy controls (islet 
autoantibody negative) were received from the TEENDIAB study (Ziegler, et al., 2012) 
(Table 3.4). Samples were collected with informed consent as part of studies that were 
approved by the ethical committees of the Technische Universität München (No. 
2149/08) or Bavaria, Germany (Bayerische Landesaerztekammer, Nr.08043). Gene 
expression profiling was performed on samples from the intranasal insulin trial (INIT II), 
which studies the immunomodulatory effect of intranasal insulin application in children 
with multiple autoantibodies (Harrison et al., 2004). 
 
Table 3.4 Study cohorts for flow cytometric phenotyping 
 
 
 
 
 Test set Validation set 
 
Healthy 
controls 
Recent 
onset T1D 
Healthy 
controls 
Auto 
antibody 
positive 
Recent 
onset T1D 
study TEENDIAB DiMelli TEENDIAB TEENDIAB DiMelli 
Average age 
(SD) years 9.4 (± 0.98) 9.1 (± 1.2) 11.1 (± 1.1) 10.3 (± 2.1) 10.1(±1.05) 
n total (n girls) 44 (23) 36 (19) 20 (7) 15 (10) 18 (9) 
Days after 
T1D diagnosis / 10.4 (±7.3) / / 10.9 (±6.5) 
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3.1.5 Cytokines and cell stimuli 
All recombinant human cytokines used in table 3.4 were of cell culture grade. If not 
indicated differently, working aliquots of cytokines and other cell culture stimuli were 
stored at -80°C in PBS supplemented with 0.1% BSA as carrier. Dexamethasone and 
Vitamin D3 were stored at -20°C. 
 
Table 3.5 Cytokines and cell culture stimuli 
Cytokine Manufacturer 
recombinant human IL-2 (1 mg) Life Technologies, Frederick, MD, USA 
recombinant human IL-4 (50 µg) R&D Systems; Minneapolis, MN, USA 
recombinant human IL-7 (25 µg) R&D Systems; Minneapolis, MN, USA 
recombinant human IL-15 (50 µg) R&D Systems; Minneapolis, MN, USA 
recombinant human GM-CSF (50 µg) R&D Systems; Minneapolis, MN, USA 
Dexamethasone (100 mg) Sigma-Aldrich, Inc., St. Louis, MO, USA 
1α,25-Dihydroxyvitamin D3 (10 µg) Sigma-Aldrich, Inc., St. Louis, MO, USA 
LPS (1 mg) Sigma-Aldrich, Inc., St. Louis, MO, USA 
 
I used commercially available αCD3/αCD28 antibody coated beads for the polyclonal 
expansion of T cells. Various antigen-specific cell stimuli were included in 5-day T cell 
assays to obtain antigen-specific T cell responses (table 3.6).  
 
Table 3.6 Unspecific and antigen-specific cell stimuli 
 
Name Catalog 
number 
Manufacturer 
Unspecific cell stimulus 
Dynabeads® Human T-
Activator CD3/CD28 
111-31D Invitrogen; Oslo, Norway 
Antigen-specific cell stimuli 
Tetanus Toxoid zur 
Injektion 
02/232 Andreae Noris Zahn-AG, Ottendorf-
Okrilla, Germany 
Begripal 2014/2015 
Influenza-Impfstoff 
PZN 
10538278 
Novartis Vaccines and Diagnostics 
GmbH, Marburg, Germany 
Tcell GAD (rhGAD65) 10-65702-16-
01 
Diamyd Medical AB, Stockholm, 
Sweden 
Human proinsulin - Eli Lilly and Co., Indianapolis, IN, USA 
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3.1.6 Antibodies 
Fluorescently conjugated monoclonal antibodies are listed in table 3.7 with their 
clones and respective suppliers. 
 
Table 3.7 Fluorescently conjugated antibodies 
Antigen Conjugate Clone Supplier 
Conjugated antibodies - surface markers 
CCR7 BV711 3D12 BD Pharmingen™; San Diego, CA, USA 
CD11c AlexaFluor® 700 3.9 eBioscience; San Diego, CA, USA 
CD127 eFluor® 450 eBioRDR5 eBioscience; San Diego, CA, USA 
CD14 FITC M5E2 BD Pharmingen™; San Diego, CA, USA 
CD154 PE TRAP1 BD Pharmingen™; San Diego, CA, USA 
CD19 APC 5J25C1 BD Pharmingen™; San Diego, CA, USA 
CD1a AlexaFluor® 647 HI149 eBioscience; San Diego, CA, USA 
Biolegend; San Diego, CA, USA 
CD25 PE 
PerCP-Cy5.5 
M-A251 BD Pharmingen™; San Diego, CA, USA 
BD Pharmingen™; San Diego, CA, USA 
CD3 APC 
APC-Cy7 
UCHT1 BD Pharmingen™; San Diego, CA, USA 
BD Pharmingen™; San Diego, CA, USA 
CD31 PE WM59 BD Pharmingen™; San Diego, CA, USA 
CD4 APC, PerCP 
PacificBlue 
Horizon V450 
AlexaFluor® 700 
SK3 
RPA-T4 
 
OKT4 
BD Pharmingen™; San Diego, CA, USA 
BD Pharmingen™; San Diego, CA, USA 
BD Pharmingen™; San Diego, CA, USA 
eBioscience; San Diego, CA, USA 
CD40 eFluor®450 5C3 eBioscience; San Diego, CA, USA 
CD45RA APC 
FITC 
APC-H7 
HI100 BD Pharmingen™; San Diego, CA, USA 
BD Pharmingen™; San Diego, CA, USA 
BD Pharmingen™; San Diego, CA, USA 
CD45RO APC 
PE-Cy7 
UCHL1 BD Pharmingen™; San Diego, CA, USA 
BD Pharmingen™; San Diego, CA, USA 
CD62L eFluor®605 DREG-56 eBioscience; San Diego, CA, USA 
CD69 FITC 
BV650 
L78 
FN50 
BD Pharmingen™; San Diego, CA, USA 
eBioscience; San Diego, CA, USA 
CD8 APC-H7 SK1 BD Pharmingen™; San Diego, CA, USA 
CD80 PE-Cy7 L307.4 BD Pharmingen™; San Diego, CA, USA 
CD86 PerCP- IT2.2 eBioscience; San Diego, CA, USA 
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Antigen Conjugate Clone Supplier 
eFluor®710 
HLA-DR APC-H7 G46-6 BD Pharmingen™; San Diego, CA, USA 
ICOS FITC C398.4A Biolegend; San Diego, CA, USA 
PDL-1 PE MIH1 eBioscience; San Diego, CA, USA 
TGFβ-LAP PE TW4-2F8 eBioscience; San Diego, CA, USA 
Antibodies used for intracellular staining 
CTLA-4 PE-Cy5 BNI3 BD Pharmingen™; San Diego, CA, USA 
FOXP3 AlexaFluor® 488 
PE-Cy7 
259D 
PCH101 
Biolegend; San Diego, CA, USA 
eBioscience; San Diego, CA, USA 
Granzyme B APC GB11 Biolegend; San Diego, CA, USA 
HELIOS APC 22F6 Biolegend; San Diego, CA, USA 
Ki-67 BUV395 B56 BD Pharmingen™; San Diego, CA, USA 
 
3.1.7 Cell dyes 
Proliferation tracking cell dyes and cell viability dyes used in this study are listed in 
table 3.8. 
 
Table 3.8 Cell dyes: proliferation tracking and cell viability 
Name of dye Supplier Purpose of use 
Carboxyfluorescein diacetate, 
succinimidyl ester (CellTrace™ 
CFSE) 
Molecular Probes, Invitrogen; 
Darmstadt, Germany 
Proliferation 
studies and cell 
tracking 
Cell Proliferation Dye eFluor®670 eBioscience; San Diego, CA, 
USA 
Proliferation 
studies and cell 
tracking 
Cell Proliferation Dye eFluor®450 eBioscience; San Diego, CA, 
USA 
Proliferation 
studies and cell 
tracking 
7-Amino-Actinomycin D (7-AAD) BD Pharmingen™; San 
Diego, CA, USA 
Dead cell exclusion 
Fixable Viability Dye eFluor®506 eBioscience; San Diego, CA, 
USA 
Dead cell exclusion 
Fixable Viability Dye eFluor®780 eBioscience; San Diego, CA, 
USA 
Dead cell exclusion 
 
Materials 
 
39 
 
3.1.8 Kits 
All commercially available kits used for molecular and cell biology methods are listed 
in table 3.9. 
 
Table 3.9 Commercial Kits 
Name Catalog 
number 
Manufacturer 
Molecular biology 
QiAamp DNA Blood Mini Kit  51104 Qiagen; Hilden, Germany 
miRNeasy Micro Kit 217084 Qiagen; Hilden, Germany 
Agilent RNA 6000 Pico Kit 5067-1513   Agilent Technologies, Santa Clara, CA, USA 
Cell biology – cell separation 
Dead Cell Removal Kit 130-090-101 Miltenyi; Bergisch-Gladbach, Germany 
CD4+ T Cell Isolation Kit II, 
human 
130-096-533 Miltenyi; Bergisch-Gladbach, Germany 
CD4 MicroBeads, human 130-045-101 Miltenyi; Bergisch-Gladbach, Germany 
Naive CD4+ T Cell Isolation 
Kit II, human 
 
130-094-131 Miltenyi; Bergisch-Gladbach, Germany 
CD25 MicroBeads II, 
human 
130-092-983 Miltenyi; Bergisch-Gladbach, Germany 
CD14 Monocyte isolation 
kit II, human 
130-091-153 Miltenyi; Bergisch-Gladbach, Germany 
Cell biology – cell staining and analysis 
Foxp3 / Transcription 
Factor Staining Buffer Set 
00-5523-00 eBioscience; San Diego, CA USA 
FOXP3 Fix/Perm Buffer 
Set 
421403 BioLegend; San Diego, CA USA 
BD™CompBeads Anti-
Mouse Ig,κ/Negative 
Control Compensation 
Particles Set 
552843 BD Biosciences; San Jose, CA, USA 
OneComp Beads 01-1111-42 eBioscience; San Diego, CA USA  
MILLIPLEXMAP Human 
Cytokine/Chemokine 
Panel 
MPXHCYTO-
60K-08 
Millipore; Billerica, MA, USA 
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Name Catalog 
number 
Manufacturer 
Human IL-10 ELISA 
Ready-SET-Go!® 
88-7106 eBioscience; San Diego, CA USA 
Human IL-12 p70 ELISA 
Ready-SET-Go!® 
88-7121 eBioscience; San Diego, CA USA 
Human IL-2 ELISA MAX 
deluxe sets 
431804 BioLegend; San Diego, CA USA 
 
3.1.9 Consumables 
The following consumables were used in this study (table 310). 
 
Table 3.10 Consumables 
Name Specification Supplier 
Pipette tips For pipettors 
ART® Aerosol resistent 
VWR Int.GmbH; 
Darmstadt, Germany 
Molecular BioProducts, 
Inc.; San Diego, CA USA 
Tips for Multipette 2.5 ml, 5 ml Combitips® plus Eppendorf AG, Hamburg, 
Germany 
Serological pipettes Cellstar®, 5 ml and 25 ml Greiner bio-one 
GmbH;Frickenhausen, 
Germany 
Pasteur pipettes 3 ml VWR, Darmstadt, Germany 
PCR tubes 0.2 ml VWR, Darmstadt; Germany 
Safelock reaction tubes 0.5 ml, 1.5 ml, 2.0 ml  Eppendorf AG, Hamburg, 
Germany 
Cryotubes Cryo.s™, 2.0 ml Greiner bio-one GmbH; 
Frickenhausen, Germany 
Conical tubes 15, 50 ml Greiner bio-one GmbH; 
Frickenhausen, Germany 
Bottle top filters Bottle top vacuum filters, PES 
Membrane 0.22 µm 
Millipore; Billerica, MA, 
USA 
Flip filters Steriflip® filter units 0.22 µm and 
20 µm PES 
Millipore; Billerica, MA, 
USA 
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Name Specification Supplier 
Cell strainers Falcon™ Cell Strainers, 40 µm 
nylon 
BD Biosciences Discovery; 
Labware, Bedford MA USA 
MACS column filters Pre-separation filters, 30 µm Miltenyi Biotech; Bergisch-
Gladbach, Germany 
MACS columns MS columns 
LS columns 
Miltenyi Biotech; Bergisch-
Gladbach, Germany 
FACS tubes BD Falcon™ Polystyrene round 
bottom tubes 5 ml 
Tube 4.5 ml, 75x12mm, conical 
base, PS  
BD Biosciences Discovery; 
Labware, Bedford MA USA 
Sarstedt, Wedel, Germany 
FACS tube filter caps Cell strainer cap BD Biosciences Discovery; 
Labware, Bedford MA USA 
Cell culture plates Nunclon™ 96, 24, 12 and 6 well Nunc, Thermo Fisher 
Scientific; Roskilde, 
Denmark 
Cell culture plates Costar® 48 wells Corning Inc., Corning, NY 
USA 
Cell culture flasks Nunclon™ 25 cm² Nunc, Thermo Fisher 
Scientific, Roskilde, 
Denmark 
96 well plate seals Adhesive PCR sealing sheets Thermo Fisher Scientific; 
Hudson, NH, USA 
 
3.1.10 Technical equipment 
The technical equipment used in this study is listed in table 3.11. 
 
Table 3.11 Technical equipment 
Device Name Manufacturer 
2-1000 µl Pipettes Research® Eppendorf; Hamburg, 
Germany 
Electronic dispenser Multipette® Xstream Eppendorf; Hamburg, 
Germany 
Pipetter CellMate® II Serological 
pipette 
Matrix, Thermo Fisher 
Scientific; Hudson, NH, USA 
Spectrophotometer NanoDrop ND 1000 Peqlab Biotechnologie GmbH; 
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Device Name Manufacturer 
 
Tecan Infinite® 200 PRO 
 
Erlangen, Germany 
Tecan Group Ltd., Männedorf, 
Switzerland 
Bioanalyzer Agilent 2100 Bioanalyzer Agilent Technologies, Santa 
Clara, CA, USA 
Heating block Thermomixer compact Eppendorf; Hamburg, 
Germany 
Micro centrifuge (fixed 
angle rotor) 
5415R MiniSpin plus Eppendorf AG; Hamburg, 
Germany 
Centrifuge (molecular 
biology, fixed angle 
rotor) 
Centrifuge 5415 R Eppendorf AG; Hamburg, 
Germany 
Centrifuge (cell culture, 
swing-out rotor) 
Allegra® X-15R/-12R Beckman Coulter, Inc., 
Fullerton, CA,  USA 
Waterbath AL12 LAUDA DR. R. WOBSER 
GmbH & Co. KG; Lauda-
Königshofen, Germany 
Incubator CB 210 Binder GmbH; Tuttlingen, 
Germany 
Inverse microscope CKX41 Olympus GmbH; Hamburg, 
Germany 
Vacuum manifold for 
filter plates 
MultiScreenHTS Vacuum 
Manifold 
Millipore; Billerica, MA, USA 
Plate shaker Titer Plate Shaker Barnstedt; Thermo Fisher 
Scientific; Hudson, NH, USA 
Luminex Luminex® 200™ System Luminex Corp.; Austin, TX, 
USA 
MACS magnets and 
stands 
MiniMACS Separator 
QuadroMACS™ Seperator 
Miltenyi Biotech; Bergisch-
Gladbach, Germany 
Flow Cytometer LSR II BD Biosciences; San Jose, 
CA, USA 
Cell sorter ARIA II, ARIA III BD Biosciences; San Jose, 
CA, USA 
Single cell profiling Biomark™ HD  
C1 
Fluidigm, South San 
Francisco, CA, USA 
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3.1.11 Software 
For data acquisition during flow cytometry and cell sorting, the FACS Diva software 
version 8.0.1 (BD Biosciences; San Jose, CA, USA) was used. Data analysis was 
performed using the FlowJo software version 7.6.5 and vX.0.7 (TreeStrar Inc., Ashland, 
OR, USA).The spectrophotometer Tecan Infinite 200 Pro was run with Tecan i-control 
v.1.10.4.0 to measure ELISA plates. The Luminex machine was equipped with 
xPONENT® 2.0 software (Luminex Corp.; Austin, TX, USA). RNA concentrations were 
measured with the 2100 Expert software for the Agilent 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA, USA). General calculations were done in Microsoft 
Office Excel 2007 and 2010 (Microsoft Corp.; Redmond, WA, USA). Graphs and 
statistics were created using GraphPad Prism® 5.04 (GraphPad Software Inc.: La Jolla, 
CA, USA), KNIME version 2.10.3 (KNIME, Zurich, Switzerland) or the R 3.1.0 software 
(R Foundation, Vienna, Austria). 
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3.2 Methods 
3.2.1 Isolation of peripheral blood mononuclear cells 
We obtained human samples from healthy blood donors as buffy coats from the DRK 
(Deutsches Rotes Kreuz) for the isolation of peripheral blood mononuclear cells (PBMC). 
The PBMC were separated from serum and residual erythrocytes by density gradient 
centrifugation. Buffy coat 10 ml was mixed with 25 ml of PBS in a 50 ml tube and 
overlaid on histopaque. The density gradient centrifugation was performed at 600 g for 
25 min at room temperature (RT) with acceleration set to 5 and deceleration turned off. 
The separated white PBMC layer was transferred with a Pasteur pipette into a fresh 50 
ml conical tube, combining two PBMC layers into each tube. PBMC were washed twice 
with PBS. Centrifugation was performed at 300 g for 15 min and 10 min, respectively. 
The acceleration was set to 10 and the deceleration was increased from 5 to 8 with each 
washing step. After centrifugation, the PBMC of all tubes were combined and the tube 
was filled up to 50 ml for counting of the cells.  
 
3.2.2 Cell counting 
Cells were counted with a hemocytometer. The counting chamber consists of four 
large quadrants each containing 16 small quadrants. For counting, the cells were first 
diluted with PBS, at different ratios depending on the respective cell concentration, and 
then stained with Trypan blue in 1:2 ratio to discriminate live cells from dead. 10 µl of the 
cell-dye mix was used for the hemocytometer. The cells were counted under an inverted 
light microscope by counting the four large quadrants. The cell count/ml was determined 
by using the following equation: 
total nr. of viable cellsViable cells / ml= dilution factor  10,000
nr. of quadrants counted
 
  
 
 
 
3.2.3 Cryopreservation and thawing of cells 
Cells were cryopreserved in fetal bovine serum (FBS) containing a final 
concentration of 10% DMSO. The desired number of cells was centrifuged at 300 g for 
10 min at 4°C. The supernatant was aspirated and the cells were resuspended in an 
appropriate amount of cold FBS. An equal volume of cold freezing medium (20 % DMSO 
in FBS) was added. Cells were placed in cold cryotubes at 1-50x106 cells/ ml. The vials 
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were slowly frozen in a controlled-rate automated freezing device to -80°C and finally 
stored in liquid nitrogen.  
When cryopreserved cells were used for experiments, the vials were warmed up in a 
37°C water bath until cell suspensions were mostly thawed. Prewarmed Dulbecco’s 
Modified Eagle Medium (DMEM) with 4.5 g/l glucose was added dropwise to each vial 
and the cells transferred to a 15 ml conical tube. Another 9 ml of DMEM were gradually 
added. In certain cases 25 U/ml benzonase was added to avoid cell aggregation. The 
suspension was centrifuged at 300 x g for 10 min at RT. The supernatant was aspirated 
and the cell pellet was resuspended in fresh DMEM medium for culture or in PBS when 
the cells were subsequently analysed by flow cytometry or stained with a cell dye. After 
another washing step, the cells were resuspended in the corresponding medium, 
counted and further processed according to the experimental guidelines. 
 
3.2.4 Flow cytometry 
Flow cytometry enables the detection of single cells based on their size, granularity 
and fluorescence. Cell characteristics can be made visible by the binding of 
fluorochrome conjugated antibodies to extra- and intracellular proteins. The cell 
suspension is introduced and cells are separated by a hydrodynamically focused fluid 
stream. The stream is directed through a flow cell where a laser beam interrogates each 
cell individually. The emitted light is detected by a forward scatter (FSC) and side scatter 
(SSC) detector giving information about size and granularity of each cell. Different lasers 
are able to excite several different fluorochromes conjugated to the antibodies. 
Fluorochrome light emission is specified by optical filters and their detectors (PMT). 
Here, a LSRII from BD was used with a laser setting of 488 nm, 633 nm, 405 nm and 
355 nm enabling the detection of up to 17 fluorochromes. The exact cytometer 
configuration is listed in Appendix table 3.1. 
 
Extracellular staining 
Before flow cytometric analysis cells were stained with fluorochrome conjugated 
antibodies. For the extracellular staining 0.2 - 0.5x106 cells were needed. If intracellular 
staining followed the cell number was increased to 0.5 – 2x106. Cells were transferred to 
a FACS tube, U-bottom or V-bottom tube, and 2 ml of FACS buffer was added. The cells 
were centrifuged at 300 g for 10 min at 4°C (standard centrifugation) and the supernatant 
was decanted or aspirated. The antibodies were added to the dissociated cell pellet in an 
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adequate amount, 3-5 µl per 100 µl staining volume. The cells were then vortexed and 
incubated for 25 min on ice. When CCR7 antibody was used, the cells were 
preincubated with the antibody before adding the other extracellular antibodies. Here, the 
CCR7 antibody was added, the cells were vortexed and incubated at 37°C for 10 min. 
This procedure ensured a better measurement of CCR7 due to the reduction of receptor 
internalization during the staining process on ice. After extracellular antibody incubation, 
2 ml of cold FACS buffer was added and cells were centrifuged at 300 g for 10 min at 
4°C. Finally, the cells were resuspended in 200-350 µl FACS buffer for flow cytometric 
analysis. 
 
Viability dyes 
Viability dyes were used to discriminate dead cells from live cells during flow 
cytometric analysis. 7-AAD is a nucleic acid dye for the exclusion of dead cells, staining 
only cells with a disrupted cell membrane. The dye was added to the cells together with 
the extracellular antibodies and incubated for 25 min on ice. Excessive dye was washed 
out with FACS buffer to reduce the fluorescence background. 
A fixable viability dye was used when cells were further stained for intracellular 
proteins. The dye irreversibly labels dead cells prior to fixation and permeabilization 
without losing signal intensity. The staining with the dye was performed after the 
extracellular staining. The cells were washed with 2 ml PBS instead of FACS buffer and 
centrifuged at standard conditions. During centrifugation, the fixable viability dye was 
prepared with a dilution of 1 µl dye/ 1 ml PBS. 0.5ml of the diluted dye was added to 
each sample and the mixture was vortexed thoroughly before incubation for 30 min on 
ice. Excessive dye was washed out by adding 2 ml FACS buffer to the sample.  
 
Intracellular staining 
Intracellular staining was usually performed in V-bottom tubes to reduce cell loss 
during the staining procedure. For intracellular staining, the Foxp3/Transcription Factor 
Staining Buffer Set from eBioscience was used. The used 1x Fixation/Permeabilization 
working solution and 1x Permeabilization buffer were prepared according to the 
manufacturer’s instructions. After the extracellular staining, the supernatant was 
aspirated and the sample was pulse vortexed to completely dissociate the pellet. 1 ml of 
the 1x Fixation/Permeabilization working solution was added to the sample and mixed by 
vortexing. The cells were incubated in the dark for 45-60 min at RT. Next, 2 ml of 1x 
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Permeabilization Buffer was added to the sample without prior washing. Cells were 
centrifuged at 1,400 g for 5 min at RT and the supernatant was discarded. 2 - 5 µl of 
intracellular antibodies were added, the sample was vortexed and incubated in the dark 
for 30 min at RT. The sample was washed twice with 2 ml 1x Permeabilization Buffer 
and centrifuged at 1,400 g for 5 min at RT. The cells were resuspended in 200 – 350 µl 
before flow cytometric analysis. 
 
Compensation controls 
For the analysis of a multicolor antibody panel the used fluorochromes need to be 
compensated for their spectral overlap. Therefore, separate compensation controls with 
the used antibodies were prepared with either cells or compensation beads. 
Compensation beads are polystyrene microbeads coated with Anti-Mouse Ig, κ (BDTM 
compBeads) or are immunoglobulin light-chain-independent (OneComp eBeads). The 
compensation controls were prepared according to each manufacturer’s instructions. 
Cells were mainly used for viability dye compensation. Here, 0.4x106 were transferred to 
a 1.5 ml Eppendorf tube and heat shock treated for 10 min at 65°C in a heat block. The 
cells were rested on ice for 1 min and then mixed with the same number of viable cells in 
a FACS tube. Staining protocols were applied as described in the previous section. 
 
Flow cytometric analysis 
The flow cytometer instrument PMT voltage settings were first adjusted based on 
unstained cells. Then, a sample of beads was run to adjust FSC/SSC voltages for 
the visualization of the beads. Each compensation control was acquired to adjust the 
PMT voltages before recording the compensation controls. The compensation was 
calculated with an automatic compensation tool from the BD FACSDiva software. Last, 
experimental samples were acquired at a speed of 200-2000 events per second and 
recorded. Data was stored as 3.0 fcs-files for further analysis with FlowJo software. 
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3.2.5 Cell subset purification 
Magnetic activated cell sorting (MACS) 
The MACS® technique was used to isolate various cell subsets from PBMC with kits 
from Miltenyi Biotech (Materials table 3.9). Such subsets included CD4+ T cells, CD25+ 
cells or monocytes. First, cells were washed with cold MACS buffer and centrifuged at 
300 g for 10 min at 4°C. The protocol for cell isolation was followed according to the 
manufacturer’s instructions. The principle of MACS is based on magnetic bead 
conjugated antibodies that bind directly to the desired subset (positive selection) or to 
other subsets (negative selection). The magnetically labeled cells were then passed 
through a column that was placed into a strong magnet. The subset was either retained 
in the column (positive selection) or in the flow through (negative selection). Cell purity 
was validated by subsequent flow cytometric analysis using 0.2x106 cells for the 
analysis. The isolated cells were either directly used for experimental setups or 
cryopreserved.  
 
Fluorescence activated cell sorting (FACS) 
Cell subsets can be sorted to a very high purity after extracellular staining under non-
toxic conditions based on their fluorescent characteristics by FACS. For the sorting 
procedure, cells were washed with PBS containing 1 % HS instead of FACS buffer pre 
and post extracellular staining. Stained cells were resuspended in PBS with 1% human 
serum up to 1x107 cells / ml. Acquisition in a flow cytometer relies on a liquid stream 
which is disrupted into droplets containing single cells. The cells are given an electrical 
charge based on their individual fluorescent characteristics and are then electrically 
deflected into up to 4 populations which can be collected in different tubes. The tubes 
were precoated with PBS containing 4 % BSA to reduce sticking of sorted cells to the 
tube wall. Collection tubes were filled with 1-3 ml of PBS with 1 % HS. For single cell sort 
a 96 well plate was used which was preloaded with 5 µl DEPC PBS. Sort speed 
depended on the size of the to-be-sorted population and the sort layout. FACS was 
conducted using a BD FACS ARIA II or III cell sorter. Sorter configurations can be found 
in Appendix table 3.1. 
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3.2.6 Stimulation of cells 
αCD3/αCD28 T cell stimulation 
One way to activate and expand T cells is the utilization of αCD3/αCD28 Dynabeads 
(Invitrogen). The superparamagnetic beads are covalently coupled anti-CD3 and anti-
CD28 antibodies. The antibodies provide the primary and co-stimulatory signals for a 
sufficient T cell activation. 
The beads were used for whole PBMC, CD4+ T cell and Treg activation and 
expansion in common culture medium. Bead:cell ratio varied from 1:1 to 1:100 
depending on the individual experimental setup. The duration of bead stimulation varied 
from overnight (O/N) up to 14 days in a humidified CO2 incubator at 37°C. If necessary, 
the paramagnetic beads were removed using a strong magnet. A 5 ml FACS tube was 
placed into the magnet and the cell suspension containing the beads was carefully 
pipetted into the tube along the walls. After 5 min the cell suspension was removed with 
a pipette without touching the walls.  
 
Antigen specific T cell stimulation 
In general, non-self or autoantigens were added to whole PBMC and stimulation was 
performed for 5 days followed by FACS analysis of activation and proliferation of T cells. 
Tetanus toxoid and influenza antigens were used as non-self-antigens. Both were 
components of commercially available vaccines and chosen for their potentially high 
activation capacity of T cells in healthy populations, due to high vaccination status or 
infection rate, respectively. The used final dilution was 1 µl/ml. T1D specific auto-
antigens were GAD65 and PI that were used in assays with PBMC from T1D patients. 
The assay concentration was 10 µg/ml. 
In some experiments T cells were also stimulated with allogeneic dendritic cells. 
Here, T cells from one individual were combined with DCs from a second individual in a 
1:10 DC to T cell ratio.  
 
3.2.7 Measurement of cell proliferation 
Proliferation of cells can be visualized and measured by flow cytometry through the 
dilution of cytoplasmic cell dyes upon cell division. In this study, the cell dyes 
Carboxyfluorescein succinimidyl ester (CFSE, Invitrogen), eFluor®450 Proliferation Dye 
and eFluor®670 Proliferation Dye (eBioscience) were used.  
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CFSE staining 
First, cells were washed with sterile PBS at 300 g for 10 min at RT and resuspended 
in 37°C prewarmed sterile PBS at up to 5x106 cells per 500 µl. The same volume of PBS 
containing 2 µM CFSE was added to the cells for a final CFSE concentration of 1 µM. 
The cell-dye suspension was resuspended by pipetting followed by short vortexing and 
incubated for exactly 10 min at 37°C in the incubator. The staining reaction was stopped 
by adding 10 ml cold medium containing (RPMI + 5 % HS). The cells were washed twice 
with medium by centrifugation at 300 g for 10 min at 4°C. The cells were counted and 
plated according to the experimental setup. An aliquot of CFSE stained and unstained 
cells was additionally plated and used as unstained and CFSE compensation control for 
flow cytometry on the day of analysis. CFSE is excited by the 488 nm laser and shows a 
peak emission at 517 nm allowing detection with the same filter set (530/30) as the 
common fluorochrome FITC. 
 
eFluor®450 and 670 Proliferation Dye staining 
To stain cells with eFluor® Proliferation Dyes, cells were washed with sterile PBS at 
300 g for 10 min at RT and up to 10x106 cells were resuspended in 500 µl sterile PBS. 
Another 500 µl PBS containing 10 µM eFluor®670 Proliferation Dye or 20 µM eFluor®450 
Proliferation Dye was added while vortexing to a final dye concentration of 5 µM or 
10 µM, respectively. The cells were placed in the 37°C incubator for exactly 10 min. The 
staining was stopped by addition of 10 ml cold serum containing medium (RPMI + 5 % 
HS). The cells were washed three times with medium by centrifugation at 300 g for 10 
min at 4°C, counted and plated according to the experimental outline. Compensation 
controls were prepared on the day of assay setup and plated for the same incubation 
period as the samples. eFluor®670 Proliferation Dye shows a peak emission of 670 nm 
after excitation with a 633 nm laser and can thus be detected with a 660/20 band pass 
filter equivalent to the common fluorophore APC. Cell Proliferation Dye eFluor®450 
can be excited with a 405 nm laser and can be detected using a 450/50 band pass 
filter.  
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3.2.8 Differentiation of monocytes into DCs 
To differentiate monocytes into dendritic cells, the monocytes were first isolated from 
PBMC using the Monocyte Isolation Kit II (Miltenyi). Depending on the experimental 
outline, 100 – 200x106 PBMC were needed for the MACS isolation. Monocytes were 
counted and the purity of the isolated cells was analyzed by flow cytometry. If not all cells 
were needed for the experiment, they were cryopreserved. 
For differentiation, 1x106 monocytes were plated in 3 ml DC medium (CellGro DC 
Dendritic Cell Medium 3 % FBS +1 % L-Glu +1 % P/S) in a 6-well cell culture plate. The 
medium was supplemented with 50 ng/ml GM-CSF (stock 100 ng/ul) and 10 ng/ml IL-4 
(stock 10 ng/ul). The cells were incubated for six days at 37°C. After six days, the 
monocytes were differentiated into immature DCs and loosely attached to the culture 
surface. Cells were detached by pipetting up and down, and, if still firmly attached, by 
washing with PBS. Here, chilled PBS was used and cells were incubated on ice. 
Detachment of immature DCs was confirmed by light microscopy.  
For DC maturation with LPS, the cells were resuspended in 100 µl DC medium per 
0.1x106 cells and plated in 48-well tissue culture plates or, if higher volumes were used, 
in 24- or 12-well plates. 100 ng/ml LPS (stock 1 ug/ul) was added to each well and 
incubated O/N at 37°C. After DC maturation, cold PBS was added to each well and the 
plate was incubated on ice until cell visibly detached. The cells were washed twice with 
cold PBS to remove all remaining LPS. All centrifugation steps were performed at 300 g 
for 10 min at 4°C. After cell counting, DCs were plated at a 1:10 DC: T cell ratio in tissue 
culture plates with the respective culture medium e.g. X-VIVO + 10 % HS. 
 
Tolerogenic DCs 
Tolerogenic DCs are kept in a semimature state. The semimature state can be 
reached by the addition of different compounds during the differentiation process. Two of 
these compounds are 1α,25-Hydroxy Vitamin D3 (VD3), the active form of VD3 and the 
glucocorticoid Dexamethasone (Dex). The generation of tolerogenic T cells was adapted 
from the group of Bart Roep (Kleijwegt et al., 2010). Monocytes were treated with IL-4 
and GM-CSF as described in the previous section. In addition, a final concentration of 
either 10-8 M VD3 (stock 10-5 M) was added on day 0 and on day 3 or 10-6 M Dex (stock 
10-3 M) was added on day 3. Tolerogenic DCs with a combination of VD3 and Dex were 
generated as well. The immature DCs were activated with LPS on day 6 by an O/N 
incubation at 37°C 
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3.2.9 Generation of Treg 
Naive T cells were utilized with tolerogenic DCs with the intention to generate in vitro 
induced Treg (iTreg) (Kleijwegt et al., 2010; Unger et al., 2009). The generation takes 14 
days and includes two rounds of 5 day stimulation with tolerogenic DCs with interrupting 
2 day resting phases. All steps during the generation of iTreg are outlined in Figure 3.1. 
Here, 0.1x106 DCs were plated into 24-well plates in 200 µl X-VIVO + 10 % HS. 
Allogeneic naive CD4+ T cells were MACS isolated using the CD25 microbeads and 
subsequently applying the CD25- fraction on naive CD4+ T Cell Isolation Kit II (Miltenyi, 
Bergisch Gladbach, Germany) to remove all CD4- and CD45RO+ cells. 1x10x6/ ml (X-
VIVO + 10 % HS) naive T cells were added to each well containing the DCs (1:10) 
resulting in a total volume of 1.2 ml/well. The cells were incubated for 5 days at 37°C. All 
cells were collected in a tube and centrifuged at 300 g for 10 min at RT. The cells were 
resuspended in fresh medium supplemented with 5 ng/ml IL-7 and 2.5 ng/ml IL-15. The 
cells were plated into fresh 24 well plates at a density of 1x106 cells/ml. After 2 days, the 
cells were washed again and replated with the tolerogenic DCs at a 1:10 ratio. 
Stimulation with DCs for 5 days and with cytokines for 2 days was repeated. On day 14, 
iTreg were collected and prepared for functional assays. 
 
 
Figure 3.1 Schematic outline of in vitro generation of Treg by tolerogenic DCs. The protocol includes 
two consecutive rounds of T cell stimulation with dendritic cells for 5 days and resting with cytokines IL7 and 
IL-15 for 2 days. Phenotyping of T cells was performed on day 0, 5, 7, 12 and 14 while aliquots of culture 
supernatant were taken on day 1, 3, 5, 7, 10, 12 and 14. In addition single cell sort was performed on day 7 
and a functional suppression assay on day 14. The 14 day protocol was adapted from Unger et. al, 2009. 
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T cells were phenotyped by flow cytometric analysis on 0.3-0.5x106 cells at day 0, 5, 
7, 12, and 14. In addition, supernatants from the cell culture were collected on various 
days to analyze IL-2 concentration by ELISA. On day 7, T cells were stained and single 
cell sorted to analyze gene expression. Last, 0.3-1x106 T cells were set aside for DNA 
isolation and subsequent analysis of the FOXP3 Treg specific demethylated region 
(TSDR) status. 
 
3.2.10 Polyclonal expansion of Treg 
CD4+CD25hi Treg were MACS isolated with the CD4+ T Cell Isolation Kit II and 
subsequently CD25 MicroBeads II. Treg were plated in X-VIVO 15 + 10 % HS and 
activated with αCD3αCD28 beads at a cell to bead ratio of 1:1. On day 2 after isolation, 
Treg expansion was promoted by adding the same volume of medium supplemented 
with IL-2 to a final concentration of 300 U/ml and 100 ng/ml rapamycin until day 7 in the 
culture with fresh medium containing 300 U/ml IL-2 at day 10 and 12. Culture medium 
was exchanged every 2-3 days with fresh medium containing 300 U/ml IL-2 and cells 
were restimulated with αCD3αCD28 beads at day 10. An outline of the 14 day expansion 
protocol is shown in Figure 3.2. Cell densities and culture dishes used during expansion 
are listed in Table 3.12 (Putnam et al., 2009). 
 
 
Figure 3.2 Schematic outline of polyclonal Treg expansion. CD4+ CD25+ Treg were isolated by MACS 
and expanded for 14 days with αCD3/αCD28 beads and IL-2 under the selective pressure of rapamycin 
(symbols in figure, D=day). During the expansion an some cells were used for phenotyping, Demethylation 
analysis, single cell sort and suppression assays. The 14 days expansion protocol is based on and adapted 
from Putnam et al., 2009. 
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Table 3.12 Treg culturing cell size and vessel. Adapted from Putnam et al., 2009 
Cell number Vessel Media Volume 
800,000 6 well 4 ml 
1,200,000 Vertical T25 flask 6 ml 
2,400,000 Horizontal T25 flask 10 ml 
 
Also, MACS isolated CD4+CD25- conventional T cells (Tconv) were expanded for 14 
days with the addition of αCD3αCD28 beads at a bead to cell ratio of 1:10 on day 0, 7 
and day 10. Beads were removed by magnets on day 2 to rest the T cells. IL-2 and 
rapamycin was not added to the culture. Medium was exchanged every 2-3 days. 
In addition to the expansion of Treg and Tconv, flow cytometric phenotyping was 
performed as well as single cell FACS on day 7 and DNA isolation on day 12.  
 
3.2.11 Suppression assays 
Expanded Treg and generated iTreg were tested for their functionality using 
suppression assays. They assess the capacity of Treg to suppress responder T cells. I 
used two assays: a 5 day conventional suppression assay and a quick suppression 
assay. The first assay evaluates the proliferation of responder cells in presence of Treg 
after 5 days co-stimulation. A quick suppression assay determines the suppression of 
responder cell activation. 
 
5 day conventional suppression assay 
Autologous or Allogeneic CD4+CD25- responder cells were thawed on the day of the 
assay. 1x106 cells were set aside as unstained control, while the remainder was stained 
with proliferation dye eflour670. Treg were stained with CFSE or proliferation dye 
efluor450. The stained and unstained cells were resuspended in X-VIVO + 10 % HS at a 
concentration of 1x106 cells/ml. A 96-well U-bottom tissue culture plate was used for the 
assay. First, 0.1x106 responder cells per well were plated in duplicates. Then Treg were 
added in a 2 fold titration ranging from 1:1 to 1:32 Treg to responder cell ratio. As 
controls, responder only (0:1) and Treg only (1:0) were plated. αCD3αCD28 beads were 
used as activation stimulus in a 1:75 bead to total cell ratio. Two wells of the responder 
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only were left unstimulated as control. Medium was added to each well to a volume of 
250 µl and cell co-cultures in each well were mixed by pipetting. Last, unstained cells 
and proliferation dye stained cells were plated as compensation controls. The outer 
empty wells of the plate were filled with PBS to minimize evaporation. The plate was 
incubated for 5 days at 37°C. Flow cytometric staining was performed using antibodies 
against CD4 (FITC or PacificBlue) and CD25 (PE). 
 
Quick suppression assay 
The quick suppression assay is based on the expression of early activation markers 
CD69 and CD154 (Ruitenberg et al., 2011). Autologous or allogeneic PBMC were 
thawed one day prior to the assay and rested O/N in X-VIVO + 10 % HS. The following 
day, Treg were counted and adjusted to 1.5x106 cells/ml in X-VIVO + 10 % HS. PBMC 
were harvested, counted and resuspended at 3x106 cells/ml. The co-cultures were plated 
as duplicates into 96-well V-bottom plates. First, 0.3x106 Treg were plated and 1:2 
serially diluted with 100 µl prefilled medium down to a dilution for 1/32. Afterwards, all 
wells should contain 100 µl cell suspensions to which 0.3x106 PBMC were added. In 
addition, Treg only and PBMC only controls were plated with and without activation. 
Next, the activation cocktail was prepared based on a 1:4 αCD3αCD28 bead to PBMC 
ratio. Per well, the cocktail contained 1.875 µl beads with 5 µl αCD154-PE antibody in 
20 µl with PBS. The cocktail was added to all co-cultures. Only 5 µl αCD154-PE antibody 
was added to the unstimulated controls. Medium was added to 220 µl where needed and 
wells were mixed with a pipette. Last, the plate was centrifuged at 250 g for 3 min at RT 
and incubated for 7 h at 37°C.  
After incubation, the plate was covered with tin foil and placed at 4°C O/N for 
analysis the next day. Cells from each well were transferred to a separate FACS tube. 
Flow cytometric staining was performed using antibodies against CD3 (APC), CD4 
(PacificBlue), CD25 (PE-Cy7) and CD69 (FITC). The αCD154-PE antibody was still 
retained on the cell surface.  
 
3.2.12 Measurement of cytokines 
Cytokine release by T cells and dendritic cells was mainly measured by enzyme-
linked immunosorbent assay (ELISA). In principle, ELISA quantitatively detects proteins, 
e.g. from cell culture supernatant, by specific antibody binding. An enzyme-based color 
change reaction allows the readout of antigen concentration by spectrophotometry. 
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Cell culture supernatants were collected in 1.5 ml tubes and stored at -80°C until 
used for ELISA. IL-2 was detected with the Human IL-2 ELISA MAXTM Deluxe Set 
(Biolegend). IL-10 and IL-12p70 were detected with the respective ELISA Ready-SET-
Go! Kits (eBioscience). All assays were performed according to the manufacturer’s 
instructions. Samples for the IL-2 ELISA were applied undiluted while IL-10 and IL-12p70 
samples were diluted 1:10 with the respective diluent. PBS + 0.05 % Tween was used as 
wash buffer and washing steps were performed with a multichannel pipette and 
aspiration by vacuum. The enzymatic reaction was stopped with 1 M H2SO4 for IL-2 and 
1 M H3PO4 for IL-10 and IL-12p70. The assays were read within 30 min after adding the 
stopping solution using the Tecan Infinite 200 Pro spectrophotometer with Tecan i-
control, version 1.10.4.0 software. The absorbance was measured at 450 nm with a 
wavelength subtraction at 570 nm. 
In one case, cytokines were measured by Luminex xMAP® technology. Multiplex. 
Luminex is based on polystyrene microspheres that can be provided in shadings based 
on the mixture of two dyes the spheres are filled with. Each colour type of beads is 
coated with capture antibodies against a specific cytokine. Bound cytokines can be made 
flow cytometrically visible by a second step which includes a PE-conjugated antibody. In 
this way, the Luminex analyser detects the signals of each microsphere. In this study, a 
cytokine Milliplex kit from Millipore was used allowing the detection of IL-2, IL-4, IL-5, IL-
10, IL-17, TNFα and IFN-γ in culture supernatants. The procedure was performed by a 
technician according to the manufacturer’s instructions. 
 
3.2.13 Molecular biology 
Isolation and measurement of RNA 
T cells were sorted by FACS or MACS isolation for subsequent transcriptomic 
analysis by whole transcriptome shotgun sequencing (RNAseq). The miRNeasy Micro 
Kit from Qiagen was used for RNA isolation and manufacturer’s instructions were 
followed. Up to 1x106 sorted cells were transferred to 1.5 ml sterile RNase-free tubes 
and centrifuged at 300 g for 10 min. The cell pellet was dissociated in 700 µl Trizol and 
vortexed for 1 min to disrupt and homogenize the cells. The cell lysates were stored at -
80°C until processed for RNA isolation. To thaw the frozen homogenates, they were 
incubated at 37°C in a heating block. The Qiagen protocol was followed and the RNA 
was eluted with 14 µl RNase free water and stored at -80°C.  
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Analysis of RNA quantity as well as quality was performed with the 2100 Bioanalyzer 
from Agilent Technologies. The system is based on an in-chip electrophoresis giving 
information on RNA concentration and RNA integrity number (RIN). The Agilent 6000 
RNA Pico kit was used following manufacturer’s instructions to measure RNA 
concentrations as low as 50 pg/µl. A 1 µl RNA aliquot was diluted 1:10 or 1:50 in RNase 
free water, depending on the initial cell input.  
The RNA was prepared for RNAseq in two ways: One was at a concentration of 
12.5ng/µl in 20 µl used for direct RNAseq and the other at 2 ng/µl in 5 µl volume for pre-
amplification before RNAseq. Transcriptomic analysis was performed by the Deep 
Sequencing Facility of Dr. Andreas Dahl. Data analysis was conducted in cooperation 
with Mathias Lesche. 
 
Isolation of DNA 
Genomic DNA was isolated from in vitro expanded T cells to analyse the FOXP3 
TSDR demethylation status. Here, the protocol of the QIAmp DNA Blood Mini Kit from 
Qiagen was followed. A cell input of 0.3 to 1x106 cells was used for DNA purification. 
First, cells were collected in 1.5 ml tubes and supernatant was removed after 
centrifugation at 300 g for 5 min at RT. The samples were resuspended in 200 µl PBS for 
further processing. DNA was eluted in AE buffer in 50 – 100 µl depending on the initial 
cell input. DNA concentration and purity was measured with the NanoDrop 1000 
Photospectrometer, which analyzes 1 µl of sample without prior dilution.  
FOXP3 demethylation analysis is based on the TSDR analyzed region of 50 bp long 
eight consecutive CpG-sites (Baron, et al., 2007). The analysis was performed by Dr. 
Rainer Fürst (Helmholtz Zentrum München, Germany). 500 ng DNA at a minimum 
concentration of 25 ng/µl were sent on dry ice. The method used for analysis was 
pyrosequencing. For this, the DNA was bisulfite-converted using the Zymo EZ DNA 
Methylation GOLD kit. Pryrosequencing was performed with 20 ng bcDNA in 4 µl. Data 
was presented as the percentage of methylation of each CpG-site.  
 
Single cell gene expression profiling 
Single cells were stored at -80°C for the purpose of gene expression profiling 
(Bonifacio et al., 2015; Eugster, et al., 2013). All following methods were performed by 
from the Single Cell Facility (Anne Eugster, CRTD, Dresden, Germany). Target genes 
and primers used for profiling are listed in Appendix 7.1.2. 
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In brief, cDNA was synthesized from cells using qScript™ cDNA Supermix (Quanta 
Biosciences, Gaithersburg, MD). Total cDNA was preamplified with the TATAA 
GrandMaster Mix (TATAA Biocenter, Göteborg, Sweden) in the presence of 48 primers 
followed by exonuclease I digestion (Thermo Fisher Scientific, Waltham, MA). 
Quantitative real-time PCR was performed using the BioMark™ HD System (Fluidigm 
Corporation, South San Francisco, CA) using the 96.96 Dynamic Array IFC. Raw data 
were analyzed using Fluidigm Real-Time PCR analysis software and GenEx Pro 5.3.6 
Software (MultiD, Göteborg, Sweden).  
 
3.2.14 Statistical analysis 
Data were analyzed with the Prism® 5.04 GraphPad Software. Results showing 
Gaussian normal distribution are reported as mean values with standard deviation (SD). 
P-values were determined by two-tailed paired or unpaired Student´s t test. Non-
Gaussian distributed results are represented as medians with interquartile range. P-
values were generated using the two-tailed Mann-Whitney U test in case of unpaired 
groups or the two-tailed Wilcoxon test in case of paired groups. 
Gene expression data was analyzed using KNIME 2.10.3 and R 3.1.0 software 
(Berthold, et al., 2009). Analysis of multivariate gene expression patterns was performed 
by t-distributed Stochastic Neighbor Embedding (t-SNE) on the pre-processed Ct values 
(van der Maaten and Hinton, 2008). For pre-processing, a linear model was used to 
correct for potential confounding effects, which can mask relevant biological variability. In 
brief, batch effects (dummy coding for each plate/batch) were modeled jointly with dose 
effects by regressing out the effect of plates on each individual gene while controlling for 
dose in order to obtain a corrected gene expression dataset (Buettner, et al., 2015). 
Further, the Hurdle model was applied for regression taking into account count data with 
overdispersion (McDavid, et al., 2014).  
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4.1 Heterogeneity of CD4+CD25+ T cells 
4.1.1 Using flow cytometry to marker phenotype CD4+T cells 
It is generally accepted that CD4+ T cells are a heterogeneous cell population 
comprised of multiple T helper subsets that are subdivided by their chemokine receptor 
expression and cytokine secretion profile, as well as regulatory T cells (Treg), which can 
be discriminated from conventional T cells (Tconv) based on CD25+ and CD127lo surface 
expression. 
In this study, I used a set of phenotypic markers that are expressed on CD4+ T cells 
to identify differences within the CD4+ T cell population that express CD25 with or without 
CD127. Further phenotypic markers used in this analysis were CD45RA, FOXP3, ICOS, 
HELIOS and TGFβ-LAP, which are markers that are used to distinguish memory and 
naive cells, and activated cells.  
A cohort of 44 healthy controls was selected for the phenotyping. PBMC were 
analyzed for lymphocytes with doublet exclusion and a live/dead marker as shown 
exemplarily in Figure 4.1A. CD4+ T cells were first categorized into three subpopulations: 
CD25-, CD25+CD127+ and CD25+CD127lo. The CD25- population represents the majority 
of peripheral blood CD4+ T cells (median, 87.8 %; IQR, 84.8 - 89.9 %), and the CD25+ 
population was further divided into CD25+CD127hi (median, 5.8 %; IQR, 4.1 – 8.6 %) and 
CD25+CD127lo (median, 6.6 %; IQR, 5.6 – 7.6 %; Figure 4.1B). 
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Figure 4.1 Flow cytometric gating strategy of CD4+ lymphocytes and major CD4+ 
subpopulations. (A) Representative sample gating on live single cell CD4+ lymphocytes by pseudocolour 
dot plots and histogram (live/dead). (B) Further discrimination of CD4+ lymphocytes based on their CD25 
and CD127 expression (left dot plot), dividing the CD4+ lymphocytes into three subpopulations: CD25-
CD127+/-, CD25+CD127+ and CD25+CD127lo. Right graph shows the frequency distribution of CD25+, 
CD25+CD127+ and CD25+CD127lo against total CD4 in 44 healthy controls. Each point represents one 
individual, median values and IQR are shown as boxplots with min to max values.  
 
For further characterization of the populations I used the transcription factor FOXP3, 
which is known to be constitutively expressed by Treg and transiently expressed in 
activated Tconv. Among the three major subsets CD25+CD127lo showed the highest 
frequency of FOXP3+ cells with 70 % of CD4+CD25+CD127lo T cells positive for FOXP3, 
representing 4.5 % (IQR, 3.4 – 5.7 %) of total CD4 (Figure 4.2A). FOXP3+ cells were a 
minority among the CD4+ CD25- and CD4+ CD25+CD127+ T cells, with a median of 1.6 % 
(IQR, 1.2 – 1.9 %) and 0.17 % (IQR, 0.12 – 0.31 %) of total CD4+ T cells, respectively 
(Figure 4.2A). For convenience, CD25-FOXP3- T cells are now referred to as resting T 
cells; CD25+CD127+FOXP3- as activated T cells, and the CD25+CD127loFOXP3+ 
population as Treg cells.  
The distribution of memory (CD45RA-) and naive (CD45RA+) among the three 
subpopulations varied considerably. The majority of resting T cells were naive CD45RA+ 
(median, 75.6 %; IQR, 69.7 – 79.3 %), the activated T cell population had relatively few 
CD45RA+ cells (median, 14.4 %; IQR, 8.8 – 18.0 %; p<0.0001) and the Treg cells were 
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intermediate in their positivity for CD45RA (median, 48.6 %; IQR, 36.6 – 53.9 %; 
p<0.0001 vs resting T cells and p<0.0001 vs activated T cells; Figure 4.2B).  
 
 
Figure 4.2 Phenotypic heterogeneity of FOXP3 and CD45RA expression among three CD4+ 
subpopulations. (A) Frequency of FOXP3- and FOXP3+ cells among total CD4 across the three CD4+ 
subpopulations CD25-, CD25+CD127+ and CD25+CD127lo. (B) Naïve T cell (CD45RA) composition of resting 
(CD25-FOXP3-), activated (CD25+CD127+FOXP3-) and Treg (CD25+CD127-FOXP3+). Upper dot plot 
represents exemplary gating strategy on CD45RA+ T cells. Data set of 44 healthy controls. Each point 
represents one individual, median values and IQR are shown as boxplots with min to max values. Statistical 
analysis was performed using the Wilcoxon matched-pairs signed-rank test, significance with a p-
value<0.0001 (***). 
 
Several markers have been described to be present on subpopulations of Treg 
and/or activated T cells, including HELIOS, ICOS and TGFβ-LAP. Here, I report the ex 
vivo heterogenic expression of the phenotyping markers among the three T cell 
populations (Figure 4.3). The transcription factor HELIOS was expressed in the majority 
(>90%) of naive and memory Treg cells, whereas it was expressed in few (<6 %) 
activated (p<0.0001) and resting (p<0.0001) T cells (Figure 4.3A). ICOS was detected on 
memory T cells and was rare in naive T cells (Figure 4.1.3B), and within the memory T 
cells was detected on: 11.5 % (IQR, 9.4 – 14.9 %) of resting T cells, 6.3 % (IQR, 5.2 – 
9.9 %) of the activated T cells and 32.2 % (IQR 26.1 – 40.3 %) on Treg (p<0.0001 vs 
resting T cells and p<0.0001 vs activated T cells). Membrane bound TGF-β LAP was, 
overall, infrequently expressed, with the most frequent expression on memory Treg cells 
(median, 2.2 %; IQR, 1.5 – 3.6 %; p<0.0001 vs resting T cells and p<0.0001 vs activated 
T cells Figure 4.3C).  
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Figure 4.3 Heterogeneity of CD4+ subpopulations based on the expression of (A) HELIOS, (B) 
ICOS and (C) TGFβ-LAP. Resting (CD25-FOXP3-) T cells, activated (CD25+CD127+FOXP3-) T cells and 
Treg (CD25+CD127loFOXP3+) were divided into naïve (CD45RA+, orange gate) and memory (CD45RA-, blue 
gate) subpopulations with the respective markers as depicted in the gating strategy of the dot plots. 
Expression was analyzed for 44 healthy controls and plotted as frequency of cells expressing the marker 
from the respective parent population, each symbol represents one individual, median values and IQR are 
shown as boxplots with min to max values. Statistical analysis was performed using the Wilcoxon matched-
pairs signed-rank test, significance with a p-value<0.0001 (***).  
 
All three additional markers appeared suitable for describing different populations of 
Treg and other CD4+ T cell subsets as well as memory and naïve, and were further used 
to compare CD4+ subpopulations between healthy individuals and patients with T1D. 
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4.2 CD25+ T cells in relation to T1D  
The homoeostatic balance of conventional T cells and Treg is crucial for the immune 
system and is thought to be disturbed in autoimmune diseases, including type 1 
diabetes. However, the findings on Treg in T1D lack consistency. In, this study I wanted 
to identify phenotypic as well as transcriptomic changes of Treg from T1D patients 
compared to healthy controls (HC).  
 
4.2.1 Phenotypic changes in T1D 
I was able to show phenotypic heterogeneity among the CD4+ T cell populations. I 
then compared PBMC samples collected from 44 HC with those from 36 age-matched 
recent-onset T1D patients (samples collected on average 10.4 days after diagnosis, 
Table 3.4). 
 
4.2.1.1 Frequency of major Treg subsets from recent-onset T1D 
patients do not differ to healthy controls 
No difference in the frequency of Treg (CD4+CD25+CD127loFOXP3+) was observed 
between healthy individuals (median, 4.5 %; IQR, 3.4 – 5.7 %) and T1D patients 
(median, 4.4 %; IQR, 3.2 – 5.7 %, Figure 4.4). Further discrimination of naive Treg 
(CD45RA+) also showed no difference between the two cohorts, with a median of 2.1 % 
(IQR, 1.3 – 2.7 %) versus 2.05 % (IQR, 1.15 – 2.9 %) naive Treg of total CD4 in HC and 
T1D, respectively.  
 
Results 
 
66 
 
 
Figure 4.4 No difference detected in major Treg populations between healthy controls (HC) and 
recent-onset T1D patients. Gating of CD4+ lymphocytes on CD25+CD127lo and subsequently on FOXP3 to 
identify Treg are shown in the upper dot plots for a representative sample. The lower dot plot shows 
exemplary gating of naïve (CD45RA+) Treg. Treg percentage of total CD4+ lymphocytes (upper right graph) 
and naïve Treg of total CD4+ lymphocytes (lower right graph, log10 scale) is shown for 44 HC (filled circle) 
and 36 age-matched new-onset T1D patients (square), median values and IQR are shown as boxplots with 
min to max values. Statistical analysis was performed using the Mann-Whitney test; n.s.= no significance 
(p>0.01).  
 
The predominantly Treg marker, HELIOS, was examined for the Treg subpopulation 
(Figure 4.5A). No difference was observed in the frequency of HELIOS+ Treg between 
HC (median, 89.9 %; IQR, 87.5 – 92.5 %) and T1D (median, 91.5 %: IQR, 89.1 – 
94.3 %). ICOS was examined for the memory T cells (CD45RA-) (Figure 4.5B). Again, 
no differences were observed between HC (median, 32.2 %; IQR, 26.1 – 40.3 %) and 
T1D (median, 38.8 %; IQR, 28.3 – 53.2 %). Although no statistically significant 
differences were observed between the two cohorts, four T1D patients exhibited 
relatively high frequencies (>70 %) of ICOS+ Treg, which was not observed for the 
healthy cohort. 
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Figure 4.5 No difference detected between Treg subpopulations of HC and T1D recent-onset 
patients. Frequency of (A) HELIOS+ Treg among total Treg and (B) ICOS+ Treg among memory (CD45RA-) 
Treg shown for 44 HC (filled circle) and 36 age-matched recent-onset T1D patients (square), median values 
and IQR are shown as boxplots with min to max values. Statistical analysis was performed using the Mann-
Whitney test; no significance (p>0.05). 
 
4.2.1.2 TGFβ-LAP+ Treg in T1D patients 
The functional marker TGFβ-LAP (LAP) is an inactive TGF complex bound to the 
Treg cell surface and is directly correlated with the suppressive function of Treg (Chen et 
al., 2008; Edwards, et al., 2014). Ex-vivo detection of LAP was very low, as shown in 
Figure 4.6A, but could be increased upon Treg activation (data not shown). Fewer Treg 
from HC expressed LAP (median, 1.3 %; IQR, 0.8 – 2.2 %) than Treg from T1D patients 
(median, 2.2 %; IQR, 1.3 – 5.8 %; p<0.001). I also observed that the spread of Treg 
expressing LAP was much more prominent in T1D than HC, as was seen previously for 
ICOS.  
I further analyzed if there was a link between increased LAP expression and ICOS 
expression. I observed that, in contrast to LAP- memory and naïve T cells, the majority of 
LAP+ memory Treg were also ICOS+ (Figure 4.6B). In HC, 74.9 % (IQR 63.7 – 86.4 %) of 
LAP+ Treg were also ICOS+ and this Treg population (LAP+ICOS+) was significantly 
increased in T1D (median, 85.7 %; IQR, 76.0 – 90.5 %; p<0.01).  
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Figure 4.6 TGFβ-LAP frequency is significantly increased on Treg of T1D children and is 
associated with ICOS expression. (A) TGFβ-LAP+ cells within the Treg subpopulation are shown for a 
representative example in the dot plot and summarized in a graph as percentage of LAP+ among total Treg 
(log2 scale). (B) Association of LAP+ Treg with ICOS is shown as a dot plot overlay of LAP+ Treg (red) on 
total Treg (black) for ICOS and CD45RA expression. The frequency of LAP+ among ICOS+ Treg is 
summarized in a graph for 44 HC (filled circle) and 36 age matched recent-onset T1D patients (square); 
median values and IQR are shown as boxplots with min to max values. Statistical analysis was performed 
using the Mann-Whitney test; p<0.01 (*), p<0.001 (**) 
 
The results revealed that the overall cell counts as well as subpopulations of Treg 
are similar, but there may be a difference in the activation of Treg as identified by the 
increased expression of LAP. I, therefore, tested a validation cohort in order to confirm 
and extend these findings.  
 
4.2.1.3 Heterogeneity in activation of CD4+CD25-CD127+/lo T cells, 
CD4+CD25+CD127+ T cells and regulatory T cells 
The validation cohort consisted of 20 age-matched HC, 18 recent-onsetT1D patients 
and 15 Aab+ children (Table 3.4). Onset of T1D was similar to the original test set with 
an average blood drawing of 10.9 days after T1D was diagnosed. Several additional 
markers were included to analyze heterogeneity among the T cell populations and to 
identify possible changes in T1D Treg in the validation study. Maturation was detected 
by CD45RA and CCR7 to discriminate naive from central memory (CM) and effector 
memory (EM) T cells. ICOS, LAP and CD69 were used to identify activated T cells and 
intra-nuclear Ki-67 for proliferation.  
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Cells from healthy controls were examined first (Figure 4.7). Data analysis was 
performed on the three T cell populations: resting (CD4+CD25-CD127+/loFOXP3-), 
activated T cells (CD4+CD25+CD127+FOXP3-) and Treg (CD4+CD25+CD127-FOXP3+). 
Based on the expression of CD45RA and CCR7, three subpopulations were identified 
that reflect the different maturation states of the T cells: naive (CD45RA+CCR7+), CM 
(CD45RA-CCR7+) and EM (CD45RA-CCR7-). The majority of resting CD4+ T cells 
consisted of naive cells (median, 69.4 %; IQR, 64.7 – 75.5 %), while 28.1 % (IQR, 22.1 – 
48.2 %; p<0.0001) of activated T cells and 48.4 % (IQR, 37.3 – 57.2 %; p<0.0001 vs. 
activated T cells) of total Treg were naïve. The expression of CM among the three 
populations showed the overall lowest frequencies: median, 18.5 % (IQR, 15.2 – 21.4 %) 
of resting T cells, 19.5 % (IQR, 14.6 – 21.2 %) of Treg and 15.5 % (IQR, 12.9 – 19.1 %) 
of activated T cells (p<0.01 vs resting T cells and Treg). A more pronounced difference 
could be detected in the EM subset. Here, the EM subset was least frequent among 
resting T cells at 9.3 % (IQR, 5.9 - 13.9 %); compared to 29.6 % for Treg (IQR, 19.1 – 
36.3 %; p<0.0001) and 50.0 % for activated T cells (IQR, 23.0 – 59.6 %; p<0.0001 and 
p<0.01 vs Treg).  
 
 
Figure 4.7 Heterogeneity of resting, activated T cells and Treg at different maturation stages. An 
exemplary gating strategy for naïve (CD45RA+CCR7+), central memory (CM) (CD45RA-CCR7+) and effector 
memory (EM) (CD45RA-CCR7-) subpopulations of resting, activated and Treg is shown (left plot). Data sets 
are shown for 20 healthy controls (right graph). Each point represents one sample, median values and IQR 
are shown as boxplots with min to max values. Statistical analysis was performed using the Wilcoxon 
matched-pairs signed-rank test, significance with p<0.01 (*), p<0.001 (**), p<0.0001 (***).  
 
Taken together, resting T cells are mainly naïve; while the major population of 
activated T cells is EM. Treg have a balanced ratio of naïve and memory T cells, 
although a prominent portion of those memory Treg are EM. 
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Next, the cell subsets were characterized using the activation markers ICOS, LAP 
and CD69, as well as the proliferation marker Ki-67 (Figure 4.8). In general, naïve T cells 
showed low expression of these markers. As compared to the naïve T cells, CM and EM 
T cells expressed elevated levels of activation and proliferation markers. No differences 
were observed between resting and activated CM and EM T cells in their expression of 
these markers. However, the Treg populations were distinct from the resting and 
activated T memory cells. As compared to resting and activated T cell counterparts, the 
Treg CM and EM exhibited an increased frequency of ICOS+ (CM: Treg 23.4 % vs 
resting 10.0 %, p≤0.0001 and vs activated 10.2 %, p≤0.001; EM: Treg 39.8 % vs resting 
12.4 %, p≤0.0001 and vs activated 8.8%, p≤0.0001), TGF-β LAP+ (CM: Treg 0.08 % vs 
resting 0.01 %, p≤0.01 and vs activated 0.00 %, p≤0.01; EM: Treg 0.09 % vs resting 
0.04 % and activated 0.02 %, p≤0.01) and Ki-67+ cells (CM: Treg 9.1 % vs resting 3.1 %, 
p≤0.0001 and vs activated 2.4 %, p≤0.01; EM: Treg 16.3 % vs resting 6.8 %, p≤0.001 
and activated 2.3 %, p≤0.001). CD69, an early activation marker, was reduced in Treg 
(CM: Treg 5.0 % vs resting 8.0 % and vs activated 16.2 %, p≤0.001; EM: Treg 3.7 % vs 
resting 9.7 %, p≤0.001 and activated 12.8 %, p≤0.001).  
Thus, in comparison to other CD4+ memory T cells, memory Treg are characterized 
by changes in activation markers, with an increase in ICOS and LAP, but decrease in 
CD69 as well as by increased proliferation. 
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Figure 4.8 Heterogeneity of activation and proliferation states in resting, activated T cells and 
Treg. Gating on naïve (CD45RA+CCR7+), central memory (CM) (CD45RA-CCR7+) and effector memory 
(EM) (CD45RA-CCR7-) subpopulations of resting, activated T cells and Treg. The subpopulations were 
evaluated for activation markers ICOS (upper left), TGFβ-LAP (upper right), CD69 (lower left) and 
proliferation marker Ki-67 (lower right) expression. Frequency of possible cells is shown for 20 healthy 
controls (right graph). Each point represents one sample, median values and IQR are shown as boxplots 
with min to max values. Statistical analysis was performed using the Wilcoxon matched-pairs signed-rank 
test, significance with p<0.01 (*), p<0.001 (**), p<0.0001 (***).  
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4.2.1.4 Validation cohort fails to confirm increase of LAP+ Treg in 
T1D  
I used the validation cohort to identify and confirm differences in the Treg phenotype 
of T1D and Aab+ patients by analyzing the expression of the maturation and activation 
markers. However, no statistically significant differences were observed with respect to 
naïve, CM and EM distribution, or frequency of ICOS+, CD69+ or Ki-67+ Treg between 
controls and either the recent-onset T1D or Aab+ samples (Figure 4.9).  
 
 
Figure 4.9 No differences in Treg subpopulation from healthy controls, autoantibody positive 
T1D patients. (A) Composition of naïve (CD45RA+CCR7+), central memory (CM) (CD45RA-CCR7+) and 
effector memory (EM) (CD45RA-CCR7-) subpopulations of Treg from healthy controls (HC), autoantibody 
positive (Aab+) and T1D patients. Activation markers (B) ICOS (upper right) and (C) CD69 (lower left) as 
well as (D) proliferation marker Ki-67 (lower right) frequency of naïve, CM and EM Treg from HC, Aab+ and 
T1D patients. Frequency is shown for 20 age matched HC, 15 Aab+ and 18 T1D patients. Each symbol 
represents one sample, median values and IQR are shown as boxplots with min to max values. Statistical 
analysis was performed using the Mann-Whitney test, no significance p>0.05. 
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Moreover, when comparing LAP expression of HC with Aab+ and T1D in the 
validation cohort I was unable to confirm my previous findings (see Figure 4.6A) and saw 
no significant differences in the frequencies of LAP+ Treg between the groups (Figure 
4.10). However, the very low frequency of LAP expressing cells was also inconsistent 
with the data from the test cohort. This was not pursued further for this thesis. 
 
 
Figure 4.10 Validation set fails to confirm differences in TGF-β LAP+ Treg among Aab+ and T1D 
patients. Evaluation of TGF-β LAP expression on naïve (CD45RA+CCR7+), central memory (CM) (CD45RA-
CCR7+) and effector memory (EM) (CD45RA-CCR7-) Treg from healthy controls (HC), autoantibody positive 
(Aab+) and T1D patients. Frequency is shown for 20 age-matched HC, 15 Aab+ and 18 T1D patients. Each 
symbol represents one sample, median values and IQR are shown as boxplots with min to max values. 
Statistical analysis was performed using the Mann-Whitney test, no significance p>0.01. 
 
Deep phenotyping of CD4+ T cells revealed major differences between resting CD25- T 
cells, activated CD25+CD127+ T cells and CD25+CD127lo Treg. Treg have a distinct 
profile by expressing HELIOS and high amounts of ICOS. Furthermore, the ex vivo 
proliferation of Treg is exceptionally high. Also, the biomarker TGFβ-LAP as an indicator 
for activation and suppressive function was shown to be more highly expressed on Treg 
compared to the other Tconv subsets. I was able to show that all those markers can 
identify Treg among other CD4+ T cell populations. However, when applying the panel to 
samples from T1D patients, consistent differences in Treg subset frequencies as 
compared to controls were not observed.  
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4.2.2 Transcriptomic analysis 
Biomarker selection and analysis by flow cytometry is relatively restricted in terms of 
the number of markers that can be analyzed and is has a number of limitations when it 
comes to looking for new markers. The flow cytometric deep phenotyping of CD4+ T cells 
and Treg provided important information on the differences among the T cell subsets; 
however, consistent differences between T1D patients compared to HC were not 
identified. Thus, I considered the use of whole transcriptomic analysis on HC and T1D 
samples. This unbiased approach allowed me to assess the transcriptomes of Tconv and 
Treg in order to search for differentially expressed genes between HC and T1D patients. 
I chose 20 age-matched HC and 20 recent-onset T1D that were enrolled into the 
TEENDIAB and DiMelli studies. For patients, blood was drawn at an average of 8.9 days 
after the diagnosis of T1D (Figure 4.11A). Cell isolation and subsequent storage at -80°C 
in Qiazol was performed directly after blood collection to avoid ex vivo activation or 
transcriptomic changes of the cells. Figure 4.11B shows an example of the isolation and 
purity of Treg and Tconv samples used for this analysis. To obtain purified Treg, I pre-
isolated CD25 positive cells from PBMC by MACS and subsequently used FACS to sort 
CD4+CD25+CD127lo Treg. Post-sort purity of Treg was ≥ 99 %. The CD25 negative cells 
were further used for CD4 MACS isolation with a detected purity of ≥ 95 %. I was able to 
obtain Treg from 20 HC and 20 T1D patients and Tconv from 15 HC and 16 T1D 
patients. Next, I isolated the mRNA and measured concentration as well as quality of the 
mRNA. Due to the limited amount of Treg mRNA, I progressed with 10 ng mRNA for pre-
amplification prior to RNAseq. Tconv mRNA was sufficient in all samples to use 250 ng 
for direct sequencing.  
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Figure 4.11 Samples used for the transcriptomic analysis of Treg and Tconv in HC and T1D 
patients. (A) Table of sample cohorts for HC and recent onset T1D patients. (B) Representative example 
from T1D for isolation protocol of Treg and Tconv from PBMC by MACS. Treg were further isolated by 
sorting CD4+7AAD-CD25+CD127locells using FACS Purity for Treg was >99 % and for Tconv >95 %. 
 
The rationale was to compare HC and T1D within the T cell subsets, rather than 
comparing the subsets. Due to the different sequencing approaches and because the 
pre-amplification step used for Treg was likely to create sequencing bias, I only 
performed limited comparisons between the Treg and Tconv CD4+ T cells. Figure 4.12 
shows a few selected genes that have been identified by other groups to be different in 
gene expression among Treg and Tconv (Ferraro, et al., 2014; Pesenacker, et al., 2016). 
CD4 expression is equally distributed among the T cell subsets. My RNAseq data 
indicates that upregulated genes in Treg were IL2RA (CD25), FOXP3, IKZF2 (HELIOS), 
FAS, CTLA4, TIGIT, RTKN2, ICOS and CCR4. IL2RA (CD25), FOXP3 and IKZF2 
(HELIOS) are also genes that I have previously shown to be highly associated with the 
Treg subset based on protein expression (Li, et al., 2013; Pfoertner, et al., 2006). Genes 
that were expressed equally or higher in Tconv were ENTPD1, HLADRA, ID2, DUSP4, 
CCL5, PECAM1 and IL2RB. These data confirm that the T cell subsets are profoundly 
different in their gene expression profile. 
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Figure 4.12 Isolated Tconv and Treg are two distinct CD4+ subpopulations. RNAseq was 
performed on 40 samples of isolated Treg and Tconv. The heat map shows a selection of cell subset 
differentially expressed genes for Treg and Tconv. CD4 is shown as a generally expressed gene. Gene 
expression values were normalized using min to max in a scale 0.0 – 1.0 (white to red). 
 
4.2.2.1 Treg transcriptome is not profoundly different in T1D 
patients 
A preliminary analysis of Treg samples was performed by a bioinformatician. 
Statistical analysis with a false discovery rate (FDR) of 0.1 was performed and is 
visualized in Figure 4.13A by a MA-plot using the fold2 change over the mean 
expression of the two cohorts to visualize the relationship between intensity and 
difference using two dimensions. A median total of 38.5 million reads (IQR, 35.8 to 
43.3 mio) was obtained. This value reflects a median of 18.6 million reads per gene 
(IQR, 17.5 to 20.7 mio; Appendix Table 4.1). Only one differentially expressed gene 
betweenT1D patients and HC was observed. This gene, EIF3L (padj=0.08) is a 
transcription factor that plays a ubiquitous role in the mRNA translation process and thus 
appeared to be unrelated to T1D. Principal component analysis (PCA) also showed that 
the HC and T1D cohorts could not be clustered by their gene expression profiles (Figure 
4.13B). PC1 had a variance of 28 % and PC2 of 18 %. Clustering could be observed on 
the PC2 axis, which might be explained by batch effects from sample handling during 
cell sample processing or RNA isolation, but common factors could not be identified to 
account for this clustering effect.  
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Figure 4.13 Transcriptome of Treg shows no difference between HC and T1D patients. RNAseq 
was performed on Treg samples from 20 HC and 20 T1D patients followed by statistical analysis with an 
FDR of 0.1. (A) MA-plot showing the log2 fold change over the mean expression for HC and T1D Treg. The 
transcription factor EIF3L was found to be significantly different padj=0.08, indicated by the red arrow. (B) 
Principal component analysis (PCA) for HC (red circle) and T1D (blue circle) is shown with a variance of 
28 % for PC1 and 18 % for PC2.  
 
I concluded that my elaborative unbiased approach using RNAseq revealed no 
differences between Treg from HC and T1D onset patients. This study suggests that 
there is no aberration in the protein profile or transcriptome of ex vivo Treg from T1D 
onset patients. There was, however, substantial variation between individuals (Figure 
4.14) and it is likely that due to the pre-amplification step, there is insufficient statistical 
power to detect differences between the two cohorts. 
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Figure 4.14 High inter-individual variation of RNAseq data. Treg gene expression data from HC and 
T1D are shown for 1000 genes (based on padj values). Each black dot represents one sample and the mean 
is plotted for each gene (red dots) to demonstrate the spread of gene expression values within the single 
genes. Gene expression values are plotted on a log10 scale. 
 
4.2.2.2 Numerous differentially expressed genes in Tconv from 
T1D patients  
I proceeded with the analysis of the Tconv data to identify differentially expressed 
genes in this cell subset. With an FDR of 0.1 94 genes were detected, which are shown 
in the MA-plot of Figure 4.15A (Appendix Table 4.2). However PCA, with variances of 
63 % for PC1 and 7% for PC2, was unable to separate the two cohorts, showing that the 
significantly expressed genes are insufficient to completely distinguish healthy from T1D 
patients (Figure 4.15B). I also performed hierarchical clustering on the genes for the two 
cohorts, which is visualized in Figure 4.15C. The heat map and Ingenuity pathway 
analysis (IPA) indicate that one set of genes was mostly upregulated in approximately 
half of the HC as compared to the T1D samples. This gene set includes genes from the 
Type I Interferon pathway i.e. STAT1, IRF1, IRF9 and MX1. A larger second set of genes 
was upregulated in T1D patients and among this second set were many genes that were 
known to be expressed by neutrophils e.g. AZU1, ELANE, DEFA3, MPO, and BPI 
(Figure 4.16).  
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Figure 4.15 Transcriptome of Tconv from HC and T1D patients. RNAseq was performed on Tconv 
samples from 20 HC and 20 T1D patients followed by statistical analysis with an FDR of 0.1. (A) MA-plot 
showing the log2 fold change over the mean expression for HC and T1D Tconv. 94 differentially expressed 
genes (red points) were identified (padj<0.1). (B) Principal component analysis (PCA) for HC (red circle) and 
T1D (blue circle) is shown with a variance of 63 % for PC1 and 7 % for PC2. (C) Hierarchical clustering on 
Tconv differentially expressed genes was performed and visualized in a heat map. A min to max 
normalization was applied to adjust gene expression values to a 0 -1 scale (white to red). 
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Figure 4.16 Differentially expressed genes in Tconv of T1D patients. Violin plots from a selection of 
up- (upper panel) and downregulated (lower panel) genes in T1D CD4+ T cells, comparing HC (blue) and 
T1D (red), show the distribution. Each sample is indicated by points within the violin plot. Data of reads per 
kilobase per million mapped reads (rpkm) was normalized by min-max to a 0-10 scale. Associated gene 
names are depicted within each plot. 
 
Differential expression of neutrophil-associated genes were a surprising result. I 
therefore sought other data that may support this finding. Using a different set of 
samples, proteomic analysis of CD4+ T cells had been performed by Marlen Lepper (in 
correspondence, Helmholtz Zentrum München). That analysis revealed that 84 proteins 
were up-regulated in the CD4+ T cells from patients compared with HC. I compared 
these proteins to the 70 genes that were upregulated in my transcriptomics data. 11 
genes, whose protein was identified using the proteomics approach, were also found by 
the RNAseq approach, with 10 genes found to be upregulated in T1D using Mass 
spectrometry and RNAseq. 1 gene, however, was found to be upregulated in T1D using 
RNAseq, but downregulated in the Mass spectrometry analysis. Of note is that these 
overlapping up-regulated genes are described in the literature as playing a role in 
neutrophil development or function (Figure 4.17). 
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Figure 4.17 Overlap for RNA and proteins show to be differentially expressed in Tconv of T1D 
patients vs HC. RNAseq identified 70 up- and 24 down-regulated genes in Tconv for T1D patients, whereas 
Mass spec approach identified 84 up- and 46 down-regulated proteins. The overlap for the genes is shown in 
the Venn diagram: 10 are upregulated in RNAseq and Mass spec (AZU1, CTSG, DEFA3, ELANE, LTF, 
MPO, PRTN3, RETN, RNASE3) and 1 is up- in RNAseq and down-regulated in Mass spec (CAMP).  
 
I came to the conclusion after extensive pheno- and genotyping of different CD4+ T cell 
subsets that there are no significant changes in the peripheral blood Treg population of 
onset T1D patients as compared with HC. In my hands, Treg were not lower in numbers 
or impaired in functional biomarker expression. Further, RNAseq data did not reveal any 
new genes that could be relevant for onset of the disease. I also analyzed resting and 
activated CD4+ T cells for their phenotype and CD4+CD25- T cells for gene expression. 
Phenotypically, the Tconv were not different in T1D disease, while RNAseq data showed 
a small set of genes that were differentially expressed. However, many of those genes 
are mainly expressed in neutrophils and it is currently unclear how these findings relate 
to type 1 diabetes pathogenesis.  
With this study, I obtained profound knowledge of the phenotypes of the different T cell 
subsets in an ex vivo state. Without further in vitro activation I was able to detect 
expression of different activation markers as well as suppression markers on Treg and 
Tconv. Overall, RNAseq shows high variability among the individuals, which made it 
difficult to identify significant changes in the Treg transcriptome of T1D patients, and thus 
no robust biomarkers for type1 diabetes were identified in Treg.  
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4.3 CD4+ T cell subset heterogeneity in response to 
stimulation 
The heterogeneity of ex vivo CD4+ T cells has been addressed in the previous 
section using flow cytometric phenotyping and whole transcriptomic analysis. We know 
from previous experiments that in vitro stimulation with antigens can change marker 
expression, such that activated T cells and Treg exhibit similar phenotypic profiles. This 
can confound the identity of bona fide Treg under activating conditions. Identifying 
differences in the stimulated T cell subsets is crucial in understanding whether the 
responsive T cell is a helper T cell or Treg. This this is particularly important for the 
analysis of treatment effects on adaptive immunity in type 1 diabetes. I reasoned that by 
starting out with non-activated Tconv and Treg, which I am able to isolate with 
confidence, I will be able to analyze the response of antigen stimulated conventional T 
cells and Treg separately and identify unique features of each. Since the number of 
responsive cells that remain after antigen stimulation was likely to be limited, I used a 
single cell gene expression analysis approach. 
 
4.3.1 Proliferation of a mixed PBMC culture 
Common in vitro antigen response assays are performed using PBMCs in order to 
achieve sufficient antigen presentation by antigen presenting cells that are already 
present in the PBMC preparation. Previous experiments (data not shown) have indicated 
that it is important to include other cell subsets, such as DCs, B cells and CD8+ T cells 
for proper antigen presentation and CD4+ T cell activation to occur. Such heterogeneity 
also resembles a more physiological setting as opposed to isolating single subsets and 
stimulating them with an antigen via APCs. Taking this, as well as the knowledge I 
obtained from the deep phenotyping into consideration, I developed a novel mixed 
PBMC culture assay, which is shown schematically in Figure 4.18A. First, I measured 
the Tconv and Treg cell subset composition of PBMC samples using flow cytometry. I 
then isolated CD4+CD25-/dim Tconv and CD4+CD25+CD127- Treg using MACS and 
subsequently FACS (Figure 4.18B, day 0). I labelled the two populations with different 
proliferation dyes and then pooled them back together with the unsorted non-CD4 cells 
such that the original proportions of these two subsets was restored in the PBMC 
sample. I used different antigens as stimuli, including the vaccine antigens tetanus toxoid 
(TT) and Influenza (Flu) as positive controls, and a combination of the autoantigens 
proinsulin (PI) and GAD65. After incubation for 5 days I single cell sorted the antigen 
responsive (Resp) cells, which were identified CD25hi cells that had proliferated, as 
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measured by dilution of the dyes efluor670 for Treg and efluor450 for Tconv. I also 
isolated the non-responsive (NR) cells, identified as non-proliferating and CD25-/dim 
(Figure 4.18B, day 5). Resp expressed a memory phenotype (CD45RO+) whereas the 
NR were a mix of naïve (CD45RO-) and memory (CD45RO+) cells. The sorted Resp and 
NR were further processed for single cell gene expression profiling using a panel of 48 
genes. 
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Figure 4.18 Mixed PBMC culture assay setup. (A) A schematic representation of the PBMC assay 
composition: FACS isolated CD4+CD25dim/- (Tconv, red cells) and CD4+CD25+CD127lo (Treg, blue cells) 
were stained with different proliferation dyes and subsequently mixed back together with non-CD4+ cells 
(grey cells) in a typical PBMC composition. Antigens such as TT, Flu or autoantigens (grey star shaped) 
were added to the culture. The mixture was incubated for 5 days in a 96-well U-bottom plate and proliferating 
Tconv and Treg (proliferation dye dim cells) were single cell sorted by FACS. (B) Exemplary FACS gating 
strategy for Tconv and Treg. Cell sorting on day 0 was performed using FACS to CD4+CD25dim/- Tconv and 
CD4+CD25+CD127lo Treg from a MACS enriched population of CD4+ cells. Post sort purity is shown in the 
right plots. On day 5, Tconv and Treg were identified by their different proliferation dyes, efluor 670 (Treg, 
blue) and efluor 450 (Tconv, red). Cells were divided into responders (Resp) and non-responders (NR) by 
their CD25 expression and dye intensity. Resp and NR were also characterized by the composition of 
memory cells (CD45RO+, right plots).  
 
4.3.2  TT and flu as model antigens 
My initial interest was to identify gene expression changes within each cell subset 
using TT since this is a strong T-cell stimulating antigen that would be expected to 
induce robust gene expression changes. For Tconv I compared 104 Resp and 65 NR 
single cells from 4 Aab+ patients. A heat map was used to visualize the differences in 
gene expression between the two cell populations (Figure 4.19A). Statistical analysis 
was performed using the Hurdle model (Figure 4.19B). The majority of genes were highly 
significantly different (p<0.0001 or p<0.001) and only IL2, IL17A, IL22 and CD40 gene 
expression was similar for Resp and NR cells. The NR cells were characterized by 
overall low gene expression, indicative of a resting state and thus low RNA content of 
these cells. Relevant to my objective, NR cells were also characterized by an absence of 
Treg signature genes such as FOXP3, HELIOS, ICOS, CTLA4 and GITR. However, 
these were expressed after 5 days of stimulation in the RESP Tconv cells (all p<0.0001). 
Further analysis by t-distributed stochastic neighbor embedding (t-SNE) was able to 
separate the cells into the two populations with little overlap (Figure 4.19C). 
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Figure 4.19 Single cell gene expression analysis of TT antigen responsive and nonresponsive 
Tconv. TT responsive (Resp) and nonresponsive (NR) cells were single-cell sorted and processed for 
multiparameter gene expression analysis for a panel of 48 genes. (A) Heat maps of the genes for Tconv TT 
Resp (104 cells) and NR (65 cells) from four patients are shown. Each bar represents an individual cell and 
expression value is shown as reverse CP values with significance indicated (* p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001). (B) The Hurdle model was used to identify statistically significant differences in 
gene expression between the two groups (p value –log10 scale). (C) t-distributed stochastic neighbor 
embedding (t-SNE) analysis visualized the distinct gene distribution for Tconv TT Resp (light blue) and NR 
(blue). 
 
Results 
 
86 
 
A TT antigen response was not always detected for Treg and as a result less cells 
could be isolated for single cell gene expression profiling. I was able to compare the 
gene expression profiles of Treg with 48 Resp cells from 2 patients and 66 NR cells from 
4 patients. Similar to Tconv, the majority of genes were more highly expressed in the 
RESP Treg as compared to the NR Treg (Figure 4.20A). These included CD4, CD3e, 
TGFbeta, TNFalpha, RORA, AHR, ICOS, CD52, RANTES, CCR4 and CCR7 (p<0.0001), 
Tbet, RORC, cMaf, CTLA4 and CD134 (p<0.001), IL13, INFg, GMCSF, FOXP3, REL 
and GITR (p<0.01), IL18RAP and Egr2 (p<0.05) which were all upregulated, and CD127 
which was downregulated in the RESP cells (Figure 4.20B). t-SNE analysis separated 
the RESP Treg and NR Treg into two clusters (Figure 4.20C).  
This data showed that an antigen-specific T-cell stimulation with TT resulted in a 
general upregulation of many genes within the individual T cell subsets; an exception 
was the downregulation of CD127 for Treg. A few genes, such as IL2, IL17A and IL22, 
were unaffected by TT antigen stimulation.  
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Figure 4.20 Single cell gene expression of TT antigen responsive and nonresponsive Tconv. TT 
responsive (Resp) and nonresponsive (NR) were single-cell sorted and processed for multiparameter gene 
expression analysis for a panel of 48 genes. (A) Heat maps of the genes for Treg TT Resp (48 cells) and NR 
(66 cells) from two and four patients are shown, respectively. Each bar represents an individual cell and 
expression value is shown as reverse CP values with significance indicated (* p<0.05, ** p<0.01, *** 
p<0.001, **** p≤ 0.0001). (B) Hurdle model was used for comparison of the two groups (p value –log10 
scale). (C) t-distributed stochastic neighbor embedding (t-SNE) analysis visualized the distinct gene 
distribution for Tconv TT Resp (dark red) and NR (pink). 
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Next, I looked at differences of gene expression between the two T cell subsets of 
NR and responders. The t-SNE analysis of non-responding Treg vs. Tconv showed a 
clear separation of the two populations and statistical analysis identified 12 out of 48 
genes as significantly different (Figure 4.21A). The most significant differences were for 
FOXP3, HELIOS, GITR and AHR (p<0.0001), followed by CTLA4, CD127 (p<0.001), 
TNFalpha, CCR4 and CD52 (p<0.01); followed by CD134, TGFbeta and REL (p<0.05). 
These genes were more highly expressed in Treg, except for CD127, which was higher 
in Tconv.  
Figure 4.21B shows the comparison of TT responding Tconv and Treg. FOXP3 and 
CTLA4 were the most promising discriminators (p<0.0001), since they are highly 
expressed by Treg, although both genes were also upregulated in Tconv. RGS16 
expression was higher in Tconv (p<0.001), which was similar for TGFbeta and CD4 
(p<0.01). Overall, the frequency of cytokine expressing T conv was higher and significant 
for IL13, IL-21 and GMCSF (p<0.05). Tbet and RANTES were more frequently detected 
in Tconv, whereas HELIOS and CCR7 was associated with Treg (p<0.05). Some genes 
were not picked up as significantly different due to the low cell numbers for TT 
responding Treg and the limitations of the hurdle model. t-SNE data also showed that 
responding Treg were not easily distinguishable from TT responding Tconv. 
Nevertheless a tight Treg cluster was observed, which appeared distinct to the Tconv 
population. 
To determine if that is the case, a cluster analysis of the t-SNE Tconv vs. Treg TT 
Resp was performed. This identified five major clusters (Figure 21C). Cluster 1 contained 
a higher frequency of Treg (30 Treg and 8 Tconv), which I compared to cluster 4, which 
had a higher frequency of Tconv (5 Treg and 37 Tconv). The heat map, with the genes 
ordered by hierarchical clustering, shows clear differences in the gene expression 
signature between the clusters. These findings were supported by statistical analysis 
using the hurdle model. The most significantly different genes were upregulated in Tconv 
(IL13, RANTES, RGS16, IL21, INFg, CCR4, Egr2, GMCSF, PD1, CD127, GITR, AHR, 
CD134, TGFbeta, Tbet, REL, IL18RAP, TNFalpha, ICOS, cMaf, IL4, IL9, CD4 and 
CXCR5). FOXP3 and HELIOS were the only genes found to be upregulated in Treg.  
The comparison of antigen-responding genes supported my previous assumption 
that activated Tconv and Treg would be difficult to discriminate due to similar 
upregulation of biomarkers. By comparing the two T cell subsets, I was able to identify 
well known biomarkers at the gene expression level in non-responding cells, which have 
been frequently used to discriminate Treg from Tconv by flow cytometry. Treg typical 
genes, such as FOXP3, HELIOS, low CD127, CTLA4, GITR and TGFbeta, were 
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extended by AHR, TNFalpha, CCR4 and CD52. Those markers can be used to 
discriminate the majority of Treg from Tconv in an inactivated state. Upon Tconv and 
Treg activation the difference became less distinctive. A Treg signature with a 
combination of FOXP3, HELIOS and reduced RGS16 can distinguish Treg from Tconv. 
Also, an overall lower expression of cytokines (IL-13, IL-21, GMCSF, IFNg) is a 
characteristic of responding Treg. 
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Figure 4.21 Comparison of Tconv and Treg single cell gene expression for TT antigen 
nonresponsive and responsive cells. TT NR and Resp Tconv and Treg were single-cell sorted and 
processed for multiparameter gene expression analysis for a panel of 48 genes. (A) Heat maps (left) of the 
genes for Treg (66 cells) and Tconv (65 cells) TT NR from four Aab+ patients are shown. t-SNE plot (right) is 
shown for Treg (pink) and Tconv (light blue) TT NR. (B) Heat maps (left) of the genes for Treg (48 cells) and 
Tconv (104 cells) TT Resp from four patients are shown. t-SNE plot (right) is shown for Treg (dark red) and 
Tconv (blue) TT Resp. For heat maps, each bar represents an individual cell and expression value is shown 
as reverse CP values with significance indicated above (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001). (C) 
t-SNE of Tconv and Treg TT Resp visualized five major clusters. Cluster 1 (8 Tconv, 30 Treg; blue) and 
cluster 4 (37 Tconv, 5 Treg; yellow) were compared by heat map with examined genes ordered by 
hierarchical clustering. The hurdle model was used for comparison of the two clusters (p value –log10 scale) 
and significantly different genes are listed (p<0.05).  
 
I performed further experiments to determine whether different antigens would 
induce different gene expression profiles, reasoning that the response to TT antigen-
based vaccine is bacterial and a response to Flu antigen is a viral. Therefore, I compared 
TT and Flu responding T-cell subsets for their gene expression profiles from the same 
individuals, with 94 Tconv and 48 Treg for Flu and 104 Tconv and 48 Treg for TT. The t-
SNE of Treg responders showed a heterogeneous distribution of Flu and TT specific 
cells without distinct clusters, but statistical analysis identified 14 differentially expressed 
genes (Figure 4.22A). Most genes were increased in TT Treg (p<0.0001: GITR, RORA, 
REL; p<0.001: cMaf, TNFalpha; p<0.01: Bcl6, AHR, RANTES; p<0.05: TGFbeta, Tbet, 
CCR5); only CD52, CD134 (both p<0.0001) and CD3e (<0.05) showed increased 
expression in Flu Treg. Similar tendencies were observed for Tconv gene expression, 
where the majority of significantly differentially expressed genes were increased in TT 
Resp as compared to Flu Resp cells (p<0.0001: CD52, GITR, RGS16, cMaf, REL, 
TNFalpha, PDA, Bcl6, AHR, ICOS, RANTES, Egr2, IL13; p<0.001: CD127, CXCR5, 
Tbet, GMCSF, IL9; p<0.01: CCR5, RORC, CD134, HELIOS, TGFbeta, CD3e; p<0.05: 
CCR7) and only RORA (p<0.0001) and CTLA4 (p<0.001) were increased in Flu specific 
Tconv (Figure 4.22B). These differences in gene expression were able to generally 
cluster the Tconv for their two stimuli in a t-SNE with some overlap of TT and Flu specific 
cells. 
I also compared unstimulated Tconv and Treg from TT and Flu conditions to 
complete the analysis. There were no significant differences between the two antigens 
for either T-cell subset, which implied that non-responsive T cells were not affected by 
the antigen stimulus (data not shown). 
 
Results 
 
91 
 
Using a panel of 48 genes, I was able to identify differences between non-responsive 
Tconv vs. Treg and their change of gene expression after antigen-specific stimulation 
with model antigens. I also showed how similar or dissimilar profiles of antigen 
responding Tconv vs. Treg were and that Tconv can also upregulate the expression of 
signature Treg genes. Despite this, I was able to identify gene expression profiles that 
will be helpful in identifying whether responding cells are likely to be Treg or Tconv.  
 
 
Figure 4.22 Flu and TT stimulation leads to different gene expression profiles in responding 
Tconv and Treg. TT Resp and Flu Resp Tconv and Treg were single-cell sorted and processed for 
multiparameter gene expression analysis for a panel of 48 genes. (A) Heat maps (left) of the genes for 48 
cells Treg Flu and 48 cells TT Resp from two patients are shown. Upregulated genes in Flu Resp are 
indicated with a green arrow. t-SNE plot (right) is shown for Treg TT (brown) and Flu (green) Resp. (B) Heat 
maps (left) of the genes for 94 cells Treg Flu and 104 cells TT Resp from three patients are shown. 
Upregulated genes in Flu Resp are indicated with a yellow arrow. t-SNE plot (right) is shown for Tconv TT 
(blue) and Flu (yellow) Resp. For heat maps, each bar represents an individual cell and expression value is 
shown as reverse CP values with significance indicated above (* p<0.05, ** p<0.01, *** p<0.001, **** 
p<0.0001).  
Results 
 
92 
 
4.3.3  Autoantigens  
Strong T cell stimulating antigens such as TT and Flu are useful for developing 
analysis tools, but may not be representative of autoreactive T cell stimuli in the context 
of type 1 diabetes autoantigens. Therefore, I used the autoantigens GAD65 and PI as 
stimuli for autoantigen responsive Tconv and Treg in T1D patient samples.  
Initial gene expression data from 3 different donors for GAD65 and PI responding 
Tconv did not identify differences in the gene expression profiles between the two 
antigens (Figure 4.23A). Hence, I combined the two autoantigens for stimulation in order 
to increase the number of responsive cells and subsequently refer to this stimulation as 
autoantigen (AA).  
Stimulation of PBMC with AA resulted in a lower frequency of Resp Tconv and Treg. 
I reasoned that stimulation with AA would not only result in fewer responsive cells but 
also in lower gene expression compared to a strong TT stimulus. I was able to analyze 
78 AA responsive Tconv and compared them with 104 TT responsive Tconv sorted from 
seven AAb+ patients. The t-SNE analysis showed a clear seperation of TT and AA 
responsive Tconv suggesting that the gene expression profiles were different (Figure 
4.23B). The heat map showed an overall upregulation of most genes for both stimuli, but 
many genes were more highly expressed in the TT Tconv Resp (p<0.0001: TGFbeta, 
RANTES, GITR, Tbet, cMaf, AHR; p<0.001: IFNg, IL13, CD134; p<0.01: FOXP3, CCR4, 
CD127, IL21, IL4, RORA; p<0.05: CCR7, PD1, REL, TNFalpha) (Figure 4.23C). Egr2 
was less expressed in the TT Resp Tconv (p<0.001). I concluded that, overall, TT 
stimulation results in a stronger activation of responsive cells as compared to AA. 
Overall, AA Resp expressed less cytokines and had a less pronounced expression of 
genes such as FOXP3, CD134 or GITR. The latter observation may allow discrimination 
of Treg and Tconv AA responsive CD4+ T cells. 
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Figure 4.23 Autoantigens GAD65 and PI do not cause different gene expression profiles and 
show an overall lower activation level compared to TT stimulation. (A) GAD65 and proinsulin (PI) 
responsive Tconv were single-cell sorted and analyzed using a multiparameter gene expression panel. t-
SNE plot is shown for GAD65 (green) and PI (dark red). (B) Autoantigen (AA, 78 cells) Resp and TT Resp 
Tconv (104 cells) from three patients were single-cell sorted and processed for multiparameter gene 
expression analysis for a panel of 48 genes. t-SNE plot (right) is shown for Tconv TT (blue) and AA (orange) 
Resp. (C) Heat maps of the genes for Tconv TT and AA Resp from three patients are shown. Each bar 
represents an individual cell and expression value is shown as reverse CP values with significance indicated 
(* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001). 
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Having observed reduced upregulation of gene expression in AA compared with TT 
responsive Tconv, I attempted to identify which genes were affected by AA stimulation. 
Therefore, I compared AA Resp with NR from Tconv and Treg. I sorted 105 NR and 78 
Resp Tconv single cells as well as 106 NR and 23 Resp Treg, and analyzed these cells 
for gene expression, taking into consideration that the Treg response for AA was 
infrequent.  
t-SNE data and the corresponding violin plot of the genes with significant differences 
in expression for Tconv showed that most genes were upregulated upon AA stimulation 
in Resp Tconv (Figure 4.24A). The genes that were not differently expressed in NR and 
Resp were CD127, CD40, CCR5 and many cytokines (IL17A, IL2, IL21, IL22, IL4, IL9). 
AA response of Treg resulted in a significant upregulation of many genes (p<0.0001: 
CCR4, FOXP3, ICOS, CCR7, TGFbeta, AHR, CD4; p<0.001: CD134, Tbet, GITR, CD3e, 
CCR6, Bcl6; p<0.01: CTLA4, RORA, cMaf, REL; p<0.05: CD52, HELIOS) shown by the 
violin plots in Figure 4.24B. These differences were visualized in a t-SNE plot by a 
separate cluster of responding Treg. Very striking was that neither the Resp nor the NR 
expressed any cytokines (IL2, IL4, IL9, IL13, IL17A, IL21, IL22, IFNg, GMCSF), except 
for TGFbeta and TNFalpha.  
Last, I compared AA responding Treg and Tconv to identify population-specific gene-
expression profiles. The t-SNE plot showed a cluster of Treg separate from the Tconv, 
but with some Treg scattered within the Tconv, which suggests that there is 
transcriptional heterogeneity within the activated T cell populations. Statistical analysis of 
the subsets identified few differentially expressed genes: FOXP3 (p<0.0001), HELIOS 
and GMCSF (p<0.01), IL13, CCR6 and IL18RAP (p<0.05) (Figure 4.24C). Other 
differences could not be picked up by the hurdle model, which could be due to the low 
cell numbers of Treg. 
A combination of high FOXP3 and HELIOS expression as well as low IL18RAP is 
able to discriminate the majority of AA Treg from Tconv. In addition, a lack of cytokine 
expression, such as IL-13, IL-21, GMCSF and IFNg, is also characteristic for responsive 
Treg.  
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Figure 4.24 Stimulation of Treg and Tconv with AA shows upregulation of genes and results in 
specific gene expression pattern. (A) t-SNE analysis (right) is shown for AA Tconv Resp (151 cells, 
orange) and NR (105 cells, grey) single cells from up to seven patients. Violin plots (left) show the 
distribution of reverse Cp values for genes showing a significance (p<0.0001 to p<0.05) in Tconv Resp vs 
NR. The proportion of cells expressing the gene ranged from light blue (0 %) to dark blue (100 %). (B) t-SNE 
analysis of AA Treg Resp (23 cells, petrol) and NR (106 cells, light turquoise) from six patients. Violin plots 
(left) show the distribution of reverse Cp values for genes showing a significance (p<0.0001 to p<0.05) in 
Treg Resp vs NR. (C) t-SNE analysis of AA Resp Tconv (151 cells, orange) and Treg (23 cells, petrol) from 
up to seven patients. Violin plots (left) show the distribution of reverse Cp values for genes showing a 
significance (p<0.0001 to p<0.05) in Resp Treg vs Tconv. Corresponding heat maps for all three 
comparisons can be found in Appendix Figure 4.1. 
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In this study I demonstrated that antigen-specific stimulation of two different T-cell 
subsets led to specific gene expression profiles. In general, antigen-responding T cells 
upregulated most genes of the panel in comparison to the non-responding T cells. Also, 
the gene expression profiles of Tconv and Treg changed upon activation. I was also able 
to show that the gene expression profile is antigen dependent and that foreign antigens 
(TT) induced a stronger upregulation of genes than auto-antigens (GAD65 and PI).  
Taken together, I was able to identify T-cell subset and antigen-specific differences 
in gene expression profiles, which will be helpful in characterizing the phenotype of CD4+ 
T-cell responses.  
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4.4 Manipulation of naïve T cells for the induction of 
Treg 
The therapeutic potential of Treg has been investigated by multiple research groups 
and is suggested to be a suitable approach to develop cellular therapies for the 
treatment of autoimmune diseases (Bluestone et al., 2015). The initial focus lay on the 
polyclonal expansion of autologous Treg, either thymus or peripherally derived. 
However, this approach has several drawbacks. First, the initial Treg cell number is small 
and therefore a large volume of patient blood is required. Second, the polyclonal 
expansion lacks the target specificity needed to efficiently treat an antigen-specific 
autoimmune disease. A more recent in vitro approach is the de novo generation of Treg, 
called induced Treg (iTreg), from naïve T cells using a suboptimal stimulus, such as 
tolerogenic dendritic cells (tDCs). The advantage of this technique is that the tDCs can 
present specific antigens to directly target autoreactive T cells for conversion to Treg.  
Here, I wanted to use the knowledge of Treg I gained from phenotyping in order to 
assess different methods that are used to generate a stable iTreg population with 
suppressor function using allogeneic tDCs. I therefore generated tDCs from CD14+ 
monocytes in the presence of Dexamethasone (Dex), 1α,25-Dihydroxyvitamin D3 (VD3) 
or a combination of both (combi). Allogeneic naïve T cells were stimulated over a period 
of 14 days for the induction of Treg. Both Dcs and Treg were characterized 
phenotypically and the suppressive capacity of iTreg was evaluated after stimulation.  
 
4.4.1 Phenotypic and morphologic characteristics of tolerogenic 
DCs 
A promising approach for the de novo generation of Treg is the use of tolerogenic 
DCs, which induce a suboptimal activation of T cells leading to the stable induction of 
Treg. tDCs can be generated by treating DCs with chemical compounds that change the 
functional phenotype i.e. modulating antigen presentation and activation potential of DCs 
to keep them in a semi-mature state. Two chemical agents that have been described to 
generate tDCs are glucocorticosteroid dexamethasone (Dex) and the biologically active 
form of vitamin D3 (VD3). Based on methods previously published by Roep and 
colleagues, I generated tDCs over a period of 7 days by inducing the differentiation of 
MACS isolated CD14+ monocytes (Ferreira, et al., 2012; Kleijwegt et al., 2010). 
Differentiation into immature DCs (iDCs) was promoted by treating monocytes with IL-4 
and GM-CSF over a time course of 6 days, where VD3 was added on days 0 and 3 and 
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Dex on day 3 to generate tDCs. Mature DCs (mDCs) were generated by treating iDCs 
with the TLR4 agonist LPS overnight.  
I generated four types of DCs: untreated normal DCs (norm), Dex treated DCs (Dex), 
VD3 treated DCs (VD3) and a combination of Dex and VD3 treated DCs (combi). I 
observed morphological differences among all four DC types while in the iDC and mDC 
state, shown in Figure 4.25A. On day 6, iDCs of norm were loosely attached with mostly 
roundish shaped cells, which was similar to Dex DCs. VD3 and combi DCs were 
adherent and cells had formed dendrites. After overnight activation with LPS, all mDC 
types had attached on the cell culture plate surface. Here, Dex DCs formed less 
dendrites than norm DCs, resulting in an easier detachment of the cells. Again, VD3 and 
combi mDCs formed long spindle-shaped dendrites.  
I compared the surface markers on monocytes, iDCs and mDCs from normDCs and 
the three tDC types (Figure 4.25B). Expression of the monocyte biomarker CD14 was 
downregulated in all iDCs and mDCs, except Dex mDCs. I detected an upregulation of 
CD11c for all iDC types, but CD1a was only upregulated by norm DCs, confirming that 
the tDCs were arrested in a semi-mature state. HLA-DR expression was increased by 
iDC and mDC populations, but expression was lower for VD3 treated DCs compared 
with the other DC types. tDCs showed a variable expression of costimulatory molecules: 
compared with norm DCs in the corresponding state, CD80 was significantly reduced in 
VD3 and/or Dex treated tDCs on both iDCs and mDCs, CD86 was only reduced on Dex 
DCs whereas CD40 expression was reduced on VD3 and combi DCs. The co-inhibitory 
molecule PD-L1 was upregulated on all tDCs especially after maturation. Anti-
inflammatory IL-10 cytokine secretion was elevated in Dex treated mDCs with up to 
4,300 pg/ml, but not in VD3 and combi mDCs compared to norm DCs (range 41-
1,564 pg/ml) (Figure 4.25C).  
Downregulation of CD1a, partial downregulation of CD11c, decreased HLADR and 
thus reduced antigen presentation capacity, lowered expression of activation receptors 
(CD80, CD86 and CD40) and upregulation of the inhibitory receptor PD-L1 are 
phenotypes that are consistent with tolerogenic characteristics. However, the three tDC 
types expressed these phenotypes to different degrees. Still, the three tDCs types were 
expected to activate T cells in a suboptimal manner through reduced antigen 
presentation and co-stimulation and, with increased IL-10 secretion, promote the 
induction of Treg. 
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Figure 4.25 Morphologic and phenotypic characterization of tolerogenic dendritic cells. (A) 
Morphological differences of tolerogenic dendritic cells (tDCs) are shown from one example for immature 
DCs (iDC) and LPS treated mature DCs (mDC). Normal generated DCs (norm) were compared to 
dexamethasone (Dex), Vitamin D3 (VD3) or a combination of both (combi) treated DCs. Light microscopic 
images were taken at a 100x magnification. (B) Phenotypic differences of norm, Dex, VD3 and combi iDCs 
(white bars) and mDCs (black bars) as well as monocytes (mono) are shown for biomarkers CD14, CD11c, 
CD1a, HLADR, CD80, CD86, CD40 and PDL-1. The median fluorescence intensity (MFI) was normalized to 
the norm iDC values and are plotted as bar graphs with mean values and SD (n=3). Statistical analysis was 
performed using the two-way ANOVA test with Bonferroni correction for multiple comparisons; p<0.01 (*), 
p<0.001 (**), p<0.0001 (***). (C) IL-10 secretion of DCs was measured by ELISA (pg/ml). Supernatants of 
iDCs and mDCs were collected and diluted 1:10 for the assay. Data is shown in a before-after graph, 
connecting the corresponding iDC with mDC samples (n=3). 
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4.4.2 Suboptimal stimulation of naïve T cells by allogeneic tDCs 
In vitro induction of Treg was promoted by stimulating naïve T cells with tDCs for two 
consecutive rounds. Naïve CD4+ T cells were isolated by MACS with a purity of 97.5% 
CD4+CD45RA+. The allogeneic T cells were stimulated with tDCs or norm DCs, as a 
control, in a 1:10 DC: CD4+ T cell ratio for five days and then rested in the presence of 
IL-7/IL-15 for two days. The stimulation and resting was then repeated a second time. 
Simultaneously, I polyclonally expanded Treg over 14 days with IL-2 and αCD3αCD28 
Dynabeads under the selective pressure of rapamycin (protocol described in section 
3.2.7). Also, a polyclonal expansion of naïve T cells by αCD3αCD28 Dynabeads into 
Tconv was used as a control for biomarker expression and suppressive capacity. 
Phenotypic analyses of induced Treg as well as expanded Treg and Tconv were 
performed on days 0, 5, 7, 10, 12 and 14 during the 14 days of stimulation (Figure 4.26). 
The expression frequency of CD25, FOXP3, CTLA4, LAP and CD45RO was compared 
for three different donors (BCI-III). Although all three donors exhibited varying 
frequencies of expressed markers on expanded Treg, Tconv and also iTreg induced by 
norm, Dex, VD3 and combi DCs, a similar trend was observed. CD25 and FOXP3 
expression was upregulated on iTreg during stimulation, but was not consistent for all 
time points. The highest CD25 expression of total CD4 was observed on day 7 after the 
first resting phase, with a decrease after the second round of stimulation on day 12 and 
then a slight upregulation after the second resting phase. Similar up- and downregulation 
was seen for FOXP3 expression of CD25+ cells, although, the expression for BCII and III 
peaked on day 5 instead of day 7. CTLA4 was expressed by almost 100 % of CD25+ 
iTreg on day 5 (98.0–99.6 %) and remained high for BCII and III, while decreased during 
the stimulation to 51-66 % for BCI. TGFβ-LAP was transiently expressed on 46.6 % of 
Dex iTreg (BCII) and on all iTreg of BCIII on days 5 and 12, but stayed otherwise low. 
The initially naïve T cells from all three BCs upregulated CD45RO at the same time point 
that CD25 was expressed. However, CD45RO expression was observed to decrease to 
70 % during the stimulation (combi iTreg BCI). In comparison, CD25 expression on 
polyclonally expanded Treg was consistently high (>96 %) during the stimulation, 
whereas CD25 expression on Tconv was highest on day 5 (86.7-98.3 %), but did not 
remain consistent over time. The FOXP3 expression coincided with CD25 expression for 
Treg and Tconv. CTLA4+ and CD45RO+ expression by CD25+ cells were similar for Treg 
and Tconv and showed no difference to iTreg populations. LAP on the other hand, was 
only expressed on Treg in high frequencies on days 5 and 12 (up to 74.9 % and 87.3 %, 
respectively), but expression was not stable during the stimulation.  
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I observed a similar phenotype for all iTreg types, although norm Treg showed the 
highest CD25 expression, followed by Dex Treg. FOXP3 expressing CD25+ Treg were 
more frequent samples stimulated with Dex and VD3 treated tDCs in two of the BC. This 
phenotype was not stable over time, but changed during the stimulation and resting 
rounds. Also, comparing the iTreg to the expanded Treg I saw less CD25 and FOXP3 
expression, as well as a lack of LAP+ cells. Tconv, however, were phenotypically very 
similar to the iTreg phenotype. 
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Figure 4.26 Phenotypic changes of T cells during 14 days of stimulation. To induce Treg naïve T 
cells were stimulated in two consecutive rounds with different tDC types (norm, Dex, VD3 and combi) for 5 
days followed by a resting phase with IL-7 and IL-15 for two days. In addition, pre-isolated Treg 
(CD4+CD25+CD127lo) and Tconv (CD4+CD25-) were stimulated by αCD3αCD28 Dynabeads and IL-2 for 14 
days. Rapamycin was added to Treg culture for Treg selective pressure. Cell samples were collected on day 
0, 5, 7, 12 and 14 for flow cytometric phenotyping. Three independent experiments (BCI-III) are shown for 
CD25, FOXP3, CTLA4, TGFβ-LAP and CD45RO expression of total CD4+ or CD25+ cells. Expression values 
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are shown for Treg (blue), Tconv (grey), norm iTreg (red), Dex iTreg (black triangle), VD3 iTreg (‘black 
diamond) and combi iTreg (black circle). 
Next, I analyzed the Treg stability by measuring the frequency of methylation of the 
FOXP3 Treg-specific demethylated region (TSDR). DNA was isolated from iTreg, 
expanded Treg and Tconv from three donors on day 12 and the percentage of 
methylation was determined by pyrosequencing (performed by Dr. Rainer Fürst, 
Helmholtz Zentrum München).  
Only expanded Treg showed some degree of demethylation, which is characteristic 
of a stable Treg phenotype (Floess et al., 2007; Polansky et al., 2008) (Figure 4.27). A 
methylation of 16.7 % was seen for one male donor and the frequency of methylation for 
the two female donors was 69 and 85 %. This sex-dependent variation was expected 
and is due to the fact that the FOXP3 gene locus is found on the X-chromosome, where 
one X-chromosome is naturally methylated in females (Wieczorek et al., 2009). iTreg 
generated from any condition and Tconv, however, showed a high percentage of 
methylation (mean 96.2 %) for all three donors, suggesting that FOXP3 expression was 
not a stable feature of iTreg. 
 
 
Figure 4.27 Detection of iTreg stability by FOXP3 methylation. Stability of Treg is determined by the 
measuring the frequency of methylation for the FOXP3 Treg-specific demethylated region (TSDR). On day 
12 of the stimulation, cell samples from Treg (blue), Tconv (grey), norm iTreg (red), Dex iTreg (black 
triangle), VD3 iTreg (‘black diamond) and combi iTreg (black circle) were collected  for DNA isolation. 
Pyrosequencing of 8 CpG regions (TSDR 1-8) were performed by Dr. Rainer Fürst (Helmholtz Zentrum 
München). Percentage methylation of FOXP3 TSDR 1-8 is shown for three independent donors (1 male and 
2 females). 
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Stimulation of T cells with dendritic cells or with αCD3αCD28 Dynabeads not only 
induced phenotypic changes, but also triggered proliferation to some extent. The fold 
expansion of norm DC and tDC induced-Treg exhibited a varied capacity for the three 
donors (Figure 4.28A). In general, iTreg expanded continuously until day 12 and then 
underwent cell death until day 14. Norm iTreg, followed by Dex iTreg, showed the 
highest proliferation capacity with 24.6 and 9.5 (BCIII) fold expansion at day 12, 
respectively. Proliferation of VD3 and combi iTreg was high for BCI and BCII, but very 
low for BCIII. Overall, the DC triggered expansion of iTreg was much lower compared 
with bead stimulation of Treg and Tconv, never exceeding a 24.6 fold expansion (norm 
iTreg BCIII). Bead-stimulated Tconv and Treg showed a continuous expansion until day 
14, at which time e Tconv reached a 3332 fold expansion and Treg reached a 409 fold 
expansion (Figure 4.28B).  
T cell proliferation is driven by autocrine IL-2 secretion, therefore, I measures IL-2 
secretion at various time points throughout the stimulation (Figure 4.28C). Aliquots of 
supernatant were taken on day 1, 3, 5, 7, 10, 12 and 14 and analyzed by ELISA. Low 
amounts of IL-2 could be detected on day 1, which peaked on day 3, but were not 
detectable from day 5 until the end of the stimulation. Similar to the expansion capacity, 
norm iTreg secreted the highest amounts of IL-2 (mean 460 pg/ml) followed by Dex 
(mean 405 pg/ml), VD3 (mean 244 pg/ml) and combi iTreg (mean 165 pg/ml). Treg and 
Tconv IL-2 secretion was not measured, because IL-2 was artificially added during the 
stimulation rounds. 
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Figure 4.28 Expansion and IL-2 secretion of T cells during 14 days stimulation. (A) The 
stimulation of iTreg by tDCs and cytokines (IL-7 and IL-15) was also measured by the iTreg expansion over 
14 days. Cell counts were taken on day 5, 7, 12 and 14 and fold expansion was determined relative to the 
initial cell input on day 0. Plots are shown for three independent experiments (BCI-III) for norm (red), Dex 
(black triangle), VD3 (black diamond) and combi (black circle) iTreg. (B) Stimulation of Treg (blue) and Tconv 
(gray) with αCD3αCD28 Dynabeads was also measured by cell expansion. Fold expansion is shown in a 
log10 scale for three independent experiments (BCI-III). (C) IL-2 secretion was measured for iTreg by ELISA, 
taking supernatant on day 1, 3, 5, 7, 10, 12 and 14 of the stimulation. Samples were diluted 1:10 for 
measurement. Plot shows the single values and mean values for IL-2 concentration (pg/ml) of three 
independent experiments with SD. 
 
4.4.3 Suppressive capacity of T cells 
After identifying changes in the phenotype and FOXP3 stability of iTreg, I next 
performed functional assays to assess the ability of the iTreg to suppress responder 
cells. Two well-described in vitro assays were used: a quick suppression assay that 
determines the capacity of Treg to suppress the upregulation of early activation markers, 
such asCD69 and CD154, and the conventional 5-day suppression assay, which 
determines the capacity of Treg to suppress responder cell proliferation. 
For the quick suppression assay, generated iTreg, expanded Treg and Tconv were 
co-cultured with DC-autologous PBMC at different ratios together with a fixed ratio of 
αCD3αCD28 Dynabeads (1:4 beads:PBMC). The cell mixture was incubated for 7 hours 
and the responder PBMC were analyzed for expression of CD69 and CD154 (Figure 
4.29A and B). The percentage of suppression was determined by calculating the 
Results 
 
106 
 
reduction of CD69 or CD154 expression with the no Treg control (0:1). I compared the 
suppressive capacity of norm iTreg to all other iTreg, as well as expanded Treg and 
Tconv. There were no statistically significant differences, which is to be expected given 
the high variation among the donors. However, there is a clear trend that expanded Treg 
exhibited the highest suppressive capacity for both CD69 and CD154 expression down 
to a Treg: responder ratio of 1:8. Although, Tconv and norm iTreg were included as Treg 
negative controls, these two cell types exhibited the next highest suppression capacities. 
Dex, VD3 and combi iTreg were least suppressive for CD69 and CD154 expression. To 
show the limitations of this assay, I also added corresponding cell numbers of 
autologous PBMC instead of Treg to the responders. The additional PBMC resulted in a 
bead diluting effect at the 1:2 ratio that could be interpreted as a 21.6 % for CD69 and 
22.8 % for CD154 suppression.  
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Figure 4.29 Quick suppression assay for the expression of activation markers CD69 and CD154. 
iTreg (norm, Dex, VD3, combi) Treg and Tconv were analyzed for their suppressive capacity on day 14 of 
the stimulation. The cells were plated at different ratios with DC-autologous PBMC together with 
αCD3αCD28 Dynabeads (1:4 beads:PBMC) for 7h. The expression of (A) CD69 and (B) CD154 was 
measured by flow cytometry. Percentage suppression was calculated based on PBMC only sample (0:1). 
Expression of activation markers CD69 and CD154 are shown for one condition from one donor in stacked 
histograms at different Treg: responder ratios as well as a histogram gating example for 0:1 and 1:2 ratio (left 
plots). The data of three independent experiments is summarized in the graphs that display the percentage 
suppression over the different Treg:responder ratios for Treg (blue), Tconv (grey), norm iTreg (red), Dex 
iTreg (black triangle), VD3 iTreg (‘black diamond), combi iTreg (black circle) and PBMC (green square). The 
PBMC control was included to analyze the effect of decreased activation marker expression due to additional 
cells on a fixed bead number. Statistical analysis was performed using the two-way ANOVA test with 
Bonferroni correction for multiple comparisons. All samples were compared to norm iTreg, no significance 
p>0.01. 
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In addition to the quick suppression assay, I analyzed the suppressive effect of Treg 
on responder proliferation using the conventional 5 day suppression assay. DC-
autologous CD4+CD25- T cells as responders were co-cultured with iTreg, expanded 
Treg or Tconv at different ratios as well as with beads at a ratio of 1:75 adjusted to the 
total cell numbers. The Treg and responders were stained with the proliferation dyes 
efluor 450 and efluor 670, respectively. After 5 days of incubation I assessed the 
proliferation of responders as determined by the dilution of the efluor670 dyes (Figure 
4.30A). The more suppressive the Treg are the less proliferation i.e. less dye dilution of 
responders was detected. For example, 47 % of responders proliferated without Treg 
(0:1) and only 3.8 % proliferated when Treg were present at a 1:16 Treg:responder ratio. 
The percentage suppression of responder proliferation was measured for all Treg types 
at different ratios (Figure 4.30B). Compared with the suppressive capacity of norm iTreg 
only, expanded Treg were superior in the suppression of responders, significantly at 
ratios 1:16 and 1:32 (p<0.01). Dex iTreg and Tconv showed a similar suppression profile, 
while combi and VD3 iTreg were least suppressive. The percentage of suppression was 
significantly reduced for VD3 iTreg at ratios 1:4 to 1:32 (p<0.001).  
 
 
Figure 4.30 Suppressive capacity of iTreg on responder cell proliferation. iTreg (norm, Dex, VD3, 
combi) Treg and Tconv were analyzed for their suppressive capacity on day14 of the stimulation. The cells 
were stained with proliferation dyes and plated at different ratios with DC-autologous CD4+CD25- responders 
together with αCD3αCD28 Dynabeads (1:75 beads:total cells) for 5 days. (A) Representative dot plots for 
two different ratios: responders only (0:1, upper left) and 1:16 Treg: responders (lower left) for Treg 
(efluor450, blue) and responders (efluor 670, red). Proliferation was detected by gating on the 
CD25+efluor670dim responders, after Treg exclusion. (B) Percentage suppression was calculated based on 
the responder only (0:1) proliferation. The data of three independent experiments is summarized in the graph 
plotting the suppression over the different Treg:responder ratios for Treg (blue), Tconv (grey), norm iTreg 
(red), Dex iTreg (black triangle), VD3 iTreg (‘black diamond), combi iTreg (black circle). Statistical analysis 
was performed using the two-way ANOVA test with Bonferroni correction for multiple comparisons. All 
samples were compared to norm iTreg; Treg p<0.01(*) and combi iTreg p<0.0001 (***). 
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Phenotypical and morphological changes of Dex and/ or VD3 treated DCs confirmed 
the generation of tDCs. The naïve T cells that were stimulated with these tDCs exhibited 
a Treg phenotype with functional suppressive potential. However, the suppression 
capacity was much less compared to expanded Treg and only expanded Treg showed 
stable FOXP3 expression. Also, norm DCs induced-iTreg and expanded Tconv showed 
a Treg-like phenotype with suppressive activity. 
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Deciphering the plasticity and heterogeneity of human CD4+ T cells has become 
increasingly important for our understanding of immune responses in health and disease. 
Over the past decades, the contribution of CD4+ Tconv and Treg to the pathogenesis of 
T1D has been intensely studied; however, published data of phenotypic characteristics is 
still contradictory and inconsistent for these T cell subsets. In my thesis, I assessed the 
heterogeneity of CD4+ Tconv and Treg in relation to CD25 expression, with an aim to 
understand how Treg can be characterized and utilized in T1D. 
The strength of my experimental data is the combination of different in vitro analyses 
of human CD4+ T cells. Based on the findings I obtained with flow cytometric 
phenotyping, I extended the analysis by transcriptomic profiling of Tconv and Treg. 
Further, I used (auto)antigen-specific response assays for single cell gene expression 
profiling to identify the heterogeneity of CD4+ T cell populations after antigen-specific 
activation. Lastly, I evaluated the tolerogenic modulation of CD4+ T cells to induce Treg 
for potential therapeutic use.  
Overall, I showed that CD4+ T cells express a natural heterogeneity on a proteomic 
and transcriptomic level. I focused on two subpopulations, Tconv and Treg, which, in an 
unstimulated state, can be distinguished by their differential expression of CD25 (IL-2Rα) 
and CD127 (IL-7Rα). The frequency of Treg was not altered in peripheral blood samples 
from recent onset T1D patients, although I observed a high inter-individual Treg variation 
compared with healthy individuals. In the stimulated state, antigen-specific T cells were 
marked by heterogeneity on a transcriptomic level in a manner that was dependent on 
the antigen stimulus, whereas alterations in surface marker expression appeared to be 
independent of the antigen stimulus.  
I was able to show that natural phenotypic heterogeneity of CD4+ T cells exists 
based on the activation markers CD25 and CD127. These markers are frequently used 
to identify Treg among the Tconv cell pool. I validated that FOXP3 expression is a 
hallmark biomarker of Treg and that only a low frequency of CD25 negative CD4+ T cells 
express FOXP3. Although human FOXP3 is known to be transiently upregulated in 
Tconv (Allan et al., 2007; Gavin et al., 2006), I did not observe an increase of FOXP3+ 
cells among the ex vivo CD25+ Tconv. Therefore, I suggest that FOXP3 is an ideal 
marker for the identification of Treg among unstimulated PBMC from healthy individuals. 
In addition, HELIOS was solely expressed on unstimulated Treg. However, I found 
HELIOS to be expressed in some antigen-responding Tconv, which supports reports that 
5 Discussion 
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HELIOS is also a CD4+ T cell activation marker (Akimova, et al., 2011). Similar results 
were observed for ICOS, TGFβ, GITR and CTLA-4, which have been described as Treg 
associated markers as well as general CD4+ T cell activation markers. Gene expression 
and, in part, also protein phenotyping (for ICOS and TGF-beta) showed that these 
markers are indeed more frequently expressed in unstimulated Treg, but are upregulated 
to a similar level in Tconv after stimulation by antigen. However, the upregulation of gene 
expression in Treg and Tconv was highly dependent on the type of antigen. I was able to 
show that foreign antigens, in my case TT (bacterial origin) and Flu (viral origin), are a 
strong stimulus for both Treg and Tconv, while autoantigens GAD65 and PI resulted in 
less upregulated gene expression in responding T cells.  
In general, the antigen-specific response of Tconv and Treg resulted in an overlap of 
gene upregulation, leading to a merged phenotype that made it difficult to distinguish 
between the two populations. The core set of Treg specific genes for TT response were 
FOXP3, HELIOS, CTLA4 and a lack of RGS16 and CD127 (see Figure 4.21). Except for 
RGS16, which is a regulator of G-protein signaling, these genes have been commonly 
associated with Treg phenotypes. A publication from 2005 showed that Treg expressed 
more RGS16 than naïve T cells and that the expression was upregulated in both cell 
types upon activation (Agenes, et al., 2005). I also observed the upregulation of RGS16 
in antigen-stimulated Tconv (see Figure 4.19). The analysis of TT responding cells 
strikingly showed that even the core Treg genes were upregulated in Tconv and, 
although differences between antigen-stimulated Treg and Tconv were observed, there 
was no defining marker for either of the T cell subpopulations. Antigen-responding Treg 
had much less pro-inflammatory cytokine expression compared to Tconv. The cytokine 
genes Il13, IL21 and IFNγ were highly expressed in Tconv. The only Treg-associated 
cytokine was TGF-beta, which was also shown to be specific for memory Treg. A lower 
expression of cytokine genes in the stimulated Treg is not surprising, since Treg have an 
anti-inflammatory function. In the context of type 1 diabetes associated autoantigens, I 
observed a mild antigen response to autoantigens (PI and GAD65) compared with TT 
and Flu. The comparison of autoantigen-responsive Tconv and Treg revealed fewer 
differences between the two subsets, with FOXP3 and HELIOS being the only Treg core 
genes. The analysis was, however, limited due to the low number of responding Treg. 
Our group has recently reported that the T cell response to an autoantigen coincides with 
the time of seroconversion and that the single cell gene expression profile of responding 
cells is diverse with a trend towards Th1/Th17/Tfh subset response (Heninger et al., 
2017). I now provide, for the first time, a profile map of gene expression in single 
antigen-responsive Treg and Tconv that will help classify responses in patients and 
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healthy individuals. Further, the profiles could also be used to distinguish between viral, 
bacterial or autoantigen responses.  
Generation of gene expression data comparing stimulated Treg and Tconv cells was 
only possible because I developed a response assay where Treg and Tconv were 
isolated with high confidence to then be stained with different proliferation dyes. With this 
assay I was able to track the origin of the antigen-responding cells. The advantage of 
this assay is that the dye-stained T-cells remain within the PBMC pool during in vitro 
stimulation, which is closer to physiological conditions where antigen presenting cells 
and B cells are present. However, a drawback is the low percentage of Treg within 
PBMC, which resulted in a low number of responding cells that could be analyzed. Also, 
the stimulation should not exceed more than 5 days, since prolonged antigen stimulation 
would lead to an overlap of proliferated cells within the proliferation dye channels due to 
the dilution of the dyes. Initially, I established assays using three dyes to also 
discriminate naïve and memory Treg, but I only observed responsive cells originating 
from the memory pool (data not shown). Therefore, I combined these two populations, 
which also simplified the assay. In this study I was able to show that up to three 
populations can be monitored simultaneously in an antigen-specific response assay 
using fluorescence based proliferation dyes. Hereby, I was able to increase the 
complexity of cell analysis without compromising the sensitivity and specificity of an 
antigen response assay. The assay may still be optimized by alternative selection of 
proliferation dyes, increasing the number of phenotypic markers to observe possible 
heterogeneity among the antigen-responsive cells or by optimizing the media 
composition that favors the specificity of antigen response and reduces background 
proliferation in medium controls.  
Regarding the phenotypic heterogeneity of CD4+ T cells in T1D patients, I chose 
age-matched samples at disease onset, with an average time of sample collection of 
10.9 days after disease onset. However, the use of recent-onset T1D patient samples 
may possibly lead to phenotypic observations caused by ongoing dysglycemia and high 
HbA1c levels. Thus, samples from autoantibody positive patients before T1D onset were 
also included in the validation study to investigate the early asymptomatic phase of 
disease. Such individuals are believed to have an ongoing functional beta-cell loss, but 
are still able to sufficiently compensate for the reduced insulin secretion. My analysis 
was primarily focused on the Treg phenotype, which has been inconsistently shown to 
be changed in T1D. My results showed that there were no differences in these two 
cohorts compared to healthy individuals. The frequencies of the overall Treg population 
(CD25+CD127loFOXP3+) as well as the composition of the naïve and memory repertoire, 
Discussion 
 
114 
 
including effector and central memory Treg, were found to be equal in patients and 
healthy individuals. Similar results have been reported by Todd Brusko et al. who 
analyzed CD4+CD25+FOXP3+ Treg from new onset and established T1D patients 
(Brusko et al., 2007). Earlier studies of Treg in T1D have showed either reduced or 
normal frequencies Treg, but mostly only CD4 and CD25 markers were used to 
distinguish Treg from Tconv (Kukreja et al., 2002; Lindley et al., 2005; Putnam et al., 
2005). In addition to the common Treg lineage markers, I included several functional 
markers, such as HELIOS, ICOS, TGF-beta, CD69 and Ki-67, that also did not indicate a 
functional Treg loss. However, the ex vivo phenotyping was not designed to cover the 
functional analysis of Treg. To identify functional deficiencies of Treg in T1D patients, in 
vitro suppression assays would have been necessary, but such experiments were 
beyond this thesis due to limited patient samples and cell numbers. To my knowledge, 
this study displays the most comprehensive phenotyping of Treg from T1D patients to 
evaluate Treg deficiencies. 
To address potential reasons why I did not detect differences in the phenotype of 
Treg from T1D patients as compared to healthy individuals, one could argue that the 
analysis was performed with frozen PBMC and not freshly isolated cells, which was 
necessary because of limited access to fresh samples. Furthermore, T1D is a local 
disease that only directly affects beta-cells in the pancreas and, therefore, immunological 
effects might not be visible in the peripheral blood. Lastly, ex vivo analysis gives no 
direct evidence of functional defects of Tconv or Treg and further in vitro stimulations 
may be required to resolve immunological differences in T1D patients compared to 
healthy individuals. There are very few reports on organ-specific human Treg 
phenotypes that show defects of Treg. In 2011, the group of Battaglia reported that 
pancreatic lymph nodes from T1D patients show a functional defect of Treg and an 
expansion of Th17, whereas this Th17/Treg imbalance was not seen in the patients’ 
blood (Ferraro, et al., 2011). Other groups identified functional Treg loss in T1D patients 
rather than a change of frequency (Glisic-Milosavljevic et al., 2007; McClymont et al., 
2011).  
A restricted number of phenotypic markers for flow cytometric analysis cannot cover 
all Treg and T1D associated molecules. Therefore, I performed RNAseq on isolated 
Tconv and Treg from T1D patients and healthy individuals. The cells were freshly 
isolated from PBMC samples to avoid freeze-thaw effects on the transcriptomic analysis. 
Due to low cells numbers, Treg cDNA was pre-amplified for RNAseq processing, which 
was not the case for Tconv. Previous reports on Treg vs. Tconv gene expression have 
shown that they differ substantially and that many of the Treg-associated genes have 
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also been validated at the proteomic level (Ferraro et al., 2014; Li et al., 2013; Pfoertner 
et al., 2006). Here though, the interest lay within the comparison of healthy vs. T1D. 
Surprisingly, the Treg comparison showed no significant differences in expression for 
any gene, except for EIF3L (padj= 0.08), a seemingly unrelated transcription factor. The 
high inter-individual variation of the Treg RNAseq data was most likely the key 
contributor to my reduced ability to identify differences in the T1D cohort. Similar 
observations have been made by other groups, although they have identified various 
differentially expressed genes. In 2014, Ferraro et al. reported that microarray analysis of 
Treg from established T1D patients vs. healthy individuals resulted in no significantly 
changed gene expression, although the T1D transcript was “subtly perturbed” (Ferraro et 
al., 2014). The group also observed large variability of Treg-associated gene expression 
that control effector function (ENTPD1, FCRL1) and lineage-specificity (FOXP3 and 
IKZF2 (HELIOS)).  
Treg phenotyping as well as whole transcriptomic analysis convinced me that 
peripheral Treg in T1D patients are not altered, neither in frequency nor in the 
expression of functional molecules. There is a natural heterogeneity among the 
CD4+CD25+ population and a high inter-individual variation that can be found in patients 
as well as healthy individuals. If there are any changes of Treg in the periphery of T1D 
patients, then they are most likely subtle and the cohort sample numbers would need to 
be increased to have sufficient power to detect such differences. 
I also compared the transcriptomic profile of Tconv (CD4+CD25-) populations from 
recent-onset T1D patients and healthy individuals and identified 94 genes that were 
differentially expressed (FDR= 0.1). A set of genes (STAT1, IRF1, IRF9 and MX1) 
associated with the Interferon I signaling pathway was significantly downregulated in 
T1D samples. Type 1 Interferons are mainly produced by monocytes and fibroblasts to 
fight viral infections. Two studies have previously reported an increase in the type 1 IFN 
response preceding T1D autoantibody seroconversion (Ferreira, et al., 2014; Kallionpaa, 
et al., 2014). Upregulation of these genes was detected by microarrays in both studies. A 
recent study from Kasela et al. identified a SNP variant of the IL27 gene locus that 
specifically reduces gene expression of IRF1 and STAT1 in CD4+ T cells (Kasela, et al., 
2017). The group further argued that the SNP is associated with a reduced risk for T1D 
(Barrett, et al., 2009). The literature indicates that there is a strong association between 
type 1 IFN pathway genes and innate cells and that upregulation of these genes is most 
commonly reported for T1D patients, rather than downregulation, as was observed in this 
study.  
Discussion 
 
116 
 
Apart from the set of downregulated genes, I identified several genes that were 
upregulated in Tconv from recent-onset T1D patients. Interestingly, 10 of those genes 
also showed upregulated protein expression using the mass spectrometry approach, 
which resulted in a 14% overlap of the identified genes (AZU1, CTSG, DEFA3, ELANE, 
LTF, MPO, PRTN3, RETN and RNASE3). Almost all of these genes are expressed in 
neutrophils: ELANE (Elastase, neutrophil expressed), CTSG (cathepsin G), and PRTN3 
(proteinase 3) are neutrophil serine proteases and are stored in the azurophilic granules 
of mature neutrophils (Kalupov, et al., 2009). Also MPO (myeloperoxidase), AZU1 
(azurocidin 1), DEFA3 (defensin, alpha 3) are major components of the azurophilic 
granules (Almansa, et al., 2012). LTF (lactoferrin) and MPO have recently been reported 
to be expressed in monocytes to form extracellular traps (ETs) apart from their function 
in neutrophil ETs (Granger, et al., 2017). RETN (resistin) has also been described to play 
a role in neutrophilic pro-inflammatory activation (Jiang, et al., 2014) and RNASE3 
(ribonuclease 3) is a cytotoxic molecule that is produced by activated eosinophils (Kang, 
et al., 2010). To date, only MPO and RETN have been reported in the context of type 1 
diabetes. In a recent study from 2017, children with T1D as well as obese children 
showed increased serum levels of MPO, and also ICAM-1, arguing that they are markers 
for inflammatory and oxidative stress (Marcovecchio, et al., 2017). Further, Shalev et al. 
reported in 2004 that resistin levels were increased in the serum of T1D patients pre-islet 
transplantation, which may be a response to the pro-inflammatory pathophysiology 
(Shalev, et al., 2004). However, none of the mentioned genes have been described in 
CD4+ T cells. I have considered possible explanations for these findings. It is possible 
that the isolation of CD4+ T cells, which was performed using MACS, may have included 
neutrophil contamination arising from attachment to the CD4+ T cells. It is also possible 
that there is in vivo transfer of material from neutrophils to CD4+ T cells. In both cases, 
the increased expression of neutrophil-associated genes and proteins in the T1D 
patients would indicate that there is elevated attachment or transfer in patients with T1D. 
T1D patients have reduced neutrophil counts (Harsunen, et al., 2013; Valle, et al., 2013), 
and it is possible that my findings in some way reflect an abnormality in the neutrophil 
population. Two reviews have summarized recent research results on the role of 
neutrophils in T1D immunopathology that point out their role in direct beta-cell 
destruction and initiation of T-cell responses (Battaglia, 2014; Huang, et al., 2016). I 
propose that a repetition of the experiments using FACS purification with a purity of ≥ 
99 % can elucidate the contamination issue and that the direct analysis of innate cells 
including neutrophils, eosinophils and monocytes might be of increased interest.  
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As a final contribution to my thesis, I used the information I obtained from my Treg 
analysis to examine the potential therapeutic modification of T cells to obtain Treg. 
Based on reports by Roep et al. that Treg can be induced by tolerogenic DCs in vitro, I 
compared tolerogenic versus non-tolerogenic conditions using a similar protocol 
(Kleijwegt et al., 2010; Unger et al., 2009). To ensure robust and reproducible results 
only allogeneic DCs were used instead of autoantigen-loaded autologous DCs. The 
compounds VD3 and Dex altered the differentiation of DCs (Ferreira et al., 2012), which I 
was able to confirm by comparing the phenotype of normal generated DCs with tDCs. In 
general, the VD3/Dex-treated DC surface marker profile revealed a semi-mature 
phenotype shown by CD14+, CD1a-, CD80lo, CD40Io, PD-L1hi expression. I also 
assessed whether the tDCs would function in a tolerogenic manner. To investigate the 
maturation and activation of immature DCs, tDC were stimulated with LPS, which is 
required for DC to present antigen (Anderson, et al., 2009). The secretion of anti-
inflammatory IL-10 is associated with tDCs, while pro-inflammatory IL-12 is produced by 
normal DCs. I was able to show that only upon activation with LPS mature DCs secrete 
IL-10, with increased levels from tDCs, especially those treated with Dex (Xia, et al., 
2005). However, I was unable to detect IL-12 (p70) secretion from mature DCs since 
DCs generally require two signals, for example LPS in combination with CD40L or IFNγ, 
in order to secrete functional IL-12 (Snijders, et al., 1998).  
To generate iTreg, tDCs or normal DCs were co-cultured with allogeneic naïve CD4+ 
T cells. The intention was to manipulate the T cells by stimulating them with DCs that 
have an anti-inflammatory character that would provide the necessary signals to induce 
a Treg phenotype with suppressor function. Two consecutive rounds of stimulation and a 
resting phase with low dose IL-7/IL-15 were included in the protocol to stabilize iTreg 
instead of solely activating T cells. Simultaneously, I polyclonally expanded isolated Treg 
according to our established protocol (Putnam et al., 2009; Theil, et al., 2015a) and also 
adapted this protocol to expand Tconv from naïve T cells. Expanded Treg and Tconv 
served as controls for all Treg assays. By phenotyping the T cells during the 14 days of 
induction, I was able to show that T cells upregulate CD25 expression, which coincided 
with FOXP3 expression, although expression levels of both proteins were not stable over 
time. In contrast, CD25+ cells constitutively expressed CD45RO and CTLA-4. 
Methylation of the FOXP3 TSDR was up to 100 % for the iTreg populations. Expanded 
Tconv showed a similar phenotype to the iTreg populations in terms of marker 
expression and methylation status, while polyclonally expaned Treg expressed stable 
CD25 and FOXP3 and exhibited variable expression of LAP in up to 90 % of Treg. 
Expanded Treg were also the only population that showed demethylation of the FOXP3 
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TSDR, where higher methylation rates of two donors were due to the sex (female) and 
therefore the silencing of one X-chromosome by methylation. It could be reasoned that 
the inconsistent Treg phenotype as well as the methylation of FOXP3 TSDR are 
indications of an unstable iTreg population. Of particular note is that tDCs, which have 
been treated with VD3, appeared to be less viable, resulting in a low yield of mature 
DCs. This was most likely due to the strong dendrite formation during DC differentiation 
and the associated difficulties to detach these cells. Similar observations have also been 
made by Ferreira et al. (Ferreira et al., 2012). I also assessed the ability of T cells to 
produce IL-2 during the stimulation. Although T cells expanded continuously until day 12, 
IL-2 was only detectable until day 3 of the stimulation. iTreg expansion was greatest in 
the presence of normDCs, however, expansion of Treg and Tconv exceeded iTreg by up 
to 1000 fold. The continuing expansion of iTreg without detectable IL-2 suggests that 
during the induction the cells lose the ability to produce IL-2 and thus consume all 
exogenous IL-2.  
The inability to secrete IL-2 has also been described for Treg populations and has 
been proposed to be a suppressive mechanism of Treg, whereby depleting exogenous 
IL-2 blocks proliferation of Tconv (Thornton and Shevach, 1998). To evaluate the 
suppressive capacity of iTreg, as well as nTreg and Tconv, I used two different assays: 
the quick suppression assay and the conventional 5 day suppression assay. Both are 
based on the suppression of allogeneic responder PBMCs, which come from the same 
donor as the tDCs, and on stimulation with αCD3/αCD28 microbeads. The quick 
suppression assay showed no difference in the suppression of responder PBMCs by 
iTreg induced by normal DCs or tDCs. Only expanded Treg were superior to all other 
populations in the suppression of activation markers. The assay was based on the 
publication of Ruitenberg et al. from 2011, where they use a fixed number of microbeads 
with increasing numbers of PBMCs and Treg (Ruitenberg et al., 2011). By adding 
additional PBMC in place of Treg, the total cell number in each well was increased and a 
“suppressive” effect observed, which is likely due to the lower cell to bead ratio. A 
reduction of up to 20 % of CD69 and CD154 expression is only due to the change in cell 
number. I therefore suggest that the PBMC only control would need to always be 
included when performing this assay in order to subtract the reduced marker expression 
from the Treg assay. The same would need to be done with the commercially available 
Fastimmune human regulatory T cell function kit provided by BD Biosciences, since it is 
based on the same published assay. The 5-day suppression assay showed a more 
distinguished picture than the quick suppression assay. Based on the proliferation of 
bead-activated CD4+ responder cells, I measured the proliferation dye dim cells in the 
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presence or absence of the Treg populations with cell-number-adjusted αCD3/αCD28 
microbead numbers. Compared to iTreg from normal DCs, only expanded Treg were 
more suppressive. Interestingly, not only responder cells proliferated, but also the Treg 
populations (data not shown). In general, there was greater proliferation of iTreg when 
the initial iTreg input was lower. Based on this observation, I reason that the suppressive 
function of iTreg is to withdraw exogenous IL-2 that has been produced by responder 
cells upon microbead activation, i.e. Treg present at low frequency can consume more 
exogenous IL-2 and therefore show an increased proliferation (McMurchy and Levings, 
2012). However, this hypothesis would need to be addressed by conducting additional 
experiments, such as measuring IL-2 secretion by responder cells in the presence of 
absence of Treg to gain insight into activation of responders. The suppressive function 
can further be evaluated by inhibitory experiments, such as the blocking of the IL-2 
receptor or by transmembrane assays, to observe if responder cells and Treg need to be 
in close contact for suppression.  
In general, I did not observe a stable iTreg phenotype induced by tDCs, despite the 
semi-mature nature of the tDCs. Only polyclonally expanded Treg were superior in 
phenotype and function. Taking together the knowledge of tDC generation, stimulation 
and expansion of T cells as well as the functional aspect, it could be interpreted that 
prolonged in vitro cultivation results in T cell exhaustion. Reports on T cell exhaustion 
have mainly described the viral burden on CD8 and less on CD4 (Jin, et al., 2011; 
Schietinger and Greenberg, 2014; Yi, et al., 2010). However, one aspect of exhaustion is 
the continuous stimulation of T cells, which was for 14 days to generate iTreg, and a loss 
of autologous IL-2 production, which results in the dependency of exogenous IL-2. Also, 
T cell exhaustion is characterized by a loss of pro-inflammatory cytokines and 
expression of inhibitory receptors including CTLA-4, TIM-3, LAG-3 and PD-1. However, 
whether IL-2 deprivation is a result of Treg function or T cell exhaustion would need to be 
determined by additional experiments. For example, single-cell sorting of CD25+ and 
CD25- T cells with further analysis by multiplex gene expression could provide insight 
into the differential expression of the above-mentioned molecules and the heterogeneity 
of the T-cell subpopulations.  
Overall, human studies rely on functional in vitro assays and therefore robust and 
sensitive methods to measure antigen-specific T cell responses are required. These rare 
events (≤ 0.5 % of total CD4+ T cells) need to be defined with high confidence. 
Therefore, our group is continuously optimizing and standardizing in vitro proliferation 
assays. Human serum (5 % HS) is used instead of fetal calf serum since it is much 
closer to physiological and self-antigen conditions. In addition, the use of whole PBMCs 
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serves as an important environment for antigen-responsive cells, including APCs, CD8 T 
cells and innate immune cells. The use of proliferation dyes to label total PBMCs or 
single subpopulations offers the possibility to track antigen-responding cells over time, 
which can then be single-cell sorted based on the dim expression of the dye with a 
combination of phenotyping surface markers. We have established a stable workflow to 
simultaneously analyze more than 75 genes by multiplex gene expression profiling, 
which provides new insights into rare populations that are difficult to analyze by standard 
RNAseq techniques. Future development of this T-cell workflow is ongoing and it has 
already been used to analyze samples collected as part of a clinical trial investigating the 
effect of immunization with oral insulin on T1D autoimmunity as early as 6 months after 
birth (PrepointEarly), which is based on the Prepoint trial (Bonifacio et al., 2015). The 
discovery of novel biomarkers for T1D risk and disease progression is not only limited to 
antigen-specific T cells, but can be expanded to other peripheral blood cell types. The 
use of multicolor flow cytometry, however, is limited due to the restricted number of 
channels that are available for fluorescence-based antibody detection. During my PhD, I 
had the opportunity to establish the state of the art Mass Cytometry approach at our 
institute. Using mass detection of metal isotope conjugated antibodies, more than 50 
markers can be analyzed simultaneously resulting in a more complex phenotype from 
one sample (Tanner, et al., 2013; Yao, et al., 2014). A future project includes the 
screening of whole blood samples from children who genetically at-risk of developing 
T1D that have been stimulated with various immune modulators, such as cytokines and 
TLR stimuli, to identify differences in the cell signaling profile compared to healthy 
controls (Fernandez and Maecker, 2015). The combination of phenotyping and functional 
assays will help us to decipher the complex structure of immune responses and their 
heterogeneity (Figure 5.1).  
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Figure 5.1 Future aspects of monitoring immune responses in children at high risk for T1D. 
Whole blood samples or isolated PBMC can be used for complex immune-phenotyping by mass cytometry 
(upper path) or to profile proliferation dye- dim antigen responsive T cells using single cell gene expression 
(lower path). The obtained results can serve as the basis to develop future T1D prevention strategies and to 
elucidate their efficacy. 
 
With this thesis, I have contributed to the understanding of human CD4+ T cell 
heterogeneity in an ex vivo state as well as under antigen-specific or modulating 
conditions. I used a combination of state of the art techniques and established assays to 
evaluate similarities and differences of Treg and Tconv. This work has already 
demonstrated an improved in vitro T cell assay setup and data analysis that can be used 
for ongoing and upcoming insulin immunization clinical trials. Overall, my data shows 
that there is a natural heterogeneity within cell populations and among individuals and 
emphasizes that it is important that such heterogeneity needs to be thoroughly 
investigated in future research to not only identify useful biomarkers, but also to 
understand disease pathology and the effect of new therapeutic treatments.   
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Background 
Regulatory T cells (Treg) are a subpopulation of CD4+ T cells that play an important 
role in the peripheral tolerance mechanisms of the immune system. Their suppressive 
function on autoreactive T cells can prevent autoimmunity. In type 1 diabetes (T1D), 
Treg have been inconsistently reported to be impaired in their capability to suppress 
autoreactive T cells (Tan et al., 2014; Zhang et al., 2012). 
Treg can be thymus derived (tTreg) or generated from naïve CD4+ CD25- T cells in 
the periphery (pTreg), which exhibit similar suppressive qualities as tTreg. They have 
also been reported to be actively induced (iTreg) under tolerogenic conditions (Kleijwegt 
et al., 2010; Yuan and Malek, 2012). Although several Treg subpopulations have been 
described, the archetypical Treg express the major markers CD4, CD25 and FOXP3, 
while CD127 is heavily downregulated. However, activated conventional T cells (Tconv) 
show a similar phenotype, at least transiently (Miyara et al., 2009). Since Treg and 
Tconv have opposing functions and therapeutic indications, it is important to obtain 
markers that confidently identify bona fide Treg.  
 
Scientific aim 
The aim of my thesis is to define the heterogeneity of human T cells with a specific 
emphasis to identify bona fide Treg. I examined heterogeneity of this population in 
healthy controls and T1D patients, as my model disease, and examined how T cells that 
are exposed to antigen can be defined as Treg or Tconv.  
 
Material and Methods 
For marker phenotyping I used samples from new onset T1D patients (age 7-11 
years), autoantibody positive (Aab+) patients and age-matched healthy controls, which 
were tested by flow cytometry with an array of Treg-associated markers. Separately, 
freshly isolated CD4+CD25+CD127lo Treg and CD+CD25- Tconv were used for 
transcriptomic analysis, which was done by RNAseq on isolated whole RNA.  
For functional analysis of antigen specific gene expression patterns I developed a 
multi-dye proliferation assay. Treg (CD4+CD25+CD127lo) and Tconv (CD4+CD25-
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CD127+/lo) were sorted from isolated peripheral blood mononuclear cells (PBMC). I 
recombined the sorted and proliferation dye stained subsets with CD4- cells to simulate 
whole PBMC assays and stimulated them with tetanus-, influenza- or auto-antigens 
(GAD65, proinsulin). Cells were incubated for 5 days and responding proliferating cells 
as well as non-responding cells were single cell sorted and analyzed by multiplex qPCR. 
In investigating therapeutic approaches to expand or generate Treg, I examined in 
vitro approaches for de novo induction of Tregs with tolerogenic dendritic cells (tDCs). 
The tDCs were differentiated from monocytes either in the presence of 1α,25-
OH(2)Vitamin D3 and/or Dexamethasone and matured with lipopolysaccharide. In a 
multistep assay, naïve T cells were incubated with DCs for two rounds and functional 
suppression assays were performed. The resultant T cells were analyzed at the DNA, 
protein, and functional level. 
 
Results 
Substantial phenotypic heterogeneity of peripheral blood CD4+ T cells was observed 
and documented for three major populations: resting Tconv (CD25-CD127+/lo), activated 
Tconv (CD25+CD127+) and Treg (CD25+CD127lo) in healthy controls. Despite this, I 
observed no differences between the Treg subpopulations from new onset T1D patients, 
Aab+ patients and healthy controls. In addition, there were no differences in the Treg 
transcriptome of T1D patients and healthy controls by RNAseq. I was, however, able to 
identify a small set of differentially expressed genes was discovered in Tconv suggesting 
a role of neutrophils in the onset of T1D. 
Heterogeneity of antigen-responsive Tconv and Treg was identified by gene 
expression profiling. I was able to define Treg specific as well as activation specific 
profiles, and found different expression profiles if T cells are foreign antigen or 
autoantigen activated and if the responding cells are Treg or Tconv. Genes that define 
the specific profiles include FOXP3, CD127, several cytokines, transcription factors and 
activation markers.  
The manipulation of naïve CD4+CD25- T cells by tDCs led to an unstable 
CD25+CD127loFOXP3+ phenotype of the generated cells. However, none of the 
subsequently performed functional assays could confirm that the resultant cells were 
iTreg or exhausted activated Tconv. In particular, methylation status of the Treg-specific 
demethylated region (TSDR) was inconsistent with stable Treg, suggesting that so-called 
tolerogenic protocols may not lead to a long-lived Treg phenotype. 
 
Summary 
 
125 
 
Conclusion 
CD4+CD25+ T cells are heterogeneous. I defined marker combinations that will help 
distinguish Treg from ex vivo and in vitro activated Tconv cells. With these tools, I was 
able to show that healthy controls and patients with type 1 diabetes cannot be 
distinguished by Treg phenotype. Comprehensive single cell analysis of antigen 
activated T cells provided the most promising avenue for identifying antigen-specific Treg 
and opens new possibilities to analyze immune therapeutic approaches, particularly 
when Treg expansion is the therapeutic objective. The findings will be used for 
monitoring children participating in antigen-based prevention studies in children at risk 
for T1D. 
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Hintergrund 
Regulatorische T Zellen (Treg) sind eine Subpopulation der CD4+ T Zellen, welche 
eine wichtige Rolle in den peripheren Toleranzmechanismen des Immunsystems 
spielen. Ihre suppressive Funktion auf autoreaktive T Zellen kann Autoimmunität 
verhindern. Verschiedene Studien berichteten widersprüchlich, dass Treg in Typ 1 
Diabetes (T1D) in ihrer Fähigkeit beeinträchtigt sind autoreaktive T Zellen zu 
supprimieren (Tan et al., 2014; Zhang et al., 2012). 
Treg können im Thymus differenzieren (tTreg) oder aus peripheren naïven 
CD4+CD25- T Zellen generiert werden (pTreg), welche ähnliche suppressive 
Eigenschaften wie tTreg besitzen. Es wurde außerdem berichtet, dass Treg aktiv unter 
tolerisierenden Konditionen induziert werden können (iTreg) (Kleijwegt et al., 2010; Yuan 
and Malek, 2012). Obwohl verschiedene Treg Subpopulationen beschrieben wurden, 
exprimieren die archetypischen humanen Treg die Hauptmarker CD4, CD25 und FOXP3 
exprimieren, während CD127 herunterreguliert ist. Jedoch zeigen auch aktivierte 
konventionelle T Zellen (Tconv) diesen Phänotyp (Miyara et al., 2009). Da Treg und 
Tconv gegensätzliche Funktionen und therapeutische Indikationen aufweisen, ist es 
wichtig Marker zu erhalten, die sicher bona fide Treg identifizieren.  
 
Fragestellung 
Das Ziel meiner Arbeit ist es, die Heterogenität von humanen T Zellen zu definieren 
mit einen spezifischen Fokus bona fide Treg zu identifizieren. Dafür untersuchte ich die 
Heterogenität dieser Zellpopulation in gesunden Individuen und T1D Patienten, als 
Krankheitsmodell, und wie T Zellen als Treg oder Tconv definiert werden können wenn 
sie einem Antigen ausgesetzt sind.  
 
Material und Methoden 
Für das Phänotypisieren habe ich Proben von Patienten mit beginnendem T1D (Alter 
7-11 Jahre), Autoantikörper positiven Patienten (Aab+) und gesunden Individuen mittels 
Durchflusszytometrie auf eine Reihe von Treg-assoziierten Markern getestet. Des 
Weiteren wurden frisch isolierte CD4+CD25+CD127lo Treg und CD+CD25- Tconv für die 
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Transkriptomanalyse (RNAseq) genutzt, welche mit der Gesamt-RNA durchgeführt 
wurden.  
Für die funktionelle Analyse von Antigen-spezifischen Genexpressionsmustern habe 
ich ein Multifarbenproliferationstest entwickelt. Treg (CD4+CD25+CD127lo) und Tconv 
(CD4+CD25-CD127+/lo) wurden aus isolierten mononukleären Zellen des peripheren 
Blutes (PBMC) sortiert. Ich habe die sortierten und gefärbten Zellen mit CD4- Zellen 
zusammengefügt, um einen Gesamt-PBMC-Test zu simulieren und habe die Zellen mit 
Tetanus-, Influenza- oder Auto-antigen (GAD65, Proinsulin) stimuliert. Die Zellen wurden 
für 5 Tage inkubiert und die Antigen-reagierenden und -proliferierenden Zellen sowie die 
nicht-reagierenden Zellen Einzelzell sortiert und mittels Multiplex qPCR analysiert.  
Um therapeutische Ansätze zum Expandieren oder Generieren von Treg zu 
untersuchen, habe ich in vitro Ansätze für die de novo Induktion von Treg durch die 
Nutzung von tolerisierenden dendritischen Zellen (tDCs) untersucht. Die tDCs wurden 
von Monozyten in Anwesenheit von 1α,25-OH(2)Vitamin D3 und/oder Dexamethason 
differenziert und mit Lipoploysaccharid maturiert. Naïve T Zellen wurden in einem 
Mehrschrittverfahren mit DCs inkubiert. Die resultierenden T Zellen wurden auf DNA, 
Protein und funktioneller Ebene analysiert. 
 
Ergebnisse 
Substantielle phänotypische Heterogenität von peripheren Blut CD4+ T Zellen wurde 
in drei Hauptpopulationen in gesunden Individuen beobachtet und dokumentiert: 
ruhende Tconv (CD25-CD127+/lo), aktivierte Tconv (CD25+CD127+) und Treg 
(CD25+CD127lo). Weiterführend ergab der phänotypische Vergleich von Patienten mit 
beginnender T1D, Aab+ Patienten und gesunden Individuen keine Unterschiede in den 
Treg Subpopulationen. Außerdem zeigten sich keine Unterschiede in den durch RNAseq 
gemessenen Treg Transkriptomen von T1D Patienten und gesunden Individuen. Jedoch 
wurde ein kleine Gruppe von differentiell exprimierten Genen in Tconv entdeckt, welche 
eine mögliche Rolle von Neutrophilen in T1D andeuten.  
Heterogenität von Antigen-spezifischen Tconv und Treg Antworten wurde durch 
Genexpressionsanalysen identifiziert. Ich konnte Treg- sowie Aktivierungs-spezifische 
Muster definieren und verschiedene Expressionsprofile finden, wenn T Zellen durch 
Fremd- oder Autoantigen aktiviert wurden und ob sie die reagierenden Zellen Treg oder 
Tconv sind. Folgende Gene waren hauptsächlich in die Profilbildung involviert: FOXP3, 
CD127, mehrere Zytokine, Transkriptionsfaktoren und Aktivierungsmarker.  
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Die Manipulation von naïven CD4+CD25- T Zellen durch tDCs führte zu einem 
instabilen CD25+CD127loFOXP3+ Phänotyp der generierten Zellen. Jedoch konnte keiner 
der weiterführenden funktionellen Analysen unterscheiden, ob die resultierenden Zellen 
iTreg oder aktivierte erschöpfte T Zellen waren. Insbesondere war der 
Methylierungsstatus der Treg-spezifisch demethylierten Region (TSDR) nicht konsistent 
mit einen stabilen Treg Phänotyp, was darauf hinweist, dass sogenannte tolerisiernde 
Protokolle nicht zu einem langlebigen Treg Phänotyp führen. 
 
Schlussfolgerungen 
CD4+CD25+ T Zellen sind heterogen. Ich habe Markerkombinationen definiert die 
helfen werden Treg von ex vivo und in vitro aktivierten Tconv Zellen zu unterscheiden. 
Mit diesen Mitteln war ich in der Lage zu zeigen, dass gesunde Individuen und Patienten 
mit Typ 1 Diabetes nicht anhand ihres Treg Phänotyps unterschieden werden können. 
Umfassende Einzelzell-Analysen von Antigen aktivierten T Zellen lieferten den 
vielversprechendsten Ansatz für die Identifizierung von Antigen-spezifischen Treg und 
eröffnen neue Möglichkeiten um immuntherapeutische Ansätze zu analysieren, 
insbesondere wenn Treg Expansion das therapeutische Ziel ist. Diese Erkenntnisse 
werden zukünftig für das Monitoring von Kindern, mit einem hohen T1D Risiko, genutzt 
die an Antigen-basierten Präventionsstudien teilnehmen. 
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Materials and Methods 
Appendix Table 3.1 Flow cytometer with laser and optical filter configurations 
Laser Channel Optical filter setting Fluorochrom example 
BD LSRII                   configuration: "6-Blue 6-Violet 2-355UV 3-Red neu" 
Red 
(635nm) 
 
635 A 
635 B 
635 C 
LP 755, BP 780/60 
LP 710, BP 730/45 
BP 660/20 
APC-Cy7 
Alexa700 
APC, Alexa647 
Blue 
(488nm) 
 
488 A 
488 B 
488 C 
488 D 
488 E 
488 F 
488 G 
LP 755, BP 780/60 
LP 685, BP 710/40 
LP 655, BP 660/20 
LP 600, BP 610/20 
LP 550, BP 575/26 
LP 505, BP 530/30 
BP 488/10 
PE-Cy7 
PE-Cy5.5, PerCP-Cy5.5 
PE-Cy5, 7AAD, (PerCP) 
PE-Alexa610, PI,  
PE,  
FITC, Alexa488 
SSC detector 
Violet 
(408nm) 
 
408 A 
408 B 
408 C 
408 D 
408 E 
408 F 
LP 750, BP 780/60 
LP 690, BP 710/50 
LP 630, BP 660/20 
LP 595, BP 610/20 
LP 505, BP 525/50 
BP 450/50 
BV786 
BV711 
BV650 
BV605 
Pacific Orange, BV510 
PacificBlue, eFluor450, BV421 
UV 
(355nm) 
355 A 
355 B 
LP 505, BP 530/30 
BP 450/50 
Emaerald, Indi-1 (blue) 
DAPI, BUV395 
BD FACS ARIA II 
Red 
(635nm) 
 
635 A 
635 B 
635 C 
LP 750, BP 780/60 
LP 690, BP 730/45 
BP 670/14 
APC-Cy7, APC-eFluor780 
Alexa700 
APC, Alexa647 
YellowGreen 
(561nm) 
 
561 A 
561 B 
561 C 
561 D 
561 E 
LP 750, BP 780/60 
LP 685, BP 710/50 
LP 635, BP 660/20 
LP 600, BP 610/20 
LP 570, BP 586/15 
PE-Cy7 
PE-Cy5.5, PerCP-eFluor710 
PE-Cy5, 7AAD 
PI, PE-Texas Red 
PE 
Blue 
(488nm) 
488 A 
488 B 
LP 685, BP 695/40 
LP 505, BP 525/50 
PerCP-Cy5.5, 7AAD, (PerCP) 
FITC, Alexa488 
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Laser Channel Optical filter setting Fluorochrom example 
 488 C BP 488/10 SSC detector 
Violet 
(405nm) 
405 A 
405 B 
LP 505, BP 525/50 
BP 450/50 
Pacific Orange, BV510 
Pacific Blue, eFluor450, 
BV421 
UV 
(355nm) 
355 A 
355 B 
LP 505, BP 530/30 
BP 450/50 
Emaerald, Indi-1 (blue) 
DAPI, BUV395 
BD FACS ARIA III 
Red 
(633nm) 
 
633 A 
633 B 
633 C 
LP 755, BP 780/60 
LP 690, BP 730/45 
BP 660/20 
APC-Cy7, APC-eFluor780 
Alexa700 
APC, Alexa647 
YellowGreen 
(561nm) 
 
561 A 
561 B 
561 C 
561 D 
561 E 
LP 735, BP 780/60 
LP 685, BP 710/50 
LP 630, BP 670/14 
LP 600, BP 610/20 
BP 582/15 
PE-Cy7 
PE-Cy5.5, PerCP-eFluor710 
PE-Cy5, 7AAD 
PI, PE-Texas Red 
PE 
Blue 
(488nm) 
 
488 A 
488 B 
488 F 
LP 655, BP 695/40 
LP 502, BP 530/30 
BP 488/10 
PerCP-Cy5.5, 7AAD, (PerCP) 
FITC, Alexa488 
SSC detector 
Violet 
(408nm) 
 
408 A 
408 B 
408 C 
408 D 
408 E 
408 F 
LP 750, BP 800/50 
LP 690, BP 710/50 
LP 630, BP 660/20 
LP 600, BP 610/20 
LP 502, BP 510/50 
BP 450/50 
BV786 
BV711 
BV650 
BV605, Qdot605 
Pacific Orange, BV510 
Pacific Blue, eFluor450, 
BV421 
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Appendix Table 3.2 Genes and primers for single cell gene expression profiling 
Gene  
qPCR 
Primer 5'  
qPCR 5' Sequence 5' 3'  
qPCR 
Primer 3'  
qPCR 3' Sequence 5' 3'  
IL4  2-5’  GGCAGTTCTACAGCCACCAT  1_3’  CTCTGGTTGGCTTCCTTCAC  
IL13  2_5’  GTACTGTGCAGCCCTGGAAT  1_3’  TTTACAAACTGGGCCACCTC  
INFg  2_5’  GGTCATTCAGATGTAGCGGA  1_3’  TGGATGCTCTGGTCATCTTT  
IL17f  2-5’  GCCTGTGCCAGGAGGTAGTA  1-3’  ATGCAGCCCAAGTTCCTACA  
IL10  2-5’  TTTAAGGGTTACCTGGGTTGC  1-3’  GCCTTGCTCTTGTTTTCACAG  
Egr2  2-5'  TGGAGAGAAGAGGTCGTTGG  1-3'  GTTGAAGCTGGGGAAGTGAC  
IL21  2-5'  TCGCCACATGATTAGAATGC  1-3'  AAGCAGGAAAAAGCTGACCA 
FOXP3  2-5’  ACATTCCCAGAGTTCCTCCAC  1-3’  GCGTGTGAACCAGTGGTAGAT 
Tbet  2_5’  CCGTGACTGCCTACCAGAAT  1_3’  ATCTCCCCCAAGGAATTGAC  
TGFβ 5'Taq2  TACCTGAACCCGTGTTGCTT  3'Taq1  CAACTCCGGTGACATCAAAA  
TNFα 2-5'  CCCGAGTGACAAGCCTGTAG  1-3'  TGAGGTACAGGCCCTCTGAT  
ICOS  2-5'  GGTTACCCATAGGATGTGCAG  1-3'  TCGTGCACACTGGATGAATA  
CTLA-4  2-5'  TGGGGAATGAGTTGACCTTC  1-3'  GTTGCCTATGCCCAGGTAGT  
CCR6  2-5'  TCAGCGATGTTTTCGACTCC  1-3'  CACCAGAATATTCCCCAGGA  
CCR7  2-5'  GTGGTGGCTCTCCTTGTCAT  1-3'  ATAGGGAGGAACCAGGCTTT  
CCR5  2-5'  GTCCCCTTCTGGGCTCACTA  1-3'  AAACACAGCATGGACGACAG  
SRP14  5’-2  TACTGTGGAGGGCTTTGAGC  3’  GCTGCTGCTTTGGTCTTCTT  
CCR3n  4-5'  TGTCTCGTTCTCCCTCTGCT  4-3'  AGCCACATTGTAGGGTGTCC  
GATA3  1-5'  CCGCCCTACTACGGAAACTC  1-3'  TTGGAGAAGGGGCTGAGAT  
HELIOS  2-5'  CGAAAGGGAGCACTCCAATA  1-3'  ATGGCCCCTGATCTCATCT  
IL-18RAP  2-5'  TTGCAGGAGAGCGAATTAAA  1-3'  GGTGAGAGTCGATTTCTGTGG  
c-Maf  2-5'  GGACGCGTACAAGGAGAAAT  1-3'  GCTTCCAAAATGTGGCGTAT  
PDCD1  1-5'  GCTTCCGTGTCACACAACTG  1-3'  GCACTTCTGCCCTTCTCTCT  
RORC new  4-5'  TCCCGAGATGCTGTCAAGTT  3-3'  TCCCTCTGCTTCTTGGACAT  
IL17A  3-5'  GCCAAATTCTGAGGACAAG  1-3'  GGGGACAGAGTTCATGTGGT  
CXCR5  2-5'  AAATGGACCTCGAGAACCTG  1-3'  CTTGAAGGAGGCCATGAGG  
IL9  2-5'  CTCATCAACAAGATGCAGGAAG  1-3'  TGTTTGCATGGTGGTATTGG  
IL22  2-5'  TCCAGCAGCCCTATATCACC  1-3'  GTTCAGCACCTGCTTCATCA  
AHR  2-5'  TAAAGCCAATCCCAGCTGAA  1-3'  GACGCTGAGCCTAAGAACTGA  
GMCSF  1-5'  CACTGCTGCTGAGATGAATGA  1-3'  AGGGCAGTGCTGCTTGTAGT  
GITR  3-5'  GAGTGGGACTGCATGTGTGT  3-3'  TGCAGTCTGTCCAAGGTTTG  
OX40/CD134  1-5'  CCACACAGGACACAGTCTGC  1-3'  GGTCCCTGTCCTCACAGATT  
RORA  4-5'  CACCAGCATCAGGCTTCTTT  4-3'  GGTCTGCCACGTTATCTGCT  
CCR10  6-5'  GCTGCTCTTCAGCCAGGAT  6-3'  GCGTAGCAGGCTACCATGAC  
Bcl6  2-5'  AGCCGTGAGCAGTTTAGAGC  1-3'  AAGTCCAGGAGGATGCAGAA  
CD4  1-5'  ACCGGGGAGTCCCTTTTAG  1-3'  CATTCAGCTTGGATGGACCT  
IL2  3-5'  TGGAGCATTTACTGCTGGATT  3-3'  GCACTTCCTCCAGAGGTTTG  
CD8  3-5'  GCTGGACTTCGCCTGTGATAT  4-3'  TTGTCTCCCGATTTGACCAC  
CCR4  2-5'  CAAATACAAGCGGCTCAGGT  1-3'  AGCCCACCAAGTACATCCAG  
CD127  1-5'  CTGAGGCTCCTTTTGACCTG  1-3'  CTGCAGGAGTGTCAGCTTTG  
CD40  2-5'  GTGAGAGCTGTGTCCTGCAC  1-3'  GCTTGTCCAAGGGTGACATT  
CD52  1-5'  GCGCTTCCTCTTCCTCCTAC  1-3'  CTGAAGCAGAAGAGGTGGATT  
RANTES  2-5'  ATCTGCCTCCCCATATTCCT  1-3'  ACACACTTGGCGGTTCTTTC  
REL  2-5'  GGAGCACAGCACAGACAACA  1-3'  CCGTCTCTGCAGTCTTTTCC  
RGS16  2-5'  CACGCTTTCCTGAAGACAGA  1-3'  GACCTCTTTAGGGGCCTCAC  
EOMES  1-5'  CACAAATACCAACCCCGACT  1-3'  GGGACAATCTGATGGGATGA  
CD3e  1-5'  GCACTCACTGGAGAGTTCTGG  1-3'  CCTCATCACCGCCTATGTTT  
NFATC2  2-5'  AAGAAGAGCCGAATGCACATA  1-3'  AGAAACTTCTGCGGCCCTAC  
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Results 
Appendix Table 4.1 Treg RNAseq total reads and gene assigned reads 
Sample PID total reads assigned % 
Treg 100102 38,092,833 18,121,378 47.6 
Treg 100106 60,499,371 27,188,967 44.9 
Treg 100379 35,919,446 17,714,420 49.3 
Treg 100431 34,813,098 17,509,818 50.3 
Treg 100453 37,356,335 18,491,588 49.5 
Treg 100461 35,819,787 18,035,139 50.3 
Treg 100492 40,432,742 21,045,976 52.1 
Treg 100512 32,550,094 15,380,335 47.3 
Treg 100549 43,507,786 20,412,570 46.9 
Treg 100570 43,094,025 17,933,929 41.6 
Treg 100589 41,250,268 20,172,666 48.9 
Treg 100590 47,065,543 23,243,619 49.4 
Treg 100608 52,915,522 25,174,730 47.6 
Treg 100669 45,199,917 21,507,674 47.6 
Treg 100694 36,567,504 18,767,335 51.3 
Treg 100700 43,256,850 20,450,679 47.3 
Treg 100716 35,118,094 17,790,165 50.7 
Treg 100791 46,394,773 23,739,947 51.2 
Treg 100837 43,920,961 20,756,670 47.3 
Treg 100838 42,737,468 21,926,465 51.3 
Treg 100936 41,564,757 19,006,638 45.7 
Treg 100946 35,967,340 17,334,858 48.2 
Treg 101021 38,059,866 17,619,239 46.3 
Treg 101084 38,699,470 19,436,042 50.2 
Treg 101163 40,259,144 17,262,140 42.9 
Treg 101207 33,525,940 16,385,197 48.9 
Treg 94579 28,359,526 14,150,250 49.9 
Treg 94581 35,091,038 18,830,277 53.7 
Treg 94582 41,956,009 20,604,489 49.1 
Treg 94583 61,591,382 31,700,739 51.5 
Treg 94588 48,280,895 23,552,355 48.8 
Treg 94592 41,344,723 18,457,739 44.6 
Treg 94599 44,235,219 20,689,599 46.8 
Treg 94605 35,625,524 15,990,182 44.9 
Treg 94620 36,246,481 16,969,925 46.8 
Treg 97087 36,384,270 17,578,804 48.3 
Treg 97141 29,549,570 13,903,483 47.1 
Treg 97196 34,802,847 14,094,186 40.5 
Treg 97353 43,137,044 20,672,439 47.9 
Treg 97399 31,865,122 15,173,794 47.6 
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Appendix Table 4.2 Tconv differentially expressed genes in T1D patients. 
Gene Ensembl ID HC (mean) T1D (mean) 
Log2 fold 
change 
padj 
AZU1 
ELANE 
DEFA4 
RNASE3 
CTSG 
BPI 
MPO 
DEFA1B 
DEFA3 
ABCA13 
CEACAM6 
PRRT4 
IQGAP3 
PRTN3 
STOX2 
MS4A3 
SEMA6A 
SLC28A3 
GBP1 
RETN 
PCOLCE2 
LCN2 
CD24 
RAB13 
SLC22A16 
OLFM4 
IRF1 
RNASE2 
DSC2 
DEFA8P 
CEACAM8 
SLC2A5 
GBP5 
RP11-1D12.2 
LINC01268 
LTF 
SHISA4 
INHBA 
GBP1P1 
ARG1 
CHIT1 
ENSG00000172232 
ENSG00000197561 
ENSG00000164821 
ENSG00000169397 
ENSG00000100448 
ENSG00000101425 
ENSG00000005381 
ENSG00000240247 
ENSG00000239839 
ENSG00000179869 
ENSG00000086548 
ENSG00000224940 
ENSG00000183856 
ENSG00000196415 
ENSG00000173320 
ENSG00000149516 
ENSG00000092421 
ENSG00000197506 
ENSG00000117228 
ENSG00000104918 
ENSG00000163710 
ENSG00000148346 
ENSG00000272398 
ENSG00000143545 
ENSG00000004809 
ENSG00000102837 
ENSG00000125347 
ENSG00000169385 
ENSG00000134755 
ENSG00000223629 
ENSG00000124469 
ENSG00000142583 
ENSG00000154451 
ENSG00000254006 
ENSG00000227502 
ENSG00000012223 
ENSG00000198892 
ENSG00000122641 
ENSG00000225492 
ENSG00000118520 
ENSG00000133063 
153.3 
68.6 
57.8 
19.5 
32.7 
180.8 
164.3 
5.2 
185.2 
69.7 
26.1 
27 
8.7 
14.9 
4.4 
35.3 
8.3 
3.8 
2470.4 
19.9 
1.4 
348.7 
69.3 
10.1 
0.8 
82.7 
20667.5 
30.2 
104.4 
0.8 
89.5 
39.3 
15066.2 
2.2 
7.3 
2230.4 
35.7 
13.8 
36.8 
43.8 
55.5 
1283.7 
694 
691.4 
269 
298.5 
1838 
1665.1 
63.3 
2736.5 
527.6 
272.1 
158 
61.3 
168.6 
39.2 
270.4 
10.2 
41.5 
403.8 
139.7 
24.2 
2209 
453.9 
46 
8 
612.9 
6214.2 
244.2 
125.7 
14.2 
598.9 
163.2 
3148.7 
19.2 
7.4 
10945.4 
9.1 
76.9 
3.8 
201.2 
228.4 
2.19 
2.18 
2.20 
2.22 
2.10 
2.12 
2.08 
2.09 
2.07 
1.95 
2.01 
1.84 
1.90 
1.98 
1.90 
1.82 
1.79 
1.83 
-1.73 
1.74 
1.80 
1.69 
1.69 
1.57 
1.71 
1.68 
-1.38 
1.68 
-1.67 
1.69 
1.63 
1.48 
-1.53 
1.56 
1.52 
1.48 
-1.41 
1.50 
-1.54 
1.45 
1.39 
1.83E-08 
1.50E-07 
1.71E-07 
1.71E-07 
3.04E-07 
3.45E-07 
7.75E-07 
1.06E-06 
2.62E-06 
2.80E-06 
3.34E-06 
3.34E-06 
4.00E-06 
6.94E-06 
1.66E-05 
5.13E-05 
6.49E-05 
8.81E-05 
0.00010 
0.00017 
0.00018 
0.00029 
0.00029 
0.00030 
0.00048 
0.00049 
0.00053 
0.00053 
0.00062 
0.00063 
0.00080 
0.00082 
0.00135 
0.00332 
0.00374 
0.00385 
0.00385 
0.00402 
0.00425 
0.00429 
0.00647 
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Gene Ensembl ID HC (mean) T1D (mean) 
Log2 fold 
change 
padj 
KIAA1244 
SERPINB10 
APOL6 
IFIT2 
TCN1 
CD24P4 
DNAH10 
CLEC11A 
E2F8 
CAMP 
ANO7 
PKMYT1 
SLC5A10 
ERG 
IRF9 
LINC01059 
CLTCL1 
ITGA9 
MX1 
CDT1 
CLSPN 
AC011513.4 
ETV7 
CLEC5A 
CCDC38 
DEFA1 
RRM2 
KIF20A 
NOD2 
LPPR3; 
LRP3 
ATP2C2 
EPS8L1 
DZIP1L 
IRF9 
ANLN 
ZNF732 
ATP8B4 
AC067945.3 
TNFSF10 
M1AP 
APOL1 
ENSG00000112379 
ENSG00000242550 
ENSG00000221963 
ENSG00000119922 
ENSG00000134827 
ENSG00000185275 
ENSG00000197653 
ENSG00000105472 
ENSG00000129173 
ENSG00000164047 
ENSG00000146205 
ENSG00000127564 
ENSG00000154025 
ENSG00000157554 
ENSG00000213928 
ENSG00000255414 
ENSG00000070371 
ENSG00000144668 
ENSG00000157601 
ENSG00000167513 
ENSG00000092853 
ENSG00000268833 
ENSG00000010030 
ENSG00000258227 
ENSG00000165972 
ENSG00000206047 
ENSG00000171848 
ENSG00000112984 
ENSG00000167207 
ENSG00000129951 
ENSG00000130881 
ENSG00000064270 
ENSG00000131037 
ENSG00000158163 
ENSG00000259529 
ENSG00000011426 
ENSG00000186777 
ENSG00000104043 
ENSG00000229023 
ENSG00000121858 
ENSG00000159374 
ENSG00000100342 
1.4 
8.3 
7468.5 
5566.6 
38.1 
1.8 
17.6 
68.6 
9.4 
165.9 
3.1 
30.8 
3.3 
17.4 
857 
7.7 
48.5 
19.8 
3241.7 
54.9 
29.3 
0.8 
109.8 
14 
0.6 
0.2 
66.4 
7 
588.9 
1.5 
15.1 
12.4 
36.8 
5.3 
407.7 
29.5 
3.6 
70 
34.1 
731.5 
2.7 
457 
10.2 
53.2 
4491.7 
903.4 
210.5 
14 
50.9 
136.6 
32.8 
747.6 
15.8 
84.9 
13.2 
54.4 
407.1 
2.9 
134.2 
60.1 
2031 
118.5 
69.6 
6.1 
21.6 
57.9 
2.9 
3.5 
178.3 
18.7 
152.3 
7.1 
48.1 
45.1 
20.7 
26.5 
179.3 
76 
0.5 
195.3 
14.2 
298.5 
12.9 
172.7 
1.49 
1.48 
-0.69 
-1.47 
1.45 
1.47 
1.20 
0.89 
1.29 
1.38 
1.39 
1.15 
1.31 
1.21 
-0.93 
-1.11 
1.13 
1.18 
-1.09 
0.95 
1.03 
1.33 
-1.30 
1.27 
1.28 
1.27 
1.10 
1.09 
-1.23 
1.25 
1.17 
1.21 
-0.74 
1.26 
-0.97 
1.05 
-1.26 
1.10 
-1.00 
-1.02 
1.24 
-1.07 
0.00698 
0.00698 
0.00714 
0.00812 
0.00812 
0.00828 
0.00875 
0.00946 
0.01179 
0.01266 
0.01517 
0.01979 
0.02074 
0.02256 
0.02575 
0.02843 
0.03116 
0.03116 
0.03116 
0.03116 
0.03302 
0.03848 
0.04467 
0.04467 
0.04514 
0.04874 
0.04943 
0.06012 
0.06241 
0.06379 
0.06389 
0.06790 
0.06991 
0.06991 
0.06991 
0.07045 
0.07045 
0.07097 
0.07326 
0.07576 
0.07588 
0.07591 
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Gene Ensembl ID HC (mean) T1D (mean) 
Log2 fold 
change 
padj 
KCTD3 
ANKRD18A 
LAP3P2 
LA16c-321D4.2 
RGS6 
LAP3 
STAT1 
GGTA1P 
CRISP3 
RASD1 
USP6 
 
ENSG00000136636 
ENSG00000180071 
ENSG00000213500 
ENSG00000262482 
ENSG00000182732 
ENSG00000002549 
ENSG00000115415 
ENSG00000204136 
ENSG00000096006 
ENSG00000108551 
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Appendix Figure 4.1 Supplementary for Figure 4.24: Stimulation of Treg and Tconv with AA 
shows upregulation of genes and results in specific gene expression pattern. AA responsive (Resp) 
and nonresponsive (NR) were single-cell sorted and processed for multiparameter gene expression panel of 
48 genes. (A) Heat map is shown for 151 AA Tconv Resp and 105 NR single cells from up to seven patients. 
(B) Heat map of 23 AA Treg Resp (petrol) and 106 NR (light turquoise)from six patients. (C) Heat map of 151 
AA Resp Tconv (grey) and 23 Treg (petrol) from up to seven patients. Each bar represents an individual cell 
and expression value is shown as reverse CP values 
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